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Summary  
 
SOCS proteins are regulators of various signal transduction cascades that are essential to 
normal physiology. The importance of a strict control of signalling is underscored by the 
contribution of aberrant SOCS functions in several pathologies. So far, eight SOCS 
members have been identified (CIS and SOCS1-7) and they are all characterised by 
common structural motifs: a central SH2 domain and a C-terminal SOCS box.  The SH2 
domain defines substrate selectivity, while the SOCS box domain mediates the interaction 
of SOCS proteins with the Elongin B/C complex, linking them to the ubiquitin/proteasome 
degradation system.  Upon stimulation, SOCS proteins are recruited to activated receptors, 
where they suppress signalling by different mechanisms including targeting of the receptor 
complex for proteasomal degradation. 
The first part of this thesis focuses on the role of SOCS proteins in leptin receptor (LR) 
signalling. Hypothalamic leptin responses play a central role in body weight regulation. In 
addition, leptin also has direct effects on peripheral cell types involved in regulation of 
diverse body functions including immune response, haematopoiesis and reproduction. 
Since alterations in normal leptin action have severe pathological implications, it is 
important to understand the mechanisms that regulate leptin signalling. Previous studies 
have demonstrated the important role of SOCS3 in leptin physiology. Using MAPPIT, a 
cytokine receptor-based two-hybrid method operating in intact mammalian cells, we showed 
that CIS and SOCS2 can also bind to the LR and we further characterised the binding mode 
and functionality of these interactions. Next, we studied the signalling events of the LR in 
haematopoiesis. Therefore, we designed a novel MAPPIT variant, βc-MAPPIT, which allows 
analysis in a haematopoietic environment. We identified several reported as well as novel 
interactions with the LR, including binding of SOCS proteins. 
The SOCS box domain of SOCS molecules was known to be involved in targeting 
associated proteins for degradation and in SOCS protein stability.  In the second part of the 
thesis, we reported novel roles for this domain. First, the SOCS box was demonstrated to 
be implicated in cross-modulation between SOCS proteins. This way, some SOCS 
members can interfere with the inhibitory functions of other SOCS proteins by targeting 
them for proteasomal degradation. This cross-regulatory mechanism may be involved in 
restoring the basal cellular responsiveness for subsequent stimulation. Secondly, we 
showed that the SOCS box can regulate substrate binding. Receptor interaction and 
functionality of CIS were found to crucially require Elongin B/C recruitment to the SOCS 
box. This Elongin B/C-dependency appears to be unique for CIS and represents a novel 
regulatory mechanism by which the SOCS box may form an on/off switch acting on the SH2 
domain. Together, our findings indicate multiple roles for the SOCS box. 
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Samenvatting 
 
De familie van SOCS eiwitten zijn essentiële regulatoren in verscheidene signalisatie 
cascades. Het belang van een strikte controle van de signalisatie wordt benadrukt door het 
voorkomen van aberrante SOCS functies die bijdragen tot verschillende ziektepatronen. Tot 
op heden zijn acht SOCS proteinen geïdentificeerd (CIS en SOCS1-7) en ze worden 
gekenmerkt door gemeenschappelijke structurele motieven: een centraal SH2 domein en 
een eindstandige SOCS box. Het SH2 domein bepaalt de substraat selectiviteit en het 
SOCS box domein staat in voor de interactie met het Elongine B/C complex dat een link 
vormt naar het ubiquitine/proteasoom afbraaksysteem.  Na stimulatie worden de SOCS 
eiwitten gerecruteerd naar de geactiveerde receptor waar ze door verschillende 
mechanismen de signaalweg zullen onderdrukken. 
In het eerste deel van dit werk gaan we dieper in op de functies van de SOCS eiwitten in 
leptine signalisatie. Leptine heeft een centrale rol in de regulatie van het lichaamsgewicht. 
Bovendien heeft leptine ook effecten op bepaalde perifere weefsels die ondermeer 
betrokken zijn bij immuniteit, haematopoiesis en vruchtbaarheid. Aangezien ongepaste 
wijzigingen in leptine responsen betrokken zijn bij verscheidene ziektes, is het van groot 
belang om de mechanismen die de leptine signaalweg regelen te ontrafelen. Vorige studies 
hebben een belangrijke rol voor SOCS3 in leptine fysiologie aangetoond.  Gebruikmakend 
van MAPPIT, een twee-hybride methode die werkzaam is in intacte zoogdiercellen, tonen 
wij aan dat CIS en SOCS2 ook met de leptine receptor (LR) kunnen binden. Vervolgens 
werden de signalisatie cascades van de LR in hematopoëse bestudeerd. Daarvoor 
ontwierpen we een nieuwe MAPPIT variant, βc-MAPPIT, die analyse in haematopoëtische 
cellen toelaat. Hiermee konden we zowel gekende als nieuwe interacties met de LR 
identificeren waaronder ook die met SOCS eiwitten. 
De SOCS box was gekend om zijn sleutelfunctie in het regelen van de SOCS stabiliteit en 
het merken van geassocieerde eiwitten voor proteasomale afbraak. In het tweede deel van 
deze thesis bewijzen we nieuwe functies voor dit domein. Eerst tonen we aan dat de SOCS 
box een functie heeft in de onderlinge modulatie van SOCS eiwitten. Op deze manier 
kunnen sommige SOCS leden interferen met de inhiberende werking van andere SOCS 
eiwitten. Dit interfererend mechanisme zou van belang kunnen zijn in het herstellen van de 
cellulaire gevoeligheid. Vervolgens tonen we aan dat de SOCS box substraat binding kan 
regelen. Receptor interactie en functionaliteit van CIS bleken immers Elongine B/C 
recrutering aan de SOCS box te vereisen. Deze Elongine B/C afhankelijkheid is uniek voor 
CIS en vertegenwoordigt een nieuw regulatorisch mechanisme waarmee de SOCS box de 
functies van het SH2 domein kan beïnvloeden. Samengevat wijzen onze bevindingen op 
veelvoudige functies voor de SOCS box.  
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Résumé 
 
Les protéines SOCS forment une famille de régulateurs impliquée dans diverses cascades 
de signalisation. Le disfonctionnement des SOCS contribue au développement de plusieurs 
maladies. Il est donc nécessaire de contrôler la signalisation rigoureusement afin d’éviter 
cela. Jusqu’à présent, huit membres SOCS on été identifiés (CIS et SOCS1-7). Ils sont 
caractérisés par des motifs communs : un domaine SH2 au centre et le SOCS box à la fin. 
Le domaine SH2 définit l’interaction avec le substrat et le SOCS box maintient l’association 
avec le complexe des Elongines B et C, reliant les SOCS au système de dégradation par le 
protéasome. Après stimulation, les SOCS sont recrutées vers les récepteurs activés et 
suppriment la signalisation par différents mécanismes. 
Dans la première partie de cette thèse nous approfondissons les fonctions des protéines 
SOCS dans la signalisation de la leptine. Non seulement la leptine joue un rôle central dans 
le réglage du poids corporel mais elle a également des effets directs sur les tissus 
périphériques où elle module diverses fonctions comme l’immunité, l’hématopoïèse et la 
reproduction. Il est nécessaire d’obtenir une meilleure compréhension des mécanismes qui 
règlent la signalisation de la leptine car un dérèglement mènerait vers des implications 
pathologiques. Plusieurs études démontrent le rôle crucial de SOCS3 dans la physiologie 
de la leptine. En utilisant MAPPIT, une stratégie deux-hybride opérant dans des cellules 
mammifères intactes, nous prouvons que CIS et SOCS2 peuvent également s’associer au 
récepteur de la leptine. Nous avons également étudié les cascades de signalisation du 
récepteur de la leptin dans l’hématopoïèse. Pour cela, nous avons conçu une variante de la 
technique MAPPIT, βc-MAPPIT, qui permet des études de cellules hématopoïétiques. Nous 
avons relevé plusieurs interactions connues mais également des nouvelles y compris celles 
des SOCS. 
Le SOCS box est connu pour son implication dans la modulation de la stabilité des SOCS, 
ainsi que pour son rôle dans la dégradation protéasomale de protéines associées. Dans la 
seconde partie de cette thèse, nous identifions de nouveaux rôles pour ce domaine. Nous 
rapportons que le SOCS box est impliqué dans la modulation réciproque entre protéines 
SOCS. Suite à cela certains membres peuvent interférer avec les fonctions suppressives 
d’autres SOCS en les marquant pour la destruction protéasomale. Il est probable que le 
mécanisme de modulation réciproque entre SOCS soit impliqué dans la reconstitution des 
réponses cellulaires à de nouvelles stimulations. Nous démontrerons ensuite que le 
domaine SOCS box est capable de régler l’association de SOCS avec leur substrat. Il 
s’avère que l’interaction avec le récepteur et la fonctionnalité de CIS nécessitent le 
recrutement du complexe Elongin B/C au SOCS box. Cette dépendance est unique pour 
CIS  et représente un nouveau mécanisme régulateur par lequel le SOCS box peut 
contrôler les interactions du domaine SH2. En conclusion, nos résultats démontrent des 
rôles variés et complexes pour le SOCS box. 
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Chapter 1: Cytokine receptors and signal transduction 
 
CHAPTER 1:  Cytokine receptors and signal transduction 
 
 
The complexity of multicellular organisms is made possible by the evolution of 
systems enabling cells to communicate and consequently respond to distinct cues.  
Cytokines and their receptors represent one such system that plays a key role in cell 
proliferation, differentiation, migration and apoptosis.  These biological activities are 
critical to processes as diverse as haematopoiesis, immune responses, growth and 
embryonic development.  
 
 
I. Cytokines 
 
Cytokines are defined as a highly heterogeneous group of small and secreted 
messenger proteins, some of which remain cell bound, that are involved in 
intercellular communication in multicellular organisms.  Two crucial features that 
characterize the cytokine network are their pleiotropy and redundancy. Pleiotropy 
indicates that one cytokine can provoke a broad range of responses depending on 
the cell type or the differentiation stage. This way, cytokines can orchestrate a 
coordinated response of different cellular processes. Redundancy implies that 
different cytokines can exert similar biological activities.  In this way, important 
cellular mechanisms are preserved by a back-up mechanism, in which one cytokine 
can compensate for the loss of another. These compensatory mechanisms can be 
explained in part by the common use of certain receptor chains and signalling 
molecules by the different cytokines.  
A cytokines’ sphere of action is limited: they are secreted in very low amounts, and 
producer and responder cells are often physically located close to each other 
(thereby cytokines differ from classical hormones).  Dispersal of some cytokines is 
also limited by binding to the extracellular matrix and soluble cytokine receptors that 
bind and inhibit the biological actions of cytokines. 
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Originally, cytokines were classified based on their biological responses.  But given 
the apparent functional pleiotropy and low sequence homology, current cytokine 
classification relies on structural similarities. According to the Cytokine Web 
(http://cmbi.bjmu.edu.cn/cmbidata/cgf/CGF_Database/cytweb/index.html) different 
fold families can be distinguished (table 1).   
 
Table 1: Classification of the cytokines based on similarity in protein folding 
 
α-helical 
structure  
 
long chain 4-α-helix bundle superfamily  
interleukin-6 (IL-6), growth hormone (GH), Leptin, erythropoietin (Epo), prolactin (PRL), 
granulocyte-colony stimulating factor (G-CSF), myelomonocytic growth factor, 
leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), 
cholinergic differentiation factor (CDF) 
 
short chain 4-α-helix bundle superfamily  
IL-2, IL-3, IL-4, IL-5,  granulocyte macrophage colony-stimulating factor (GM-CSF), 
macrophage-colony stimulating factor (M-CSF)  
 
dimeric 4-α-helix bundle superfamily 
interferon γ (IFNγ), interferon β (IFNβ), IL-10 
β-sheet 
structure 
Β-Trefoil  
IL1-α, IL1-β, fibroblast growth factor (FGF)  
 
β-sandwich  
tumour necrosis factor α (TNFα), tumour necrosis factor β (TNFβ)  
 
β-EGF-like  
transforming growth factor α (TGF-α)  
 
β-Cystine knot dimerization domains  
gonadotropin, nerve growth factor (NGF), platelet-derived growth factor (PDGF), 
transforming growth factor-β2 (TGF-β2)  
α/β-structure 
 
IL-8, platelet factor 4 (PF-4), macrophage inflammatory protein 1 alpha (MIP-1α), MIP-
1β, melanoma growth stimulating activity (MGSA) 
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Cytokines studied in this work, including leptin, GH, Epo and IFNβ, belong to the 4-
α-helical bundle cytokine family. These share a typical fold consisting of 4 α-helices 
arranged in an up-up-down-down orientation, linked together with 2 loops.  The 
‘long chain’ subgroup has long α-helices and their loops contain additional helices, 
while the subgroup of the ‘short chain’ cytokines has shorter α-helices and their 
loops comprise two short antiparallel β-strands.  Cytokines of the third subgroup 
form dimeric structures (figure 1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:  Structures of 4 α-helix bundle cytokines 
GH, a long chain 4-α-helical bundle cytokine (left). GM-CSF, a short chain 4-α- 
helical bundle cytokine (right). IFNγ, a dimeric 4-α-helical bundle cytokine (under) 
(adapted from ‘The Cytokine Web’) 
Chapter 1: Cytokine receptors and signal transduction 
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II. Cytokine receptors 
 
Since cytokines are unable to cross the cellular membrane themselves and have no 
intrinsic enzymatic activity, they require specific transmembrane receptor proteins to 
transmit their signal to the inside of cells.  Based on (predicted) secondary and 
tertiary structure similarities, cytokine receptors can be divided into 4 classes (table 
2).  In general, there is a clear correlation between the structural class of the 
cytokine ligands and their receptors. 
 
Table 2: Classification of the cytokine receptors based on structure similarities. 
 
class name characteristics
I. haematopoietin/interferon receptors Ig-like and FNIII-like domains in the extracellular part
unstructured intracellular part
II. TNF/IL-1 receptors repeat of 6 Cys in the extracellular part 
often presence of a death domain (induction
of apoptosis) in the intracellular part 
III. receptor kinases intrinsic kinase activity: phosphorylation of Tyr 
(e.g. insulin receptor) or Ser/Thr (e.g. TGFβR)
IV. serpentine receptors cross the cellular membrane seven times
Ser/Thr residues in intracellular part, acting as 
phosphorylation sites for receptor regulation 
 
 
Cytokine receptors examined in this thesis are part of the class I receptor family. 
Members of this receptor class are characterized by a conserved extracellular 
module, known as the  cytokine receptor homology domain (CRH), along with a 
range of other structural modules including immunoglobulin (Ig)-like and fibronectin 
type III (FNIII)-like domains, a transmembrane and intracellular domains (Bazan, 
1990; Kishimoto et al., 1994).  The CRH domains consist of two homologous barrel-
like structures of 7 β strands resembling the FNIII fold.  The cytoplasmatic domains 
of the members of this receptor class are more heterogeneous.  Unstructured 
intracellular part (see table 2) points to the lack of structural information, either by 
NMR or by crystallography studies, on the cytoplasmatic domains of the class I 
Chapter 1: Cytokine receptors and signal transduction 
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cytokine receptors. This may well reflect the absence of clearly structured 
subdomains. Moreover, beside the membrane-proximal box1 and box2 motifs and 
conserved tyrosine residues there are no well-conserved sequences or elements 
within the cytosolic tails of these receptors. Haematopoietin receptors are divided 
into two groups which have divergent CRHs (Bazan, 1990).   
 
 
Chapter 1: Cytokine receptors and signal transduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Structure of a class I cytokine receptor 
GH in complex with two extracellular domains of its receptor 
(adapted from ‘The Cytokine Web’) 
 
The type I receptors are characterized by two conserved disulfide bonds and a 
canonical Trp-Ser-X-Trp-Ser (WSXWS) motif in their CRH (Bazan, 1990).   Some 
members are composed of a single receptor subunit, like the GH receptor (GHR), 
Epo receptor (EpoR) or PRL receptor (PRLR) and are assembled in homomeric 
structures (figure 2).  However, the majority of type I cytokine receptors consists of 
different receptor chains and fall into three major families based on usage of shared 
receptor chains. These receptor complexes combine a ligand-specific subunit with a 
shared signal transducing chain.  Such shared receptor subunits are (i) the gamma 
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common receptor (γc) chain, predominantly utilized by the IL-2 subfamily (IL-2, IL-4, 
IL-7 and others) (Ozaki and Leonard, 2002); (ii) the beta common (βc) chain, used 
by the IL-3 subfamily (IL-3, IL-5 and GM-CSF) (Boulay et al., 2003; Ozaki and 
Leonard, 2002) and (iii) the glycoprotein 130 (gp130) chain, shared by the IL-6 
subfamily (IL-6, IL-11, LIF and others). Type II receptors have also two pairs of 
cysteines but with a different arrangement and they lack the WSXWS motif (Bazan, 
1990). The common use of receptor chains  results in 10 receptor complexes 
formed from a pool of 12 type II receptor chains (Kotenko and Langer, 2004; Langer 
et al., 2004). Type II receptor members are activated by the IFN and IL-10 family 
and they are primarily involved in antiviral and inflammatory responses (Renauld, 
2003) 
 
III. The JAK-STAT pathway 
 
Members of the class I cytokine receptor family have no intrinsic kinase activity and 
therefore typically depend on intracellular associated janus kinases (JAKs) to trigger 
signal transduction. A schematic outline of the JAK-STAT pathway is shown in 
figure 3. Binding of a cytokine to its receptor complex (step 1) will induce clustering 
and/or reorganization of the receptor chains in such a way that the associated JAKs 
will be brought in close proximity, allowing them to activate each other by cross-
phosphorylation (step 2).  These activated kinases will then phosphorylate tyrosine 
residues in the cytoplasmatic portion of the receptor (step 3). These 
phosphotyrosines provide docking sites for various signalling proteins containing a 
phosphotyrosine-binding domain, like a Src homology 2 (SH2) domain or the less 
common phosphotyrosine-binding domain (PTB).  Signal transducers and activators 
of transcription (STAT) proteins dock to these phosphotyrosine containing motifs.  
The STAT molecules then become phosphorylated themselves by the JAKs upon 
receptor association (step 4). Subsequently, the activated STATs dissociate from 
the receptor (step 5) and migrate to the nucleus as dimers (step 6), where they act 
as transcription factors to initiate transcription of specific target genes (Ihle et al., 
1994; Kisseleva et al., 2002; O'Shea et al., 2002).   
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Figure 3: Schematic representation of the JAK/STAT pathway 
(for more details, see text) 
 
 
A. The JAK family 
This kinase family is named after Janus, the Roman god of gates and doors, 
beginnings and endings. Therefore Janus is represented with a double-faced head, 
each looking in an opposite direction. This is reminiscent of the distinctive feature of 
JAK structure: their kinase and pseudokinase domain. In mammals, the JAK family 
comprises four members: JAK1-3 and Tyk2.  JAK1, JAK2 and Tyk2 are expressed 
ubiquitously, while the expression of JAK3 is restricted to cells of haematopoietic 
origin (Leonard and O'Shea, 1998).  
 
Structure of JAKs 
JAKs are relatively large proteins of approximately one thousand amino acids (AA).  
Comparison of JAK sequences reveals seven regions of high similarity, called JAK 
homology (JH) domains 1 to 7 (for an overview see (Leonard and O'Shea, 1998) 
(figure 4). The C-terminal JH1 and JH2 domains encode respectively a kinase and 
pseudokinase domain. Although this latter domain contains structural features of a 
Chapter 1: Cytokine receptors and signal transduction 
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tyrosine kinase, it is devoid of any catalytic activity. Reports suggest that this 
domain modulates the catalytic activity of the kinase domain (Saharinen et al., 2000; 
Velazquez et al., 1995; Yeh et al., 2000).  The JH1 kinase domain behaves like a 
classical tyrosine kinase: it contains tyrosine residues that become phosphorylated 
upon activation, thereby inducing conformational changes that allow binding of the 
substrates in the catalytic site of the JAK (Rane and Reddy, 2000).  The N-terminal 
part of the JAKs, containing JH3-7, is involved in association with the receptor.  
Specifically, JAKs associate with the proline-rich, membrane-proximal box1 and 
box2 domains of class I cytokine receptors.  The JH3-JH4 regions form a structural 
domain resembling a SH2 domain, but appear not to be implicated in 
phosphotyrosine-dependent interactions, as SH2 domains typically do.  However, 
this region is structurally important for receptor association and receptor surface 
expression (Radtke et al., 2005).  Finally, the structure of the N-terminal (JH5-JH7) 
domains resembles that of Four-point-one, Ezrin, Radixin and Moesin (FERM) 
domains, which are known to mediate protein-protein interactions with for example 
phosphatidylinositolbisphosphate (PIP2) and inositoltrisphosphate (IP3) (Girault et 
al., 1998).  This region mediates receptor binding and is involved in the 
maintenance of catalytical activity (Hilkens et al., 2001; Zhou et al., 2001). 
 
 
 
 
 
 
 
 
 
Figure 4: Schematic representation of the JAK structure 
JAKs share seven regions of high similarity (JH1-7). N-terminal domains mediate receptor 
association; JH1 and JH2 encode respectively a kinase and pseudokinase domain. The 
ruler underneath indicates the number of AA. 
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Biological functions – lessons learned from JAK knock-outs 
JAKs have non-redundant functions in vivo as is reflected by the phenotypes of JAK 
knock-out mice (table 3).    
 
JAK1 - JAK1 knock-out mice die perinatally of a poorly characterized defect that 
may be neurologic. JAK1-deficient cells are unresponsive to IFNs, γc-dependent 
cytokines, and to most cytokines signalling through the gp130 receptor subunit 
(Rodig et al., 1998).   
 
JAK2 – Targeted disruption of the JAK2 gene results in embryonic lethality due to 
failure of erythropoiesis.  Cells from these mice showed that this kinase is essential 
for different cytokine responses including IL-3, IL-5, GM-CSF and IFNγ (Neubauer 
et al., 1998; Parganas et al., 1998).  Humans with JAK2 mutations exhibit 
myeloproliferative disorders (Baxter et al., 2005; James et al., 2005).  
 
JAK3 - Deletion of the murine JAK3 gene results in a viable phenotype.  
Nevertheless, these mice suffer from severe combined immune deficiency (SCID) 
and profound B and T cell defects due to impaired signalling via the γc receptors 
(Nosaka et al., 1995; Park et al., 1995). Humans that are deficient for JAK3 have 
SCID and suffer from severe T cell defects, but their B cell populations remain 
unaffected (Thomis and Berg, 1997).   
 
TYK2 – In comparison to the other JAKs, TYK2 deficiency in mice caused only a 
modest phenotype characterized by a shift toward Th2 immune responses and an 
impaired response to lipopolysaccharide (LPS) (Karaghiosoff et al., 2003). 
Surprisingly, only subtle defects were observed in IL-12, type I and II IFNs 
(Karaghiosoff et al., 2000; Karaghiosoff et al., 2003; Shimoda et al., 2000). The role 
of TYK2 in murine IFN-dependent signalling appears to be limited to specific 
antiviral activities at low IFN concentrations.  By comparison, TYK2-deficient 
humans exhibit a more severe phenotype. In those individuals, the combined 
aberrations in IFN, IL-6, IL-10, IL-12 and IL-23 responses are associated with 
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enhanced allergic and impaired antimicrobial responses (Watford and O'Shea, 
2006).  
 
Table 3: Overview of the major phenotypical differences associated with JAK 
deficient mice 
 
knock-out major phenotypical differences references
JAK1 early postnatal lethality, neurological deficiencies, Rodig et al., 1998
defective responses to IFNs and cytokines
 using γc or gp130 receptor subunits
JAK2 embryonic lethality, impaired erythropoiesis Neubauer et al., 1998
Parganas et al., 1998
JAK3 viable, fertile, defective lymphoid development Nosaka et al., 1995
Park et al., 1995
TYK2 viable, fertile, defective type I and II IFN responses, Karaghiosoff et al., 2000
reduced antiviral response Shimoda et al., 2000
 
 
 
B. The STAT  family 
The family of mammalian STAT proteins consists of seven members: STAT1, 
STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. They function as 
transcription factors which reside predominantly in the cytoplasm in unstimulated 
cells, most probably as preformed dimers (Mertens et al., 2006; Neculai et al., 2005; 
Schroder et al., 2004). STAT1, STAT3 and STAT4 can form both homo- and 
heterodimers while for STAT5 and STAT6 only homodimers have been observed.  
STAT2 is only functional when complexed with STAT1 or STAT4.  Receptor binding 
and subsequent phosphorylation on tyrosine and serine residues will activate 
STATs followed by their nuclear translocation. In the nucleus, they initiate 
transcription by associating with specific response elements in the promoter of 
target genes.  These consensus binding sites are typically palindromic sequences. 
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The mechanisms underlying the transport of the STATs between the cytoplasm and 
the nucleus are only partially understood. The predominantly cytosolic localisation 
for inactive STATs has been shown to reflect a steady-state, where continuous 
basal nuclear import is balanced by continuous basal nuclear export.  After 
activation, the balance is shifted toward nuclear accumulation and during signal 
decay toward nuclear export. Translocation of STAT dimers to the nucleus is 
mediated by specific nuclear localisation signals (NLS) and involves an active 
nuclear import mechanism depending on Ran and importin-α5 (Fagerlund et al., 
2002).  An alternative way of nuclear import by which activated receptors mediate 
nuclear transport of whole receptor/STAT complexes has been proposed (Larkin et 
al., 2000; Subramaniam et al., 2000). A nuclear export signal (NES) drives the 
nuclear export of STATs mediated by Ran and exportin 1. STAT dephosphorylation 
and dissociation from the DNA unmasks the NES sequence and activates the export 
mechanism (Bhattacharya and Schindler, 2003; McBride and Reich, 2003; 
Vinkemeier, 2004). 
 
Structure of STATs 
STATs are about 800 AA long and six structurally and functionally conserved 
domains have been identified (figure 5). The N-terminus contains a dimer-dimer 
interaction domain that apparently allows STAT dimers to form tetramers that can 
cooperatively associate with multiple tandem STAT response elements in the 
promoter (John et al., 1999; Murphy et al., 2000; Vinkemeier et al., 1996; Xu et al., 
1996). It was also reported that this domain is involved in nuclear translocation and 
STAT deactivation (Strehlow and Schindler, 1998).  The N-terminal region is linked 
to the DNA binding domain by a coiled-coil domain which consists of four helices. 
This domain can interact with other transcription factors and is also implicated in 
receptor binding, tyrosine phosphorylation and nuclear export (Begitt et al., 2000; 
Zhang et al., 2000).  The centrally located DNA binding domain harbours a typical β-
barrel with an Ig fold, a structure found in various transcription factors, like NF-κB 
and p53. Obviously, it is implicated in DNA association but there are only little direct 
interaction sites (Becker et al., 1998; Chen et al., 1998).  
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Figure 5 :  Schematic representation of the STAT structure 
P indicates phosphorylated residues. The ruler underneath indicates the number of AA. 
 
The SH2 domain is crucial for docking of the STAT to the phosphorylated tyrosine 
motifs in the receptor or in JAK kinases and it also mediates dimerisation of the 
STATs.  The SH2 domain consists of a β-sheet flanked by two α-helices, which form 
a pocket structure. A conserved arginine residing in this pocket is essential for the 
interaction with phosphotyrosine residues (Chen et al., 1998).  C-terminal to the 
SH2 domain, STATs have a conserved tyrosine residue which becomes 
phosphorylated by the JAK kinases upon receptor binding.  Dimerization of the 
activated STATs is based on the reciprocal interaction of the SH2 domain with this 
phosphorylated tyrosine.  The more variable C-terminus of STATs encodes a 
transcription activation domain (TAD).  This divergence provides an opportunity to 
associate with distinct transcriptional regulators.  This domain can be serine 
phosphorylated, which enhances the transcription of some genes (Decker and 
Kovarik, 2000).  
 
 
Biological functions – lessons learned from STAT knock-outs 
Specific deletion of STAT genes revealed distinctive functions for the various STAT 
proteins.  An overview of the different knock-out mice phenotypes is given in table 4. 
 
STAT1 - STAT1 deficient mice confirmed the pivotal role that STAT1 plays in the 
biological response to both type I and type II IFNs.  These mice are highly 
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susceptible to bacterial and viral infections (Durbin et al., 1996; Meraz et al., 1996).  
Consistent with this, naturally occurring mutations in human STAT1 exhibit 
increased susceptibility to viral and bacterial infections (Chapgier et al., 2006).  
STAT1 seems to be also implicated in non immune-responses, like chondrocyte 
proliferation (Sahni et al., 1999) and IFNγ-mediated growth inhibition, as was 
revealed by the enhanced tumor susceptibility of STAT1-/- mice (Shankaran et al., 
2001).   
 
Table 4: Overview of the major phenotypical differences associated with STAT 
deficient mice 
knock-out major phenotypical differences references
STAT1 viable, IFN responses absent, highly Durbin et al., 1996
sensitive to viral/microbial infection Meraz et al., 1996
STAT2 viable, type I IFN responses impaired, Park et al., 2000
defective antiviral response
STAT3 embryonic lethality Takeda et al., 1997
STAT4 viable, defective Th1 differentiation Kaplan et al., 1996b
Thierfelder et al., 1996
STAT5a viable, impaired mammalian gland development Liu et al., 1997
STAT5b viable,impaired growth Udy et al., 1997
STAT6 viable, defective Th2 differentiation, Kaplan et al., 1996a
impaired B cell functions Takeda et al., 1996
 
    
STAT2 - STAT2 null mice also display deficiencies in antiviral responses.  Their 
defective phenotype is principally due to impaired type I IFN signalling that is 
dependent on STAT1/STAT2 heterodimers (Park et al., 2000). STAT1/STAT2 
double knock-out mice are totally refractory to both classes of IFNs and are more 
vulnerable to infections than either single knock-out mice. 
 
STAT3 - STAT3 gene targeting has underscored the vital developmental role for 
STAT3 as deficient mice die embryologically before gastrulation (Takeda et al., 
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1997). In contrast, tissue-specific knock-outs have highlighted an important anti-
inflammatory role for STAT3.  Macrophages and neutrophils depleted of STAT3 
exhibit a higher susceptibility to endotoxin shock and a higher production of 
inflammatory cytokines due to impaired IL-10 responsiveness (Takeda et al., 1999).  
STAT3 deficiency in T cells abrogates their proliferative response to IL-6 (Takeda et 
al., 1998). STAT3 deficient hepatocytes have an impaired induction of acute phase 
genes in response to IL-6 (Alonzi et al., 2001).  Finally, lack of STAT3 in 
keratinocytes results in impaired wound healing and hair growth (Sano et al., 1999).  
Consistent with these findings, STAT3 directs the expression of pro-proliferative and 
anti-inflammatory cytokines, thereby contrasting with the anti-proliferative and pro-
inflammatory activities of STAT1. 
 
STAT4 - Genetic targeting of STAT4 has revealed a crucial role in directing the 
biological response to IL-12 and in regulating the differentiation of Th1 and Th2 
cells.  STAT4 deficient mice have defects in IL-12 mediated responses by natural 
killer cells and T lymphocytes, including the production of IFNγ, mitogenesis, 
enhancement of natural killer cytolytic function and Th1 differentiation (Kaplan et al., 
1996b; Thierfelder et al., 1996).  More recently, STAT4 was shown to be important 
in the IL-23 dependent expansion of Th17 cells and associated autoimmunity 
(Hunter, 2005). 
 
STAT5 - Although extensive sequence similarity between STAT5a and STAT5b 
(~96% AA identity) explains their functional redundancy observed in vitro, the 
phenotypes of the single knock-outs reflect striking differences.  STAT5a null mice 
are predominantly defective in PRL-mediated gland development (Liu et al., 1997), 
whereas STAT5b deficiency causes aberrations in sexual dimorphic growth, 
reminiscent of the phenotype of GH deficient mice (Udy et al., 1997).  STAT5a/b 
double knock-outs exhibit a more severe phenotype.  Many of these mice die within 
weeks after birth. The surviving mice are smaller and infertile with mammary gland 
defects, underscoring the essential role of the STAT5 proteins in GH and PRL 
responses {Teglund, 1998 #34}.  Recent STAT5a/b gene targeting studies have 
revealed an important role for the STAT5 molecules in erythropoiesis and 
lymphopoiesis (Yao et al., 2006). 
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STAT6 - STAT6 deficient mice have confirmed a critical role for STAT6 in the IL-4 
and IL-13 dependent polarization of naive lymphocytes into Th2 effector cells, as 
well as in mast cell activation.  The gene targeting studies have also highlighted an 
important role for STAT6 in promoting B cell function, including proliferation, 
maturation, and MHC-II and IgE expression (Kaplan et al., 1996a; Takeda et al., 
1996). 
 
Table 5: Cytokine-specific JAK and STAT activation 
Based on the composition of receptor chains and their use of JAKs and STATs, cytokine 
receptors can be divided into five subfamilies. Adapted from (O'Sullivan et al., 2007). 
 
ligand JAK kinase STATs
IFN family
IFNα/β Tyk2, JAK1 STAT1, STAT2 (STAT3, STAT5)
IFNγ JAK1, JAK2 STAT1 (STAT3, STAT5)
IL-10 Tyk2, JAK1 STAT3  (STAT1, STAT5)
gp130 family
IL-6 JAK1, JAK2, TYK2 STAT1, STAT3 (STAT5)
IL-11 JAK1, JAK2, TYK2 STAT1, STAT3 (STAT5)
IL-12 JAK2, TYK2 STAT4
OSM JAK1, JAK2, TYK2 STAT1, STAT3 (STAT5)
LIF JAK1, JAK2, TYK2 STAT1, STAT3 (STAT5)
G-CSF JAK1, JAK2, TYK2 STAT3 (STAT1, STAT5)
Leptin JAK1, JAK2 STAT3 (STAT1, STAT5)
γc family
IL-2 JAK1, JAK3 STAT5
IL-4 JAK1, JAK3 STAT6
IL-7 JAK1, JAK3 STAT5
IL-9 JAK1, JAK3 STAT5
IL-15 JAK1, JAK3 STAT5
βc family
IL-3 JAK2 STAT5
IL-5 JAK2 STAT5
GM-CSF JAK2 STAT5
Single chain family
Epo JAK2 STAT5 
GH JAK2 STAT5 (STAT3)
PRL JAK2 STAT5
TPO JAK2 STAT5
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 Text box 1: Specificity of the JAK-STAT pathway 
 
Almost 40 cytokine receptors signal through combinations of four JAK and seven STAT 
family members, suggesting commonality in the JAK-STAT signalling cascade.  Based 
on their use of JAKs and STATs, cytokine receptors are divided into five subfamilies 
(overview in table 4).  Although only a limited number of JAK and STAT proteins are 
implicated, activation of the pathway by divergent stimuli will lead to unique biological 
responses. 
 
The specificity of JAK-STAT signalling first originates from the preferential association of 
one JAK (or JAK combination) to certain receptor classes. Second, each receptor will 
use its own set of STAT molecules, leading to transcription of a defined collection of 
target genes. STAT specificity is largely determined by the binding preference of their 
SH2 domains for phosphorylated tyrosine residues on specific receptors. Third, 
posttranslational modifications and formation of STAT heterodimers, tetramers or higher 
order complexes expands the range of STAT/DNA binding opportunities. Fourth, specific 
gene expression is refined by genomic accessibility and other cofactors that act in 
synergy with STATs. These cofactors are often cell type specific or are activated by 
other receptor signalling pathways. 
 
Despite extensive study, there remain substantial gaps in understanding how the JAK-
STAT cascades are activated and regulated.  There is for example still a lack of 
structural information on the cytoplasmatic domains of cytokine receptors, particularly in 
association with JAKs and STATs. We also do not fully understand how specificity in 
gene expression is generated by receptors that use identical JAK and STAT members.  
Further, it is intriguing that despite the large amount of cytokine receptors, the number of 
JAKs or JAK combinations remained so small during evolution. 
 
IV. A selection of other cytokine-induced signalling pathways 
 
In mammals, the JAK-STAT pathway is the principal signalling mechanism for a 
wide array of cytokines and growth factors.  However, other pathways are also 
contributing to the signal transduction originating from cytokine receptors. A number 
of adaptor molecules can be recruited to the receptor or the kinase and may provide 
a link to other signalling pathways upon JAK-dependent phosphorylation. This 
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further emphasizes the major role of JAK kinases in the total signalling event 
induced by a cytokine. Most cellular responses are derived from a combined effort 
of several activated signalling pathways, which are often intertwined by cross-talk 
actions. An example is the potential role of mitogen-activated protein kinases 
(MAPK) in activation of STAT proteins by serine phosphorylation.  
 
  
 
 
 
 
Figure 6: Schematic overview of the MAPK and PI3K/Akt pathways. 
Transcription factors that are activated in the different pathways are shown in yellow. 
 
The MAPK pathway - The MAPK signalling cascade is initiated by receptor and/or 
JAK binding of a set of adaptors including SH2 domain containing phosphatase-2 
(SHP2), growth receptor bound protein 2 (Grb2), insulin receptor substrate (IRS) 
and Shc to the activated receptor complex.  As illustrated in figure 6, binding of Grb2 
can link the receptor to a guanine nucleotide exchange factor like son of sevenless 
(SOS). The latter protein activates membrane-anchored small GTP binding proteins 
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like Ras, which in turn stimulate the core unit of this cascade composed of series of 
serine-threonine kinases: MAPKKK (Raf), MAPKK (MEK1/2) and MAPK (Erk1/2) 
(Morrison and Cutler, 1997; Rubinfeld and Seger, 2005).  Three major groups of 
MAP kinases exist: the p38 MAP kinase family, the extracellular signal-regulated 
kinase (Erk) family, and the c-Jun NH2-terminal kinase (JNK) family (Chang and 
Karin, 2001; Johnson and Lapadat, 2002).  Activation of the different MAPKs will 
generate diverse, often conflicting cellular responses including inflammation, cell 
growth, differentiation and survival (Dong et al., 2002; Platanias, 2003). 
 
The PI3K/Akt pathway - Another example is the phosphatidylinositide 3-kinase 
(PI3K)/Akt pathway that induces cell growth and anti-apoptotic mechanisms upon 
stimulation by many cytokines. The PI3K family is a group of related lipid kinases, of 
which the classical form is built up of two subunits, a regulatory (p85) and a catalytic 
subunit (p110) (Fruman et al., 1998). The p85 subunit can interact with 
phosphotyrosines of activated receptors or adaptor proteins and thereby recruits the 
p110 subunit to the membrane, where it phosphorylates phosphoinositides (Fruman 
et al., 1998; Okkenhaug and Vanhaesebroeck, 2001). These phosphorylated lipids 
serve as docking sites for several signalling molecules containing a pleckstrin-
homology (PH) domain, like the Ser-Thr kinases Akt and phosphoinositide-
dependent kinase 1 (PDK1) (Coffer et al., 1998). Phosphorylation of Akt by PDK1 
and other kinases stimulates the catalytic activity of Akt (Anderson et al., 1998; 
Brazil et al., 2002), resulting in the phosphorylation of other signalling proteins, 
thereby altering their function in cell growth and survival (Krasilnikov, 2000). This 
pathway is often deregulated in cancer, since aberrations in this signalling can lead 
to uncontrolled cell growth (Fresno Vara et al., 2004; Hennessy et al., 2005; 
Krasilnikov, 2000). 
 
Other pathways - Activated JAK kinases can phosphorylate other adaptor proteins 
including Vav, resulting in the activation of the Rho family of GTPases and 
phospholipase C gamma (PLCγ), which will induce the release of Ca2+ from 
intracellular stores and activate the family of phosphokinase C (PKC) molecules 
(Carpenter and Ji, 1999; Nobes and Hall, 1995; Patterson et al., 2005). 
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CHAPTER 2:  Major mechanisms controlling cytokine 
signalling  
 
Cytokines are involved in many vital biological processes. Therefore, it is of crucial 
importance that cytokine signals are rapidly and finely tuned to avoid physiological 
derangements.  In order to keep signalling events under tight control, cellular 
mechanisms have evolved to ensure that adequate signalling thresholds are 
achieved and maintained for the correct duration.  Regulation of the initiation, 
duration and magnitude of cytokine signalling occurs at multiple levels: limiting the 
availability of cytokine to initiate a response, regulating the expression and half-life 
of cell surface receptor components, controlling the intracellular signal transduction 
machinery and transcriptional control.  Some of the most important mechanisms and 
protein families involved in negative regulation of signalling will be discussed in this 
chapter (figure 7). Since the scope of the thesis concerns suppressor of cytokine 
signalling (SOCS) proteins, the following chapter will discuss this important family of 
regulatory proteins in greater detail. 
 
I. Soluble receptors 
 
Soluble receptors regulate biological responses by functioning as agonists or 
antagonists of cytokine signalling. A soluble counterpart of a cytokine receptor can 
be generated in two distinct ways: alternative mRNA splicing or proteolytic cleavage, 
which sheds the ectodomain of membrane-spanning receptors. Secreted receptor 
subunits were initially proposed to be antagonists, blocking or reducing cytokine 
potency by competing with their membrane-anchored homologues for common 
ligands. In this respect, the activity of IL-18 can be neutralized by the IL-18-binding 
protein (IL-18BP) that binds IL-18 with high affinity (Novick et al., 1999). In many 
cases however, soluble receptors are protecting the ligand from degradation or 
excretion. In this case, the receptor variant acts as a carrier for the ligand, thereby 
increasing the halflife of the cytokine. This function is for example of particular 
interest in case of the GH, where the site of cytokine production is remote from the 
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target tissue (Baumann, 1995). A secreted receptor may also substitute for an 
absent endogenous binding subunit, thereby converting a ligand-resistant cell into a 
sensitive one. This principle of transsignalling was originally described for IL-6 
signalling. This cytokine can bind its soluble receptor and signal through the gp130 
receptor subunit on a target cell, not expressing the membrane bound IL-6R subunit 
(Heinrich et al., 1995; Peters et al., 1996). 
 
II. Internalisation and degradation 
 
Internalisation and subsequent degradation of the receptor complex is an effective 
mechanism to turn of cytokine actions. Several internalisation mechanisms using 
the clathrin-coated pit pathway or clathrin-independent ways have been described. 
Frequently, a di-leucine motif in the cytoplasmatic part is found to be involved in 
receptor internalization (Aarts et al., 2004; Dittrich et al., 1994; Thiel et al., 1999). 
Internalised receptors are routed to the lysosomes and degraded, although receptor 
subunits may be recycled back to the plasma membrane like was for example 
demonstrated for the IL-2Rα (Hemar et al., 1995).   
The ubiquitin/proteasome system is another way of dismantling the receptor 
complex. Destruction of a protein via this system involves two successive steps: 
attachment of a chain of ubiquitin molecules to the target, resulting in recognition 
and degradation of the poly-ubiquinated protein by the 26S proteasome complex 
with release of reusable ubiquitin.  Ubiquitination is described in more detail in text 
box2.  Several signalling molecules are susceptible to ubiquitination, predestining 
them for proteasomal degradation (Callus and Mathey-Prevot, 1998; Kim and 
Maniatis, 1996; Wang et al., 2000; Yu and Burakoff, 1997).  In this context, it was 
reported that proteasome-dependent degradation of receptor complexes including 
the GHR and EpoR can be mediated by members of the family of SOCS proteins 
(see further) (Verdier et al., 1998). Beside proteasomal degradation, SOCS proteins 
can also direct the internalisation and routing of cytokine receptors as was for 
example demonstrated for the GHR, granulocyt-colony stimulating factor receptor 
(G-CSFR) and epidermal growth factor  receptor (EGFR) (Irandoust et al., 2007; 
Kario et al., 2005; Landsman and Waxman, 2005).  
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Text box 2: The Ubiquitination System 
 
      Ubiquitin (Ub) is a highly conserved protein of 76 amino acids that functions as a protein-modifier by 
covalent coupling via its C-terminus to target proteins. This ubiquitination marks these proteins, thereby 
affecting their stability, activity and/or subcellular localization. The binding of Ub to its substrates is a multi-
step process that involves successive action of three classes of enzymes. The Ub-activating enzyme E1 
activates Ub by forming a thioester bond.  Activated Ub is then transferred to an Ub-conjugating enzyme E2 
by transthiolation.  Finally, an Ub ligase E3 couples Ub to a lysine residue or the N-terminus of the E3 
associated target protein (Breitschopf et al., 1998; Glickman and Ciechanover, 2002).  The association of the 
E3 ligases with their target protein determines substrate specificity for ubiquitination.  Ubiquitination is a 
reversible and dynamic process, balanced by deubiquitinating enzymes (DUBs) that decouple Ub 
(Weissman, 2001). 
  
      Proteins can be modified by a single or multiple Ub moieties, termed mono-, multi- or poly-ubiquitination.  
Poly-Ub chains are formed by coupling of Ub to any of the seven lysines in the previously conjugated Ub.  
The different types of ubiquitination are proposed to direct the target protein for different cellular events. 
Mono-ubiquitination is for instance involved in receptor internalisation and histone regulation (Belouzard and 
Rouille, 2006; Hicke and Dunn, 2003; Osley, 2004). In many cases, poly-ubiquitination results in protein 
turnover by the proteasome, but it can also be involved in ribosomal function, DNA repair or signal 
transduction (Geetha et al., 2005; Spence et al., 2000; Wilkinson et al., 2005). Lys48-linked poly-Ub chains 
usually target proteins for destruction by the 26S proteasome (Kim and Rao, 2006; Pickart, 2001; Thrower et 
al., 2000). A well-studied example is the degradation of the hypoxia-inducible transcription factor (HIF)-1α by 
the Von Hippel Lindau (VHL) tumor suppressor.  The turnover of HIF-1α is oxygen-regulated: under normal 
oxygen conditions, hydroxylation of HIF-1α will result in its recognition and destruction by VHL (Hon et al., 
2002; Iliopoulos et al., 1996; Iwai et al., 1999; Lisztwan et al., 1999; Salceda and Caro, 1997). Conversely, in 
hypoxic conditions, HIF-1α is refractory to ubiquitination by VHL and will be able to induce expression of 
hypoxia-inducible genes regulating angiogenesis and erythrocytosis (Huang et al., 1996; Semenza, 1999; 
Wang and Semenza, 1993). VHL acts as the substrate recognition unit for an E3 ubiquitin ligase complex.  It 
contains a substrate-interaction domain and a SOCS box which is conserved amongst different protein 
families, including the SOCS protein family.  The SOCS box is proposed to serve as a common link of these 
proteins with the proteasomal degradation system (Hilton et al., 1998; Kile et al., 2002; Zhang et al., 1999). A 
small conserved motif in the SOCS box, named the B/C box, functions as a docking site for the adaptor 
molecules Elongin C and B (Aso et al., 1996; Duan et al., 1995; Kibel et al., 1995).  Together with a Cullin 
box motif that is situated downstream of the B/C box (Kamura et al., 2004), the Elongin B/C dimer will bridge 
the substrate to a Cullin2 scaffold protein. Cullin2 in turn binds a RING finger-containing protein Rbx1 and 
together these proteins form an E3 ubiquitin ligase complex which will ultimately direct the ubiquitination and 
proteasomal degradation of HIF-1α (Iwai et al., 1999; Pause et al., 1997). Poly-ubiquitination that is not 
based on Lys48-linked Ub chains can be associated with processes as diverse as protein translation, 
activation of transcription factors and DNA repair (Geetha et al., 2005; Kim and Rao, 2006; Spence et al., 
2000; Wilkinson et al., 2005). 
 
       Besides Ub, several other Ub-like (Ubl) proteins can also modify target proteins using a similar 
mechanism for their covalent conjugation.  Examples include SUMO (small Ub-related modifier), ISG15 
(interferon stimulated gene product 15), Nedd8 and Atg8, and these Ubls function as critical regulators of 
many cellular processes such as transcription, DNA repair, signal transduction and cell-cycle control 
(Dohmen, 2004; Kerscher et al., 2006; Ritchie and Zhang, 2004). Ub-like domains with a characteristic Ub 
fold can occur as stable regions within other proteins, as was demonstrated for Elongin B (Stebbins et al., 
1999).  These domains do not couple to other proteins but probably function in Ub-mediated processes 
(Pickart and Eddins, 2004; Weissman, 2001). 
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The turnover of some receptors such as the EGFR and IFNaR1 is dependent on 
both lysosomal and proteasomal activity (Kumar et al., 2003; Longva et al., 2002). 
Also for the EpoR it was suggested that the receptor complex is degraded by two 
proteolytic systems that proceed successively: the proteasome removes part of the 
intracellular domain of the EpoR at the cell surface, and the remaining part of the 
receptor-hormone complex is degraded in the lysosomes (Walrafen et al., 2005). 
 
A number of receptors are subjected to regulated intramembrane proteolysis (RIP).  
After ectodomain cleavage, the cytoplasmatic part is recognized by intracellular 
proteases, resulting in proteolysis and release of the intracellular domain. This 
domain may then translocate to the nucleus, where it participates in transcriptional 
activation or functions as a substrate for proteasomal degradation. 
 
III. Phosphatases  
 
Since phosphorylation is a crucial trigger in the activation of cytokine signalling 
cascades, dephosphorylation by protein tyrosine phosphatases (PTPs) is an 
obvious mechanism that contributes to negative control.  
 
SHP-1 and -2 - SH2 domain containing phosphatase (SHP)-1 and -2 are 
constitutively expressed phosphatases responsible for the dephosphorylation and 
inactivation of JAK kinases. Both proteins bind to either phosphorylated JAKs or 
receptors via two src homology (SH2) domains. Whereas SHP-2 is broadly 
expressed, SHP-1 expression is restricted to haematopoietic cells (Ahmad et al., 
1993; Yi et al., 1992).  The important role of the SHP-1 and -2 phosphatases is 
underscored by the lethal phenotype of their knock-outs. Mice with a naturally 
occurring mutation in the SHP-1 gene die shortly after birth, due to multiple 
abnormalities in immune responses (Kamata et al., 2003; Shultz et al., 1997). SHP-
2 deficient mice are embryonic lethal and this is caused by defects in EGF signalling 
(Qu et al., 1999; Saxton et al., 1997). A positive regulatory role for SHP-2 in the 
MAPK pathway was reported for several cytokine systems: SHP-2 becomes 
phosphorylated itself, which in turn can lead to docking of the Grb2/Sos complex, 
thereby activating the MAPK pathway (Bennett et al., 1994; Cunnick et al., 2002). 
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SHP-2 was also reported to interact with STAT molecules and positively regulate 
their phosphorylation and activity (Chughtai et al., 2002). In contrast, SHP-2 may be 
responsible for tyrosine dephosphorylation of STAT5 in the cytosolic compartment 
(Yu et al., 2000). 
 
 
 
 
Figure 7: Schematic overview of the negative regulation of cytokine signalling. 
For detailed information, see text. 
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Others - Genetic and biochemical approaches have implicated several other 
phosphatases in the inhibition of JAK kinase activity, including CD45 (Irie-Sasaki et 
al., 2001), PTPεC (Tanuma et al., 2000) and PTP1B (Elchebly et al., 1999; Myers et 
al., 2001).  Similar approaches have underscored a role for SHP-2, PTP1B, TC45 
and PTP-basophile like (PTP-BL) in STAT dephosphorylation (Aoki and Matsuda, 
2000; Kerscher et al., 2006; Lund et al., 2005; Mustelin et al., 2005; Nakahira et al., 
2007; ten Hoeve et al., 2002), which appears to be critical for STAT nuclear export 
(McBride and Reich, 2003; Vinkemeier, 2004). 
 
 
IV. PIAS proteins 
 
The Protein inhibitors of activated STAT (PIAS) protein family consists of four 
members; PIAS1, PIAS2 (also referred to as PIASx), PIAS3 and PIAS4 (also 
referred to as PIASy) (Shuai and Liu, 2005). Except for PIAS1, two isoforms were 
identified for each PIAS protein. These proteins have a central Zn-binding RING-
finger domain, a conserved SAP (SAF-A/Acinus/PIAS) domain at the N-terminus, 
and a less conserved C-terminal part.  The latter domains are involved in substrate 
binding. PIAS proteins bind to activated STAT dimers and prevent them from 
binding DNA.  STAT1 and STAT3 are specifically inhibited by respectively PIAS1 
and PIAS3 (Chung et al., 1997; Liu et al., 1998).  Yet, PIAS2 and PIAS4 recruit 
additional co-repressing factors to inhibit the STAT transcriptional activity of 
respectively STAT4 and STAT1 (Arora et al., 2003; Liu et al., 2001).  Furthermore, 
PIAS proteins have been shown to function as E3 type SUMO ligases that 
conjugate SUMO moieties to target proteins (Jackson, 2001). Although there is 
evidence that STATs can be modified by sumoylation (Rogers et al., 2003; Schmidt 
and Muller, 2003), the function of that modification in negative regulation is not yet 
clear.     
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CHAPTER 3:  The SOCS protein family  
 
 
SOCS are a family of intracellular proteins that play a major role in the regulation of 
cytokine responses. The founding member of the SOCS family, the cytokine-
inducible SH2 domain containing (CIS) protein, was cloned in 1995 and was 
originally identified as an immediate early response gene induced in haematopoietic 
cells in response to Epo or IL-3 (Yoshimura et al., 1995).  Following that report, 
SOCS1 was identified by three different groups in 1997 as a novel JAK regulatory 
protein (Endo et al., 1997; Naka et al., 1997; Starr et al., 1997). Database searches 
led to the identification and cloning of 6 additional SOCS proteins based on 
sequence homology (Hilton et al., 1998; Masuhara et al., 1997; Starr et al., 1997).  
So at present, the SOCS family counts eight members: CIS and SOCS1 through 
SOCS7.   
 
I. Expression of SOCS proteins 
 
SOCS proteins are often expressed at low or undetectable levels in resting cells.  
They are rapidly up-regulated in response to a broad spectrum of cytokines and, in 
turn, control the duration and intensity of cytokine responses by blocking various 
aspects of the signalling pathways. SOCS proteins function in a typical negative 
feedback loop, since they can down-modulate the signalling pathway that stimulates 
their production.  The pattern of SOCS expression by a particular cytokine tends to 
vary according to the cell type or tissue. The induced SOCS proteins can attenuate 
responses of various cytokines and may be involved in inhibitory cross-talk between 
different cytokine systems, providing a mechanism by which concurrent signalling 
processes can modulate each other. An overview of SOCS induction patterns and 
inhibition of cytokine signalling is given in table 6. Although SOCS proteins are 
induced by a range of cytokines and show a high structural and functional overlap, 
large evidence indicates the potential of specific SOCS proteins to modulate 
cytokine signalling with exquisite control. The SOCS expression is tightly regulated 
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through multiple mechanisms in order to avoid inappropriate interference with 
physiological responses (reviewed in chapter 11).   
 
Table 6: SOCS induction, inhibition patterns and cross-regulation 
 
SOCS induced by inhibits signal transduction of
CIS Leptin, Epo, GH, PRL, LIF, G-CSF, GM-CSF, Leptin, Epo, GH, PRL, IGF1, G-CSF, IL-2, IL-3
TPO, CNTF, IFNα, IFNγ, IL-1, IL-2, IL-3, IL-4,
IL-6, IL-9, IL-12, IL-13
SOCS1 Leptin, Epo, GH, PRL, LIF, insulin, G-CSF, GM-CSFLeptin, Epo, GH, LIF, PRL, Epo, Insulin, TNFα, 
CNTF, IFNα/β, IFNγ, IL-2, IL-3, IL-4, IL-6, OSM, TPO, IGF1, IFNα/β, IFNγ, IL-2, IL-4, 
IL-13, LPS, CpG DNA IL-6, IL-7, IL-12, IL-15
SOCS2 Leptin, GH, PRL, Insulin, Estrogen, EPO, CNTF, Leptin, GH, PRL, LIF, IFNγ, IGF1, EGF, IL-6
G-CSF, GM-CSF, TNFα, LIF, IFNα, IFNγ, IL-1,  
IL-2, IL-3, IL-4, IL-6, IL-9, IL-10, Lipoxins
SOCS3 Leptin, Epo, GH, PRL, Insulin, GM-CSF, M-CSF,  Leptin, Epo, GH, PRL, OSM, CNTF, IGF1, 
G-CSF, CNTF, TPO, TNFα, LIF, IFNα, IFNγ, IL-1, Insulin, LIF, IFNα/β, IFNγ, IL-2, IL-3, IL-4, 
IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-10, IL-11, IL-6, IL-9, IL-11
IL-12, IL-13, LPS, CpG DNA
SOCS4 EGF EGF 
SOCS5 EGF, IL-6 EGF, LIF, IL-4, IL-6
SOCS6 Insulin, Kit Leptin, Insulin, Kit
SOCS7 GH, PRL, Insulin, IL-6, IFNγ, IL-1β Leptin, GH, PRL, Insulin
 
 
SOCS can be induced by stimuli other than cytokines,  including growth factors, 
chemokines,  hormones, pathogens and their products such as CpG DNA or LPS 
(Baetz et al., 2004; Crespo et al., 2000; Dalpke et al., 2001; Dogusan et al., 2000; 
Krebs and Hilton, 2003; Leong et al., 2004; Stoiber et al., 1999). SOCS expression 
was also found to be developmentally regulated in the absence of cytokine 
signalling (Ilangumaran et al., 2004; Kubo et al., 2003).  
 
STAT proteins are the major regulators of SOCS gene expression. STAT binding 
sequences were identified in the SOCS promoter region and electrophoretic mobility 
shift assays confirmed STAT association to these motifs (table 7). In some cases, 
STAT induced SOCS expression is indirect.  STAT1 is for example indirectly 
implicated in IFNγ mediated upregulaton of SOCS1 since it drives expression of the 
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interferon regulatory factor-1 (IRF-1) transcription factor which is responsible for 
SOCS1 induction (Saito et al., 2000). 
 
Table 7: STAT-responsive elements in SOCS promotors 
 
 STAT binding elements references 
CIS STAT5 (Matsumoto et al., 1997) 
 
SOCS1 STAT1, STAT3, STAT6 (Naka et al., 1997; Saito et al., 2000) 
 
SOCS2 STAT5 (Vidal et al., 2007) 
 
SOCS3 STAT1, STAT3, STAT5 (Auernhammer et al., 1999; Davey et al., 1999; 
Emanuelli et al., 2000; Gatto et al., 2004) 
 
SOCS proteins not only control kinetics and magnitude of signalling but can also be 
involved in the shaping of the cytokine responses.  For example, SOCS3 regulates 
both the quantity and type of STAT signalling generated from the pro-inflammatory 
IL-6R.  Loss of SOCS3 will alter the functional outcome of IL-6 signalling by 
prolonging STAT activation.  IL-6 then behaves more like the immunosuppressive 
cytokine IL-10 and induces IFN gene expression owing to respectively an excess of 
STAT3 and STAT1 phosporylation (see below) (Croker et al., 2003; Lang et al., 
2003; Yasukawa et al., 2003).   
 
 
II. SOCS protein structure and molecular mechanisms of action 
 
Comparative sequence analysis of the SOCS members revealed that CIS and 
SOCS2, SOCS1 and -3, SOCS4 and -5 and finally SOCS6 and -7 form closely 
related pairs (Hilton et al., 1998).  CIS and SOCS2 are the most related with around 
35% of AA identity while the rest of SOCS pairs share approximately 25% of AA 
sequences.  SOCS homologues were also identified in D. melanogaster and C. 
elegans (Kile et al., 2002; Starr et al., 1997).  The general structure of SOCS 
proteins is evolutionary well preserved and common features include an N-terminal 
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pre-SH2 domain, a central SH2 domain and a C-terminal SOCS box (figure 8). The 
N-terminal part varies in length and sequence similarity while the SH2 domain and 
SOCS box are most conserved.   
 
 
 
 
 
Figure 8: Domain structure of the SOCS protein family 
The major structural characteristic of the SOCS family is the presence of two domains with 
relatively well conserved AA sequence: an SH2 domain in the middle portion and a SOCS 
box at the C-terminus. Only SOCS1 and -3 possess a KIR immediately upstream of the 
SH2 domain. Conserved tyrosines in the SOCS box are represented by a black line. 
 
 
The N-terminal domain: JAK kinase inhibition. 
The N-terminus varies greatly in length among the SOCS members and contains no 
homology to known structural domains. Nevertheless, an extended SH2 subdomain 
(ESS) helix was identified as a conserved structural element in CIS and SOCS1-3 
and appeared to be critical for high affinity SH2 substrate interactions (Yasukawa et 
al., 1999).  Both SOCS1 and 3 can be distinguished from the other SOCS proteins 
by an additional small kinase inhibitory region (KIR) of 12 AA located in the N-
terminal portion and involved in inhibition of the JAK kinases.  This region was found 
functionally interchangeable between the two SOCS suggesting a common 
inhibitory mechanism (Nicholson et al., 1999).  The KIR region displays some 
sequence similarity with the activation loop of JAK2, suggesting that it acts as a 
pseudosubstrate by mimicking the activation loop that regulates access to the 
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Figure 9: Schematic representation of molecular mechanisms of SOCS actions 
 
catalytic groove (Yasukawa et al., 1999). Based on a structural model of SOCS1 in 
complex with JAK2 it was proposed that the KIR region suppresses JAK activity by 
obstructing the access of both ATP and substrate to their respective binding sites 
(Giordanetto and Kroemer, 2003). Although the SH2 domain of SOCS3 does not 
have a high affinity for JAK kinases, the KIR domain of SOCS3 shows a stronger 
potential for both binding and inhibition of JAKs than that of SOCS1 (figure 9) 
(Sasaki et al., 1999). The wide range of actions exhibited by SOCS1 and SOCS3 is 
most probably due to their additional ability to inhibit the catalytic activity of JAK 
kinases. 
Chapter 3: The SOCS protein family 
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The SH2 domain: substrate specificity and competition for receptor motifs. 
The central SH2 domain determines the target of the SOCS protein.  It allows 
interaction with phosphorylated tyrosine residues of other proteins, like receptors, 
JAKs or adaptors. This way, SOCS proteins can exert their inhibitory effects by 
competing with other signalling molecules including STATs for phosphorylated 
tyrosine motifs in the receptor complex. Because of direct association and steric 
hindrance by the SOCS molecules, the docking sites then become inaccessible for 
other signal transductors (figure 9).  
SOCS1 directly interacts with all JAK members, thereby inhibiting their catalytic 
activity (Endo et al., 1997; Naka et al., 1997; Nicholson et al., 1999). It targets the 
phosphotyrosine at position Y1007, which lies within the activation loop of JAK2 
(Giordanetto and Kroemer, 2003; Yasukawa et al., 1999).  Activation of the kinase is 
dependent on phosphorylation of this particular tyrosine. The SOCS1 SH2 domain is 
sufficient for JAK2 interaction. However, as mentioned above, an additional region 
of approximately 30 residues immediately N-terminal to the SH2 domain (the ESS) 
and the KIR are additionally required for high affinity binding and inhibition of JAK2 
activity (Giordanetto and Kroemer, 2003; Yasukawa et al., 1999).  Remarkably, 
SOCS1 has also been shown to bind directly to the type I and type II IFN receptors, 
which might provide a very efficient inhibitory effect of SOCS1 on IFN signalling 
(Fenner et al., 2006; Qing et al., 2005).  SOCS3 showed only weak affinity for JAK2 
itself and it is proposed to bind with phosphotyrosine motifs in the receptor close to 
the kinase to inhibit its activity through the KIR domain (Suzuki et al., 1998). High 
affinity interaction of SOCS3 was demonstrated for gp130 (Nicholson et al., 2000) 
and other related receptors (Bjorbaek et al., 2000; Eyckerman et al., 2000; Hortner 
et al., 2002; Ram and Waxman, 1999; Yamamoto et al., 2003). NMR and crystal 
structures of SOCS3 with a bound gp130 phosphotyrosine peptide showed the 
importance of the residue at position Y+3 (Babon et al., 2006; Bergamin et al., 
2006). While residues at positions Y+1 and Y+2 are solvent exposed, the 
hydrophobic character of the pocket residue is conserved in all SOCS proteins, 
suggesting a similar hydrophobic pocket. An overview of the reported 
phosphotyrosine binding preferences of the SH2 domains of SOCS1 and SOCS3 is 
given in table 8. The SH2 domains of SOCS2 and CIS are reported to interact 
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primarily with phosphotyrosines of receptors such as the EpoR or the GHR, of which 
several are known to be STAT recruitment sites (Ram and Waxman, 1999; Verdier 
et al., 1998). 
 
Table 8:  Phosphotyrosine binding preferences of SOCS1 and SOCS3 
               (Φ = hydrophobic) 
 
 -2 -1 Y(p) +1 +2 +3 +4 +5 references 
SOCS1  E Y    K E (Giordanetto and Kroemer, 
2003) 
  Y S/A/V/Y/F Φ V/I/L Φ H/V/I/Y (De Souza et al., 2002) 
V E Y   V V H (Bergamin et al., 2006) 
SOCS3 
V  Y   V V  (Babon et al., 2006) 
 
 
The SOCS box: proteasomal targeting and protein stability 
As mentioned before, the C-terminal SOCS box is conserved throughout the SOCS 
family, thus suggesting an important role for this region in the function and 
regulation of SOCS proteins.  Different SOCS box containing protein families have 
been identified. Instead of possessing SH2 domains they contain other protein-
protein interacting motifs, such as ankyrin repeats, SPRY domains or WD40 repeats 
(Hilton et al., 1998).  Clues to understand the function of the SOCS box came from 
the initial finding that the Von Hippel-Lindau (VHL) tumor suppressor protein 
interacts with its Elongin B/C complex via the SOCS box, linking VHL to the 
ubiquitin/proteasome degradation system (figure 9) (Iwai et al., 1999; Kibel et al., 
1995).  The Elongin B/C-Cullin-SOCS box (ECS) complex was characterized as a 
family of E3 ubiquitin ligases in which the SOCS box protein acts as the substrate 
recognition unit of the complex (Kile et al., 2002). The SOCS box domain of these 
proteins mediates the interaction with Elongin C by the B/C box, a 
xxLxxxCxxx(A/I/L/V) conserved sequence (Aso et al., 1996; Duan et al., 1995; 
Kamura et al., 1998; Kibel et al., 1995). Recently, the B/C box was characterized as 
a (S,T,P,L)xxx(C,S,A)xxxΦ sequence (Mahrour et al., 2008). Elongin B binds 
Elongin C and this dimer acts as a linker that bridges the substrate recognized by 
the SOCS box protein to a Cullin scaffold protein. This association with a Cullin 
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protein will further be supported by a conserved Cullin box motif, located 
downstream of the B/C box in the SOCS box (Kamura et al., 2004). Cullin in turns 
recruits a RING finger-containing protein Rbx, thereby completing the assembly of 
the E3 ligase complex (figure 10) (Iwai et al., 1999; Pause et al., 1997).   
 
 
 
                                  
           Figure 10: Model for proteasomal target degradation by SOCS proteins     
 
 
VHL and SOCS1 were shown to interact with a Cul2-Rbx1 module, whereas the 
other SOCS proteins associate with a Cul5-Rbx2 complex (Kamizono et al., 2001; 
Kamura et al., 1999).The Cul2 box and Cul5 box were defined as key determinants 
of the association between Elongin B/C binding proteins and a specific Cullin-Rbx 
module. The Cul5 box corresponds to the C-terminal portion of the canonical SOCS 
box and has the consensus sequence ΦxxLPΦPxxΦxx(Y/F)(L/I), where the central  
LPΦP is particularly important for Cullin5 binding (Hilton et al., 1998; Kamura et al., 
2004; Mahrour et al., 2008). Recently, the consensus sequence for the Cul2 box 
was defined as a ΦPxxΦxxxΦ motif, sharing some sequence similarity with the Cul5 
box (Mahrour et al., 2008).            
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Figure 11: Model for the assembly of SOCS2-Elongin C-Elongin B into an E3 
ubiquitin ligase complex (from (Bullock et al., 2006)). 
 
Together with an E1 ubiquitin activating enzyme and the E2 conjugating enzyme, 
the E3 ubiquitin ligase participates in the polyubiquitin tagging of associated 
proteins and is responsible for substrate specificity (figure 11) (Glickman and 
Ciechanover, 2002). This way, SOCS box proteins may suppress signalling by 
linking associated signalling components for degradation (Kamura et al., 2001). 
Consistent with this idea, proteasomal inhibitors block the inhibitory functions of 
SOCS and induce sustained JAK-STAT signalling (Callus and Mathey-Prevot, 1998; 
Kim and Maniatis, 1996; Verdier et al., 1998; Yu and Burakoff, 1997). The functional 
importance of the SOCS box was confirmed by the generation of transgenic mice 
expressing a C-terminal truncated variant of SOCS1 or SOCS3. These mice exhibit 
impaired regulation of respectively INFγ and G-CSF signalling, suggesting that the 
SOCS box is essential for complete SOCS activity (Boyle et al., 2007; Zhang et al., 
2001).   
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In this thesis, we studied the multiple roles of the SOCS box. Other functions of this 
domain are: (i) the control of protein stability, (ii) an adaptor function linking SOCS to 
other signalling pathways like the MAPK pathway, (iii) an implication in SOCS cross-
regulation (chapter 9) and (iv) regulation of receptor interaction (chapter 10). 
Considering the different characteristics and functions of the SOCS box, a complex 
biological role for this domain emerges which is the focus of a review (chapter 11). 
 
III. Posttranslational modification of SOCS proteins 
 
Ubiquitination of CIS and SOCS3 was reported (Sasaki et al., 2003; Verdier et al., 
1998), as well as phosphorylation of SOCS1 and SOCS3 (see table 9 for overview). 
One of the tyrosines phosphorylated in the SOCS box of SOCS3 is highly 
conserved in all SOCS family members. It will thus be important to determine 
whether other SOCS proteins can also be regulated as a result of phosphorylation. 
 
Table 9: Phosphorylation of SOCS proteins 
 
 phosphorylation 
sites 
kinase/stimulus effect references 
Ser/Thr in the N-
terminus  
PIM kinase  
 
stabilisation of SOCS1  
 
(Chen et al., 2002) SOCS1 
Ser/Thr PIM kinase potentiates STAT5 
inhibition (through 
SOCS1 stabilisation?) 
(Peltola et al., 2004) 
 
Tyr204 and 221 in 
the SOCS box  
 
JAK kinase 
 
disrupts Elongin 
interaction and 
destabilises SOCS3   
(Haan et al., 2003) 
Tyr204 and 221 in 
the SOCS box  
JAK and Src kinases, 
RTKs  (in response to IL-
2, EPO, EGF, PDGF) 
maintains activation of 
ERK-MAPK  
(Cacalano et al., 
2001) 
 
Tyr 
 
JAK kinase (in response 
to IL-2) 
 (Cohney et al., 1999) 
 
Tyr 
 
JAK kinase (in response 
to insulin) 
 (Peraldi et al., 2001) 
 
Tyr221 in the 
SOCS box  
RTK (in response to 
PDGFR) 
interacts with and 
regulates  Nck and 
Crk-L adaptors 
(Sitko et al., 2004) 
SOCS3 
Ser/Thr 
 
PIM kinase potentiates STAT5 
inhibition (through 
SOCS1 stabilisation?) 
(Peltola et al., 2004) 
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IV. Structural determination of SOCS proteins 
 
The first SOCS structure to be resolved was that of SOCS3 (lacking the first 21 AA 
and the SOCS box) in complex with a phosphotyrosine peptide from the gp130 
chain (Babon et al., 2006).  This structure revealed the basis for an extended SH2 
domain that provides an interaction interface for phosphotyrosine motifs. Also an 
unstructured PEST (proline-, glutamic acid-, serine and threonine rich) motif in the 
SH2 domain was identified that negatively regulates SOCS3 protein stability (Babon 
et al., 2006).  
 
 
 
 
Figure 12: Alternative domain organisation in the SOCS2 and -4 ternary complexes 
Comparison of the SOCS2-ElonginB/C and SOCS4-ElonginB/C structures highlighting the 
switch in packing between the SOCS2/SOCS4 C-terminus and the N-terminal ESS helix 
(from (Bullock et al., 2006; Bullock et al., 2007)). 
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The crystal structures of the ternary complexes of SOCS2 and SOCS4 with Elongin 
B/C revealed a common tripartite domain structure for SOCS proteins with an N-
terminal ESS helix that stabilizes the central SH2 domain and a C-terminal SOCS 
box that mediates  a conserved four helix bundle interaction with Elongin C (figure 
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12).  Nonetheless, two distinct SOCS subclasses were defined that each make 
alternative use of N- and C-terminal structures to stabilise the SH2-SOCS box 
interdomain interface (Bullock et al., 2006; Bullock et al., 2007). 
 
Based on the structural information of SOCS2, it was proposed that in SOCS1-3 
and CIS the C-terminus is buried in the core of the structure where it stabilizes the 
interaction between the SH2 domain and the SOCS box. This packing partially 
exposes the N-terminal ESS providing better accessibility for the SOCS1 and 
SOCS3 KIR domain. Evidently, this domain organization precludes C-terminal 
extensions and explains the strictly conserved length of the C-terminal parts in CIS 
and SOCS1-3 (Bullock et al., 2006). In contrast, the SOCS4-7 subclass contains 
extended C-termini and there the N-terminal ESS helix is buried in the SOCS box 
and SH2 interface to fulfil an equivalent packing role as could be demonstrated in 
the SOCS4 structure.  The function of the C-terminus is then redefined to stabilize 
an interface with the N-terminal domain (Bullock et al., 2007). 
As a result of the apparent structural and functional interdependence of the different 
SOCS domains, studies using domain deletions or mutations of core positions in the 
interface have to be interpreted with caution as these may lead to a loss of structural 
integrity. However, structural alterations can act as a physiological control 
mechanism used to regulate the activity and interplay between SOCS family 
members.  Phosphorylation of the SOCS3 C-terminus will for example prevent its 
core interaction resulting in loss of Elongin C binding and proteasomal degradation 
(Haan et al., 2003).  In the same line, Elongin B/C association to CIS has a 
structural impact on SH2 functionality as disruption of this interaction can lead to 
loss of receptor binding (chapter 10). 
 
 
V. The physiology of SOCS functions 
 
In vitro studies reveal the potential of SOCS family members to inhibit multiple 
cytokine induced signalling pathways.  Studies based on ectopic expression of 
SOCS have provided valuable insights into the mechanisms of SOCS functions.  
But as they rely on overexpression, these studies may overestimate the range of 
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SOCS actions and have to be interpreted in function of physiological expression 
levels. Therefore, gene targeting analyses have been used in order to elucidate the 
physiological actions of SOCS proteins (table 10).  Studies in transgenic mice 
revealed that SOCS have essential roles in the regulation of various cytokines and 
exert more specific actions than those expected from overexpression studies in vitro 
(Greenhalgh and Alexander, 2004). Of note, loss-of-function studies can only 
identify the non-redundant functions of each SOCS protein. It will be interesting to 
explore whether SOCS have overlapping actions that are not revealed by mice 
lacking single SOCS genes.  
 
SOCS1 
In vitro studies implicated SOCS1 in the inhibition of multiple signalling systems 
including GH, Epo, PRL, IL-6, IFNα/β, IFNγ and IL-4 (Adams et al., 1998; Dif et al., 
2001; Hansen et al., 1999; Song and Shuai, 1998).  The potent inhibition and wide 
range of action exhibited by SOCS1 is most probably due to its ability to inhibit the 
catalytic activity of JAK kinases. Moreover, SOCS1 induces the ubiquitination and 
destruction of VAV, JAK2 and the TEL-JAK2 oncogene in a SOCS box dependent 
fashion (De Sepulveda et al., 2000; Frantsve et al., 2001; Kamizono et al., 2001; 
Ungureanu et al., 2002). Regulation of NF-κB by ubiquitin-mediated proteolysis of its 
p65/RelA subunit was also found to be facilitated by SOCS1 (Ryo et al., 2003). 
Furthermore, SOCS1 (and SOCS3) can promote destruction of Insulin Receptor 
Substrate (IRS) 1 or IRS2 and focal adhesion kinase (FAK), inhibiting respectively 
insulin- and FAK-dependent signalling events (Liu et al., 2003; Rui et al., 2002). 
Despite these observations, in vitro studies have generally failed to prove a 
requirement of the SOCS box for the inhibitory functions of SOCS1 (Narazaki et al., 
1998; Nicholson et al., 1999; Yasukawa et al., 1999). Nevertheless, a clear 
contribution of this domain was found for the inhibition of in vivo cytokine action. 
Mice expressing a C-terminal truncated variant of SOCS1 were hyper-responsive to 
IFNγ and died prematurely due to an inflammatory disease similar to, but less 
severe than the pathology SOCS1-/- mice (Zhang et al., 2001). This demonstrates 
that the SOCS box is required for optimal functioning. 
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SOCS1 knock-out mice die within three weeks after birth with a phenotype 
characterized by stunted growth, fatty degeneration of the liver, severe 
lymphopenia, monocytic infiltration of major organs and peripheral T cell activation 
(Naka et al., 1998; Starr et al., 1998).  These multiple deregulations of the immune 
system were attributed to uncontrolled IFNγ signalling caused by constitutive 
activation of STAT1.  In support of this, the complex disease in SOCS1-/- mice was 
prevented by administration of neutralizing anti-IFNγ antibodies and did not occur in 
double knock-out mice also lacking the IFNγ gene (Alexander et al., 1999; Marine et 
al., 1999b). Anyway, SOCS1 is not restricted to IFNγ actions, as studies in the 
combined SOCS1-/-IFNγ-/-  double knock-out mice revealed lethality at later stages 
due to a range of inflammatory diseases (Metcalf et al., 2002). Indeed, SOCS1 
deficient mice also lacking STAT6 or STAT4 that are downstream effectors of IL-4 
or IL-12 signalling, respectively, are rescued from neonatal lethality (Eyles et al., 
2002; Naka et al., 2001), suggesting that SOCS1 affects not only IFNγ but also IL-4 
and IL-12 signalling in vivo.  Further studies of SOCS1-/- mice revealed that SOCS1 
regulates signals of TNFα, LPS and insulin (Kawazoe et al., 2001; Kinjyo et al., 
2002; Morita et al., 2000; Nakagawa et al., 2002). SOCS1 conditional knock-out 
mice demonstrated an inhibitory role for SOCS1 on γc cytokines, such as IL-2 or IL-
7 (Chong et al., 2003; Cornish et al., 2003). SOCS1 transgenic mice are 
characterized by defective thymocyte development and perturbed homeostasis of T 
cells (Fujimoto et al., 2000). 
 
SOCS3 
Although SOCS3 is structurally similar to SOCS1, the mechanisms by which these 
two molecules negatively regulate signalling differ in more than one aspect.  
Whereas SOCS1 blocks signalling by binding directly to JAK kinases, SOCS3 
adequately inhibits activation of JAKs only when bound in close proximity to the 
kinase. Membrane proximal association of SOCS3 was found for different cytokine 
receptors including gp130, LR, EpoR, LIFR, IL-6R, IL-12R and GHR (Bjorbaek et 
al., 2000; Eyckerman et al., 2000; Hortner et al., 2002; Lehmann et al., 2003; Ram 
and Waxman, 1999; Sasaki et al., 2000; Yamamoto et al., 2003). SOCS3 was also 
found to promote degradation of target proteins like IRS adaptors, FAK kinase and 
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Siglec receptors (Liu et al., 2003; Orr et al., 2007a; Orr et al., 2007b; Rui et al., 
2002).  Deletion of the SOCS box of SOCS3 in transgenic mice leads to impaired 
regulation of G-CSF signalling and response to inflammatory stimuli, establishing a 
role for the SOCS box in the in vivo actions of SOCS3 (Boyle et al., 2007). 
 
Table 10: Overview of the phenotypes of SOCS knock-out and transgenic mice 
SOCS knock-out phenotype transgenic phenotype references
SOCS1 neonathal lethality due to severe defects in T cell development Naka et al., 1998
defects in immune system Starr et al., 1998
Fujimoto et al., 2000
SOCS3 embryonic lethality due to embryonic lethality due to defective Marine et al., 1999a
placental insufficiency foetal liver erythropoiesis Roberts et al., 2001
Takahashi et al., 2003
CIS no defects defective in growth, immune responses Marine et al., 1999a
and mammary gland development Matsumoto et al., 1999
SOCS2 excessive growth excessive growth Metcalf et al., 2000
Greenhalgh et al., 2002b
SOCS4 not reported not reported
SOCS5 no defects altered Th1/Th2 cell balance Seki et al., 2002
Brender et al., 2004
SOCS6 mild growth retardation improved insulin and glucose tolerance Krebs et al., 2002
Li et al., 2004
SOCS7 high lethality due to hydrocephalus not reported Krebs et al., 2004
 
 
Both SOCS3 knock-out mice and transgenic mice die in utero.  Lack of SOCS3 
results in placental insufficiencies caused by uncontrolled LIF signalling, while 
SOCS3 overexpression results in defective foetal liver erythropoiesis (Marine et al., 
1999a; Roberts et al., 2001; Takahashi et al., 2003). Studies in conditional SOCS3 
knock-out mice demonstrated that SOCS3 is an important negative regulator of G-
CSF (Croker et al., 2004; Kimura et al., 2004) and IL-6 (Croker et al., 2003; Lang et 
al., 2003; Yasukawa et al., 2003).  As mentioned before, SOCS3 not only controls 
the magnitude of IL-6 signalling but also shapes its responses. Upon deletion of 
SOCS3 in macrophages IL-6 loses its pro-inflammatory function but elicits STAT3-
mediated immunosuppressive actions, similar to IL-10 (Yasukawa et al., 2003). 
Furthermore, IL-6 also strongly activates STAT1, thereby inducing the expression of 
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IFN-responsive genes in these SOCS3 deficient macrophages (Croker et al., 2003; 
Lang et al., 2003). Together, these data suggest that SOCS3 is a negative regulator 
of the gp130 family of cytokine receptors in vivo. Essential roles for SOCS3 in the 
endocrine system like in leptin and insulin signalling have also been identified 
(Bjorbaek et al., 1998; Emanuelli et al., 2000). Consequently, SOCS3 was reported 
to be involved in leptin and insulin resistance associated with respectively obesity 
and type II diabetis (see below) (Howard et al., 2004; Mori et al., 2004; Ueki et al., 
2004). 
 
CIS 
CIS is induced by cytokines that activate STAT5, such as Epo, GH, PRL, IL-2 and 
IL-3 and was reported to subsequently suppress these particular signalling 
cascades by masking the STAT5 binding sites in their receptors (Aman et al., 1999; 
Dif et al., 2001; Endo et al., 2003; Hansen et al., 1996; Matsumoto et al., 1997; Ram 
and Waxman, 1999; Verdier et al., 1998; Yoshimura et al., 1995). Based on the 
non-overlapping binding pattern, direct competition of CIS with STAT5 for common 
phosphotyrosine binding sites was recently excluded for the GHR (Uyttendaele et 
al., 2007). Also at the G-CSFR CIS does not compete with STAT5 for binding to 
receptor motifs, reflecting a reliance on other inhibitory mechanisms.  Indeed, CIS 
association was found to induce proteasome-dependent degradation of the EpoR 
and GHR and in the latter case, CIS also was reported to play a role in GHR 
internalization (Landsman and Waxman, 2005; Ram and Waxman, 2000; Verdier et 
al., 1998).   
 
Mice deficient for CIS expression are phenotypically normal, perhaps due to 
functional compensation by other SOCS proteins (Marine et al., 1999a).  CIS 
transgenic mice exhibit growth retardation, impaired mammary gland development 
and immune defects like reduced numbers of natural killer (NK) and NK T cells 
(Matsumoto et al., 1999).  These phenotypes are remarkably similar to those 
observed in STAT5a and/or STAT5b knock-out mice, lending support for CIS as a 
specific negative regulator of STAT5-mediated cytokine signalling (Matsumoto et al., 
1999; Teglund et al., 1998).  
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SOCS2 
The mechanism by which SOCS2 exerts its regulatory functions remains more 
elusive.  SOCS2 can probably attenuate signalling in a similar way as CIS, involving 
competition at receptor sites.  Interaction of SOCS2 with phosphotyrosine motifs on 
the GHR, PRLR, EGFR, EpoR and LR has been reported (Eyckerman et al., 2001; 
Goldshmit et al., 2004; Greenhalgh et al., 2005; Lavens et al., 2006; Pezet et al., 
1999).  Receptor association of CIS and SOCS2 are studied in more detail in part II. 
SOCS2 might act as an ubiquitin ligase as the SOCS box of SOCS2 appeared to be 
crucial for the negative regulation of GH signalling (Greenhalgh et al., 2005).  
Furthermore, the solving of the SOCS2-Elongin B/C crystal structure revealed a 
prototypical SOCS box ubiquitin ligase architecture (Bullock et al., 2006), further 
supporting a role for SOCS2 in E3 ligase activity.   
Initial in vitro studies reported a dual effect of SOCS2 in GH signalling: low SOCS2 
concentrations moderately inhibit GH signalling while higher levels positively 
regulate signalling by blocking the inhibitory effects of other SOCS proteins (Favre 
et al., 1999).  Interference of SOCS2 with other SOCS proteins was observed in 
several cytokine receptor systems including PRL (Dif et al., 2001; Pezet et al., 
1999), IL-2 and IL-3 (Tannahill et al., 2005), IFN type I and leptin signalling (Lavens 
et al., 2006; Piessevaux et al., 2006).  A positive role for SOCS2 was also proposed 
in mesenchymal precursor cells where it could potentiate osteoblast differentiation 
through upregulation of JunB expression, possibly through its negative effect on 
other SOCS proteins (Ouyang et al., 2006).  While SOCS1 and SOCS3 are typically 
induced in a rapid and transient manner upon receptor activation, expression of 
SOCS2 usually occurs later after cytokine stimulation and is more prolonged 
(Adams et al., 1998; Brender et al., 2001; Pezet et al., 1999; Rico-Bautista et al., 
2004; Tannahill et al., 2005; Tollet-Egnell et al., 1999).  This is in line with the cross-
regulatory potential of SOCS2 that can downregulate expression of other SOCS 
molecules and restore cellular sensitivity (discussed in chapter 9).  
 
Mice lacking SOCS2 exhibit gigantism associated with increases in bone and body 
length and enhanced weight of organs and carcass (Metcalf et al., 2000). This 
phenotype is due to prolonged STAT5 signalling in response to GH stimulation 
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(Greenhalgh et al., 2002a).  SOCS2-/-STAT5b-/- double knock-out mice showed 
normal growth (Greenhalgh et al., 2002a), suggesting that SOCS2 is involved in 
negative regulation of the GH signalling pathway. SOCS2 transgenic mice also grew 
significantly larger than their wild type littermates, further supporting a dual role for 
SOCS2 (Greenhalgh et al., 2002b). 
 
 
SOCS4  
 
The remaining SOCS members, SOCS4-SOCS7, which represent the direct 
orthologs of ancestral SOCS family members, have been poorly examined.  
Especially about SOCS4 very little is known concerning expression and molecular 
mode of action.  It was reported that Mycobacterium tuberculosis infection in mice is 
correlated with augmented levels of type IFNs, SOCS4 (and SOCS5) (Manca et al., 
2005), suggesting a role in immunity. SOCS4 (and its closest homolog SOCS5) are 
upregulated upon epidermal growth factor (EGF) stimulation and markedly reduce 
EGFR levels thereby inhibiting the mitogenic signalling (Kario et al., 2005). The 
STAT3 binding site in EGFR was identified as a high affinity SOCS4 substrate and 
the structural resolution of the SOCS4-Elongin B/C complex defined a molecular 
basis for SOCS mediated EGFR degradation (Bullock et al., 2007).  No SOCS4 
knock-out or transgenic mice are reported, leaving the biological role of this SOCS 
member unclear. 
 
SOCS5 
SOCS5 is expressed in many tissues and especially in hematopoietic tissues 
(Magrangeas et al., 2000).  As mentioned above SOCS5 is induced upon EGF 
stimulation and subsequently promotes SOCS box dependent turnover of EGFR 
(Kario et al., 2005; Nicholson et al., 2005). Accordingly, the Drosophila SOCS36E, 
highly similar to mammalian SOCS5, was found to temper EGF responses  (Callus 
and Mathey-Prevot, 2002). SOCS5 was also demonstrated to mildly suppress IL-6 
and LIF-induced signalling (Nicholson et al., 1999) and to promote Th1 
differentiation by inhibiting STAT6 dependent IL-4 signalling (Seki et al., 2002).  
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Accordingly, T cells from transgenic mice constitutively expressing SOCS5 exhibited 
a significant reduction of IL-4 mediated Th2 development. Unexpectedly, no 
abnormalities in Th1/Th2 differentiation were found in SOCS5 deficient T cells and 
SOCS5 knock-out mice showed normal susceptibility to pathogen infections 
(Brender et al., 2004). This may be explained by SOCS5 being compensated for by 
other SOCS proteins such as SOCS4, as SOCS4 shares significant identity with 
SOCS5.  Analyses of SOCS4-/-SOCS5-/- double knockout mice will be required to 
address the function of SOCS5 in vivo. 
 
SOCS6  
SOCS6 is induced by insulin and subsequently interacts with the insulin receptor (Li 
et al., 2004; Mooney et al., 2001).  This association may occur indirectly since 
SOCS6 binding with signal transductors including IRS-2, IRS-4 and the p85 
regulatory subunit of PI-3K, was reported in response to insulin stimulation (as well 
as IGF-1 stimulation) (Krebs et al., 2002).  SOCS6 expression can also be 
upregulated by stem cell factor (SCF) and the interaction of SOCS6 with the KIT 
receptor upon SCF stimulation was shown to affect upstream signalling components 
leading to MAPK activation (Bayle et al., 2004).  After insulin or SCF stimulation, an 
inhibitory effect is observed on ERK1/2 stimulation but not on Akt activation (Bayle 
et al., 2004; Li et al., 2004; Mooney et al., 2001). SOCS6 may even have a positive 
effect on activation of Akt upon insulin stimulation, possibly due to binding to the 
p85 subunit of PI3K, thereby overcoming the negative effects that p85 monomers 
have on PI-3K signalling (Li et al., 2004). SOCS6 was found to associate with the 
leptin receptor (Montoye et al., 2006). It also interacts with haem-oxidized IRP2 
ubiquitin ligase 1 (HOIL1), driving ubiquitination and degradation of proteins 
associated with SOCS6 (Bayle et al., 2006). Recently, SOCS6 was proposed to 
negatively regulate STAT3 protein levels and a nuclear function for SOCS6 was 
proposed, depending on its N-terminus (Hwang et al., 2007). 
 
SOCS6 deficient mice develop normally and exhibit no defects in haematopoiesis or 
glucose homeostasis. However, they weighed approximately 10% less than wild-
type littermates (Krebs et al., 2002). It was suggested that the closely related 
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SOCS7 could functionally compensate for SOCS6 deficiency. By contrast, SOCS6 
transgenic mice displayed improvement in insulin signalling and glucose metabolism 
(Li et al., 2004). 
 
SOCS7 
In contrast to other SOCS proteins, the N-terminal domain of SOCS7 contains 
several recognizable motifs: multiple poly-proline motifs, which are possible docking 
sites for SH3 domain containing proteins and a putative nuclear localisation signal 
(NLS), indicating a potential role for SOCS7 in the nucleus (Matuoka et al., 1997). 
The N-terminus of SOCS7 mediates interactions with the cytoskeletal protein 
vinexin and several signalling molecules like PLCγ, Grb2 and Nck, which are 
involved in signalling mediated by a large number of receptors (Martens et al., 2004; 
Matuoka et al., 1997). SH2 dependent interactions of SOCS7 were demonstrated 
with the EGFR and LR and several components of the insulin pathway including 
IRS1, IRS2, IRS4, p85 and the insulin receptor (Banks et al., 2005; Krebs et al., 
2002; Matuoka et al., 1997; Montoye et al., 2006). SOCS7 can suppress PRL, GH 
and leptin signalling by interacting with STAT5 or STAT3 and attenuating their 
nuclear translocation (Martens et al., 2005).  
 
SOCS7 deficient mice exhibit no defects in haematopoiesis or circulating glucose or 
insulin concentrations but they are smaller than their wild-type littermates (Krebs et 
al., 2004). The pancreatic islets of Langerhans are in some cases exceptionally 
large (Banks et al., 2005; Krebs et al., 2004).  Within 15 weeks however, about 50% 
of the SOCS7 knock-outs died as a result of hydrocephalus (Krebs et al., 2004). 
Accordingly, prominent expression of SOCS7 was found in the brain, suggestive of 
an important functional role of SOCS7 in this organ (Banks et al., 2005; Krebs et al., 
2002). Older mice also develop increased glucose tolerance and insulin sensitivity 
together with a mild hyperglycaemia and hyperinsulinemia (Banks et al., 2005). 
Although deficiency of SOCS6 or SOCS7 in mice results in relatively mild 
phenotypes at birth (Krebs et al., 2004; Krebs et al., 2002), the double knock-out 
animals are embryonically lethal, perhaps pointing to the loss of redundant functions 
of SOCS6 and SOCS7 (Dr. Hilton, personal communication). 
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SOCS proteins and immunity  
Cytokines mediate communication between cells of the immune system and a tight 
control of cytokine receptor signalling is of crucial importance to balance anti-
microbial and tissue-destructive effects.  Mainly SOCS1 and SOCS3 are critical 
mediators of both innate and adaptive immunity through the regulation of cytokine 
signalling in T cells and antigen-presenting cells, including macrophages and 
dendritic cells (DCs).  
 
SOCS in innate immunity - Toll-like receptor (TLR) signalling that initiates innate 
immune responses to pathogens, induces expression of SOCS proteins (Baetz et 
al., 2004; Dalpke et al., 2001; Naka et al., 2005; Stoiber et al., 1999).  SOCS1-
deficient mice are highly sensitive to sepsis induced by lipopolysaccharide (LPS), a 
known TLR activator, and endotoxin tolerance was absent. Additionally, 
macrophages, DCs and fibroblasts from SOCS1-/- mice produce increased levels of 
pro-inflammatory cytokines such as TNF, IL-12 and IFNγ, as well as nitric oxide, in 
response to TLR ligands  (Chinen et al., 2006; Hanada et al., 2005; Kinjyo et al., 
2002; Nakagawa et al., 2002).  A direct effect of SOCS1 on the TLR pathway has 
been proposed as SOCS1 was found to bind to the p65 subunit of NF-κB and 
promotes its turnover (Ryo et al., 2003).  SOCS1 also mediates ubiquitination and 
degradation of the tyrosine phosphorylated TLR adaptor MyD88 Adaptor-Like (Mal), 
thereby leading to the suppression of Mal-dependent p65 phosphorylation and 
transactivation of NF-κB (Mansell et al., 2006).  In addition to the NF-κB pathway, 
SOCS1 might also target the JUN N-terminal kinase (JNK) and p38 MAPK 
cascades by inducing the degradation of the upstream activator apoptosis signal-
regulating kinase 1 (ASK1) (He et al., 2006).  Other groups reported that the 
principal mode of suppression of SOCS1 is the inhibition of the secondary activated 
type I IFN signalling pathway (Baetz et al., 2004; Gingras et al., 2004). The 
induction of SOCS1 by chemotactic factors such as fMLP and IL-8 provides 
evidence for SOCS mediated cross-talk between chemoattractants and cytokine 
signalling pathways (Johnston, 2004).  
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SOCS3 is a key determinant for regulating and shaping the divergent activities of IL-
6 and IL-10 in macrophages following TLR stimulation (Croker et al., 2003; Lang et 
al., 2003; Yasukawa et al., 2003). SOCS2 was found to be crucial for the anti-
inflammatory effects of lipoxins, although the molecular mechanism remains elusive 
(Machado et al., 2006).   
 
SOCS in adaptive immunity - SOCS proteins are crucially involved in T-helper cell 
differentiation and T and B cell responses of the adaptive immunity.  This is well 
illustrated by the SOCS1-/- mice in which those aspects are massively disturbed 
(Alexander et al., 1999; Chong et al., 2003; Eyles et al., 2002; Fujimoto et al., 2002; 
Marine et al., 1999b; Naka et al., 1998).  The pivotal role of SOCS1 in Th1 
differentiation and inhibition of IFNγ and other cytokines involved in lymphocyte 
homeostasis, such as IL-2, IL-4, IL-7 and IL-12 appeared from studies in knock-out 
mice (see above) (Eyles et al., 2002; Naka et al., 2001). More specific effects have 
been reported for SOCS family members such as SOCS5 that has the capacity to 
impair IL-4 mediated Th2 differentiation and thus promote Th1 cell differentiation 
(Seki et al., 2002).  SOCS3 displays an expression pattern reciprocal to that of 
SOCS1 and SOCS5 and is exclusively associated with Th2 cell differentiation 
(Egwuagu et al., 2002; Li et al., 2006).  
CD25(+)CD4(+) regulatory T cells (Tregs) are actively engaged in the maintenance 
of immunologic self-tolerance by suppressing the autoreactive responses mediated 
by effector T cell functions. SOCS1, SOCS2 and CIS are highly induced in activated 
CD4(+)CD25(+) Tregs (McHugh et al., 2002).  In a DNA microarray analysis, 
performed to identify Treg-specific molecules controlled by the transcription factor 
Foxp3, SOCS2 was one of the predominantly expressed genes (Sugimoto et al., 
2006). SOCS1 was reported to prevent the development of dextran sulfate sodium 
(DSS)-induced colitis (a model of colitis resembling human IBD) by inhibiting 
IFNγ/STAT1 signalling and by subsequently regulating Treg cell 
development.(Horino et al., 2008). Elevated SOCS levels in Tregs may be required 
to strictly control their immunosuppressive functions to achieve a balance between 
the necessity to suppress autoreactivity and the ability to allow appropriate 
responses to foreign antigens.  
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VI. SOCS proteins in disease 
 
Through their impact on cytokine- and growth factor-activated signalling pathways, it 
seems inevitable that disruption of normal SOCS function will contribute to disease 
onset and progression. Accordingly, therapeutic strategies based on the 
manipulation of SOCS activity might be of clinical benefit. 
 
Infectious disease pathogenesis (hijacking the host’s SOCS system) 
Interfering with SOCS regulation of cytokine signalling is an effective strategy used 
by various microbial pathogens to manipulate cytokine signalling and as a result 
escape detrimental immune responses. The parasites Toxoplasma gondii and 
Leishmania can for instance induce host SOCS expression to evade immune 
responses (Alexander et al., 1999; Mun et al., 2005; Zimmermann et al., 2006). 
Also, bacteria such as Mycobacteria, Salmonella typhimurium and Listeria 
pseudomellei, are able to induce endogenous SOCS and consequently exploit 
these host negative regulatory mechanisms for their own purpose (Blumenthal et al., 
2005; Manca et al., 2005; Stoiber et al., 2001; Uchiya and Nikai, 2005; Vazquez et 
al., 2006).  Finally, viruses will also target host immunity by misusage of 
endogenous SOCS proteins.  Hepatitis C Virus (HCV) core protein was reported to 
impair IFNα-induced signal transduction via SOCS3 expression in hepatic cells 
(Bode et al., 2003).  Human immunodeficiency virus (HIV) induces SOCS 
expression known to interfere with Th differentiation and Ig class switching, thereby 
promoting HIV infection (Moutsopoulos et al., 2006; Qiao et al., 2006).  Recently, 
SOCS1 was reported to associate with the HIV-1 p55 Gag polyprotein to enhance 
its stability and trafficking, resulting in the efficient production of HIV-1 particles (Ryo 
et al., 2008). 
It is of note that, similar to SOCS molecules, some viral proteins can act as the 
substrate recognition unit of an E3 ligase complex, targeting host proteins for 
ubiquitination and proteasomal degradation. In this respect, HIV-1 encoded viral 
infectivity factor (Vif) associates with an ElonginB/C-Cullin 5 module in order to 
direct the turnover of APOBEC3G, a host factor that induces hypermutations in 
newly synthesized viral DNA (Rose et al., 2004).  Other examples of viral proteins 
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that assemble ECS-based E3 ligases are the Respiratory Syncytial Virus NS1 and 
the adenovirus E4orf6 that respectively target STAT2 and p53 for proteasomal 
destruction (Elliott et al., 2007; Luo et al., 2007).  Possibly, this sequestering of E3 
components and especially Elongin B/C, will further deregulate the host SOCS 
actions. 
Targeting SOCS proteins for improving the defense against pathogens might thus 
be a beneficial approach in case of infection.  Nevertheless, therapeutic modulation 
of SOCS will have to be done cautiously since inhibition of SOCS to counter 
microbial infection may also lead to an enhanced immune response associated with 
pro-inflammatory effects. 
 
Inflammatory diseases 
SOCS proteins are crucially implicated in the regulation of JAK/STAT signalling in 
inflammation.  Accordingly, alterations in SOCS protein levels, and more specific 
SOCS3, has been associated with the pathogenesis of various inflammatory 
diseases including rheumatoid arthritis (RA), Crohn’s disease and inflammatory 
bowel diseases (IBD) (Egan et al., 2003; Isomaki et al., 2007; Lovato et al., 2003; 
Rakoff-Nahoum et al., 2006; Suzuki et al., 2001). SOCS3 expression is induced by 
a wide variety of inflammatory and anti-inflammatory cytokines, including IFNγ, IL-3, 
IL-6 and IL-10 and will function to counteract STAT3 activation associated with 
inflammatory disorders.  Additionally, exogenous SOCS3 delivery was proven to be 
an effective therapy to attenuate inflammation as was shown in different models 
including mice with experimental induced colitis and arthritis (Fang et al., 2005; Jo et 
al., 2005; Shouda et al., 2001; Suzuki et al., 2001).  SOCS3 was also demonstrated 
to have an important role in regulating the onset and maintenance of Th2 mediated 
allergic immune diseases.  Enhanced SOCS3 levels in T cells have for example 
been associated with asthma pathogenesis (Seki et al., 2003). Humans with allergic 
conjunctivitis showed a correlation between the level of expression of SOCS3 and 
the severity of the disease (Ozaki et al., 2005; Seki et al., 2003).  A similar role for 
SOCS5 has also been reported in a mouse model of this disease (Ozaki et al., 
2005), as well as in murine experimental autoimmune uveitis, an autoimmune 
disease of the retina (Takase et al., 2005). Single nuclear polymorphisms (SNPs) in 
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SOCS1 that result in SOCS1 upregulation in T cells have been associated with 
asthma pathogenesis (Harada et al., 2007).  Clearly, therapeutical targeting of 
SOCS might attenuate inflammatory cytokine circuits in autoimmune and other 
inflammatory diseases.  Modulation of SOCS expression or function will also be an 
important therapeutic strategy for immunological diseases induced by an abnormal 
Th1/Th2 balance.   
 
Metabolic diseases (leptin and insulin resistance) 
Different observations put SOCS3 forward as a crucial inhibitor of LR signalling and 
suggest a prominent role for increased SOCS3 levels in leptin resistance and 
consequent obesity (Bjorbaek et al., 1998; Dunn et al., 2005; Howard et al., 2004; 
Mori et al., 2004). SOCS factors are critically implicated in attenuation of insulin 
signalling and SOCS1 and SOCS3 might be players in the development of insulin 
resistance associated with type 2 diabetes (Emanuelli et al., 2001; Emanuelli et al., 
2000; Kawazoe et al., 2001; Ueki et al., 2005; Ueki et al., 2004).  Some evidence 
also points to SOCS2 as a modulator of insulin signalling (Rico-Bautista et al., 2006) 
and interestingly, the prevalence of SNPs in the SOCS2 gene was correlated with 
type 2 diabetes (Kato et al., 2006). Additionally, it was suggested that aberrations in 
the ubiquitin-proteasome pathway might as well be one of the molecular mechanism 
behind insulin resistance through inappropriate degradation of IRS1 or IRS2 by 
SOCS proteins (Balasubramanyam et al., 2005).  It can be envisaged that blocking 
SOCS actions can be used clinically to treat leptin or insulin resistance, and 
accordingly SOCS3 might be a potential therapeutic target for prevalent human 
metabolic disorders such as obesity and diabetis. 
 
Growth related pathologies 
Haplotype insufficiency for SOCS2 promotes trophic actions of GH in small intestine 
and promotes preneoplastic growth in colon during excess GH. Small variations in 
SOCS2 expression levels may thus significantly influence the outcome of 
therapeutic GH or acromegaly in intestine (Michaylira et al., 2006). Hepatic growth 
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hormone resistance during sepsis is associated with increased SOCS expression 
and impaired growth hormone signalling (Yumet et al., 2006). Pharmacological 
targeting of specific negative regulators of growth signalling, like SOCS2, may be 
valuable in the development of novel therapies targeting growth disorders.  
Moreover, it may have the potential to enhance the beneficial actions of GH in 
growth and metabolism, without the side effects associated with direct GH 
treatment.  
 
Cancers and haematopoietic disorders  
Several oncologic disorders are associated with enhanced JAK-STAT activity, 
promoting cell proliferation and survival which will contribute to malignant growth 
(Chai et al., 1997; Frank et al., 1997; Gouilleux-Gruart et al., 1996).  Inactivation of 
SOCS by gene mutation/deletion or reduced SOCS expression due to silencing by 
DNA hypermethylation are frequently found in hepatocellular, pancreatic, lung, 
ovarian and breast carcinomas (Farabegoli et al., 2005; He et al., 2003; Komazaki 
et al., 2004; Nagai et al., 2003; Wikman et al., 2002; Yoshikawa et al., 2001). 
Compellingly, constitutive activation of the JAK-STAT pathway in several 
haematological malignancies including leukemia and lymphoma was also 
associated with SOCS downregulation (Galm et al., 2003; Melzner et al., 2005; 
Watanabe et al., 2004; Weniger et al., 2006).  SOCS proteins appear to have tumor 
suppressor functions that need to be bypassed for transformation to occur.  This 
implies that the forced expression of SOCS might be beneficial for the treatment of 
some malignancies. 
 
However, tumor cells upregulating or constitutively expressing SOCS have also 
been described (Arany et al., 2001; Evans et al., 2007; Faderl et al., 2003; Haffner 
et al., 2007; Hakansson et al., 2008; Huang et al., 2007; Raccurt et al., 2003; 
Roman-Gomez et al., 2004) and this may be indicative of a tumor protecting 
function for SOCS proteins.  The in vivo elevation of SOCS gene expression will 
confer resistance to some host cytokines and may be part of the host/tumour 
response.  In this respect, constitutive SOCS3 expression was found to grant a 
growth advantage to human melanoma cells by inducing resistance towards the 
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growth inhibitory effects of cytokines like IL-6 and oncostatin M (OSM) (Komyod et 
al., 2007).  A therapeutic consequence is that anti-tumoral therapy with IFN may fail 
in some cancers due to constitutive SOCS1 or SOCS3 expression levels (Fojtova et 
al., 2007; Roman-Gomez et al., 2004; Sakai et al., 2002).  
In the case of SOCS2, increased expression levels may enhance sensitivity to 
cytokine signalling by overcoming the inhibitory effects of other SOCS molecules, 
thereby contributing to the constitutive active phenotype related to oncogenesis. It 
was proposed that the increased JAK activity in VHL-mediated renal cell carcinoma 
(RCC) may be due to SOCS2 recruiting SOCS1 for proteasomal destruction (Wu et 
al., 2007). SOCS2 expression was enhanced by several cytokines and hormones in 
leukemic leukocytes (Dogusan et al., 2000). Furthermore, SOCS2 overexpression 
was clearly found to correlate with advanced stages of chronic myeloid leukemia 
(CML) (Schultheis et al., 2002; Zheng et al., 2006)  or acute myeloid leukemia 
(AML) (personal communication, Dr. I Touw) (Faderl et al., 2003). This upregulation 
can be abrogated by STI571, a compound that inhibits the activity of the BCR-ABL 
tyrosine kinase, which is fundamental for CML pathogenesis (Schultheis et al., 
2002).  Surprisingly, no haematologic abnormalities were observed in SOCS2 
deficient mice. However, as SOCS2 is clearly involved in the development of 
leukemia, it is conceivable that in the haematopoietic system aberrant SOCS2 
upregulation rather than a deficient expression is the important pathologic 
determinant. As Elongin C overexpression was observed in a number of prostate 
and breast cancer cell lines (Porkka et al., 2002), this could also possibly lead to a 
deregulation of signalling via its effect on SOCS stability and functionality. 
 
Some transformation processes result from aberrant SOCS phosphorylation thereby 
hindering the assembly of the E3 ligase complex and consequently allowing JAKs to 
evade SOCS regulation. In this context, the JAK2V617F mutant that is associated 
with myeloproliferative disorders has been demonstrated to evade negative 
regulation due to hyperphosphorylation of SOCS3.  This modification extends 
SOCS3 half-life time but renders it unable to suppress the activity of the mutant 
kinase and even stabilizes the mutant JAK, thus potentiating its myeloproliferative 
capacity (Hookham et al., 2007).  Another example concerns the cytokine 
independent Ser/Thr phosphorylation of SOCS1 by v-Abl in transformed pre-B cells.  
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This will disrupt the interaction with Elongin B/C, thereby stabilizing SOCS1 
expression and blocking JAK degradation, which will contribute to the transformation 
process (Limnander et al., 2004).   
 
Therapeutic applications of SOCS 
As mentioned above, therapeutic application of SOCS proteins could be valuable for 
the treatment of diseases in which overshoot cytokine signalling is involved, such as 
those related with inflammation or cancer.  One approach would be the 
overexpression of SOCS molecules.  In this respect, the adenovirus-mediated 
administration of SOCS3 was demonstrated to prevent the development of RA in 
experimental mouse models (Shouda et al., 2001).  Fusion of SOCS proteins with 
membrane-permeable peptides might be an alternative way to introduce them into 
cells. In this context, intracellular delivery of a cell-penetrating form of SOCS3 was 
proven to be effective for treatment of various types of inflammation and septic 
shock (Jo et al., 2005).  A second approach is the generation of small-molecule 
mimetics of SOCS proteins.  The tyrosine kinase inhibitor peptide (TKIP) is an 
example of a mimetic of SOCS1 and effectively inhibits JAK2-mediated 
phosphorylation of STATs.  This peptide prevented the development of experimental 
allergic encephalomyelitis (EAE) in mice (Mujtaba et al., 2005) and blocked the 
proliferation of prostate cancer cell lines (Flowers et al., 2005).  A third approach 
might be blocking SOCS degradation in vivo. 
 
On the contrary, inhibiting SOCS effects could be beneficial in case cytokine action 
needs to be enhanced.  This may be useful for enhancing anti-tumoral or anti-viral 
immunity, modulating the Th1/Th2 balance, promoting GH signalling or blocking 
SOCS-mediated resistance against cytokine therapies.  Neutralization of SOCS 
functions could be achieved by the use of their dominant-negative forms. SOCS 
gene expression could also be silenced by a siRNA or antisense oligonucleotide 
approach or by the use of specific transcriptional inhibitors. Administration of 
SOCS1 siRNA by a nanotube carrier could for instance retard the growth of B16 
tumours in mice (Yang et al., 2006).  siRNA based SOCS1 silencing in DCs elicit 
HIV-specific T cell and antibody responses, which may open an alternative 
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possibility for the development of effective HIV vaccines (Song et al., 2006).  
Another example is the downregulation of SOCS1 and SOCS3 expression in livers 
of obese diabetic mice by antisense RNA therapy that improved insulin sensitivity 
and ameliorated hepatic steatosis and hypertriglyceridemia (Ueki et al., 2005).  
Alternatively, the structural insights in SOCS interactions may provide a basis for the 
design of SOCS inhibitors.   
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I. Techniques to study protein-protein interactions 
 
Interactions between proteins form the basis of practically all cellular processes. 
Protein complexes can form stable structures such as the cytoskeleton or the 
proteasome complex.  On the other hand, protein-protein interactions are also 
involved in the regulation of cellular processes and these interactions are often 
temporary and dependent on the modification of one or more of the binding 
partners. Identification of the interaction profile of a given protein can contribute 
considerably to its functional characterization in a specific cellular context.  
Mutations in proteins may cause altered protein-protein interactions, which can 
result in the onset of diseases. Hence, the identification and manipulation of such 
protein-protein interactions can offer new strategies towards therapeutic 
interventions.  For this reason, a broad range of both biochemical and genetic 
methods for studying protein-protein interactions has been developed.   
 
Biochemical approaches 
Biochemical methods such as protein affinity chromatography and co-
immunoprecipitation aim at isolating protein complexes from cell lysates or from 
solution. Initially, identification of binding partners by these methods was limited to 
immunological detection and Edman degradation. However, the introduction of 
sensitive protein identification by mass spectrometry in combination with database 
searches led to the development of high-throughput biochemical techniques. A 
widely used large-scale approach relying on tag-based affinity purification is the 
tandem affinity purification (TAP) procedure (Puig et al., 2001; Rigaut et al., 1999). 
Following cellular expression of a bait protein linked to a dual affinity-tag and cell 
lysis, the protein complexes are precipitated in a two-stage purification step. 
Proteins are then separated by gel electrophoresis and subsequently identified by 
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mass spectrometry.  This technique has been successfully used to identify yeast, 
plant as well as mammalian protein complexes (Bouwmeester et al., 2004; Gavin et 
al., 2002). Luminescence-based mammalian interactome mapping (LUMIER) is an 
automated high-throughput technology, to map protein-protein interaction networks 
systematically in mammalian cells (Barrios-Rodiles et al., 2005). The strategy uses 
Renilla luciferase enzyme fused to proteins of interest, which are then coexpressed 
with individual Flag-tagged partners in mammalian cells. The interactions are 
determined by performing a luciferase enzymatic assay upon immunoprecipitation 
using an antibody against Flag. A limitation of these techniques is that the lysis step 
may cause disruption of weak interactions. Another large-scale technology relies on 
protein micro-array chips. High-throughput screening of binary interactions is done 
by covalently linking proteins to a solid support and screening with fluorescently 
labelled protein-probes (MacBeath and Schreiber, 2000; Zhu et al., 2001).  
 
Methods for characterization of known interactions include: analytical 
ultracentrifugation, isothermal titration calorimetry (ITC) and Biacore. This latter 
technique relies on surface plasmon resonance (SPR), which is an optical 
phenomenon that occurs when surface plasmon waves are excited at a metal/liquid 
interface.  Biacore allows real time measurement of binding kinetics between two or 
more molecules. They do so by monitoring the changes in refractive index at the 
surface layer of a sensor chip, which results from the interaction between surface 
immobilized and solution-borne binding partners.  
 
Genetic approaches 
Genetic approaches are in vivo techniques that rely on hybrid bait and prey proteins 
designed in such a way that their interaction will generate a detectable signal.  The 
yeast two-hybrid method is based on reconstitution of a transcription factor (Fields 
and Song, 1989). Bait and prey are genetically fused to either the DNA binding 
domain or the transcription activation domain of the transcription factor. Interaction 
of bait and prey protein restores transcriptional activity, leading to induction of 
reporter genes or selection markers. The yeast two-hybrid method has become the 
most widely used genetic technique, mainly because it is cost-effective, relatively 
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easy to implement and scalable. A proteome-wide interactome has for example 
been generated for yeast and C. elegans (Ito et al., 2001; Reboul et al., 2003) and a 
human interaction map is on its way (Rual et al., 2005; Stelzl et al., 2005). However, 
although the yeast two-hybrid method is thus far the only approach capable of 
proteome-wide analyses, the method also suffers from some intrinsic limitations. As 
functional complementation must occur in the nucleus, failure in nuclear localisation 
of either bait or prey results in false negatives. Moreover, correct posttranslational 
modifications, often essential in eukaryotic signalling transduction processes, are 
hard to reproduce in yeast.  Some of the shortcomings described for the yeast two-
hybrid system, can be overcome by the use of mammalian cell systems.   
 
The first mammalian two-hybrid methods were mere adaptations of the yeast two-
hybrid system. They make use of a similar transcription factor complementation 
strategy and are accordingly dependent on nuclear localisation of bait and prey 
(Dang et al., 1991). Several other mammalian systems have been described 
allowing detection of protein interactions in their physiological context.  These 
methods include the mammalian Ras recruitment system, split-ubiquitin 
approaches, protein-splicing based assays, reporter enzyme fragment 
complementation systems, proximity-ligation in situ assay (P-LISA)  and MAPPIT 
(reviewed in (Eyckerman and Tavernier, 2002; Lievens and Tavernier, 2006)).  The 
MAPPIT technology will be described in more detail in the next section. P-LISA 
allows the study of endogenous protein complexes in intact cells (Soderberg et al., 
2006). The technique makes use of oligonucleotides attached to antibodies against 
the two target proteins that will direct the formation of circular DNA strands when 
bound in close proximity. The DNA circles in turn serve as templates for localized 
rolling-circle amplification (RCA). The RCA reaction product is a single-stranded 
DNA molecule that remains attached to the antibody-protein complex, and is 
detected through hybridization of a fluorescently labeled oligonucleotide, allowing 
individual interacting pairs of protein molecules to be visualized. 
 
To visualise protein interactions in real time, methods like fluorescence resonance 
energy transfer (FRET), bioluminescence resonance energy transfer (BRET) or 
bimolecular fluorescence complementation (BiFC) can be applied. The FRET 
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technique depends on the energy transfer between two different fluorophores to 
monitor the interaction and dissociation of the attached proteins.  Light emission of 
the excited donor fluorophore results in excitation of the acceptor fluorophore only 
when both are brought in close proximity by their fusion partners (Jares-Erijman and 
Jovin, 2003; Wallrabe and Periasamy, 2005). In the BRET system, excitation of the 
acceptor fluorophore is induced via enzymatic bioluminescence instead of a donor 
fluorescence (Angers et al., 2000). In the case of BiFC the target proteins are fused 
to fragments of a single fluorescent protein, which results in functional 
complementation upon protein interaction (Hu et al., 2002; Kerppola, 2006).  
 
 
II. Mammalian protein-protein interaction trap (MAPPIT) 
 
MAPPIT is a mammalian two hybrid technique that was developed in our laboratory 
and is based on type I cytokine receptor signalling (Eyckerman et al., 2001). In the 
MAPPIT system (figure 13), a bait protein is coupled C-terminally to a chimeric 
receptor consisting of the extracellular part of the EpoR and the transmembrane and 
intracellular parts of the LR that has been deprived of its STAT3 recruiting tyrosine 
(Y1138) to prevent STAT activation. The other LR tyrosines (Y985 and Y1077) are 
also mutated to prevent negative feedback, thereby maximizing the signal intensity.  
MAPPIT prey proteins are linked to a part of the cytoplasmatic tail of the gp130 
receptor carrying several STAT3 recruitment sites. When bait and prey interact, 
phosphorylation of the prey gp130 tail leads to STAT3 recruitment, activation and 
migration to the nucleus, ultimately resulting in transcription of a reporter gene under 
the control of the STAT3-responsive rPAP1 promoter.   
 
The MAPPIT technique offers several advantages: first, the mammalian cell context 
provides a physiological background for the study of posttranslational-dependent 
interactions. Intrinsic to the strategy, both modification-independent and tyrosine 
phosphorylation-dependent interactions can be detected. MAPPIT is therefore very 
suitable for studying protein-protein interactions involved in signal transduction. 
Second, the physical separation of the bait-prey interaction (cytosol) and the signal 
read-out by endogenous STATs (nucleus), avoids interference of the chimeric bait 
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and prey proteins with reporter activity, a common drawback in many two-hybrid 
methods leading to background signals. Third, MAPPIT is an inducible system 
based on cytokine stimulation which allows exclusion of ligand-independent 
interactions, further limiting false positives. 
 
 
 
 
Figure 13: Principle of MAPPIT 
(A) Schematic representation of the JAK/STAT pathway. (B) MAPPIT, for details see text. 
 
 
Several variants of the basic MAPPIT approach have been developed. The LR-
based MAPPIT, GGS-MAPPIT and βc-MAPPIT were used during this thesis (figure 
14).  The LR-MAPPIT variant was generated to specifically identify interaction 
partners of the LR.  The GGS-MAPPIT was created to improve the flexibility of the 
system and to avoid interactions due to interaction with the LR.  βc-MAPPIT relies 
on functional complementation of STAT5 signalling and allows the analysis of 
protein interactions in haematopoietic cells. 
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Figure 14: Variants of MAPPIT 
(A) LR-MAPPIT. The LR itself, devoid of its STAT3 recruiting tyrosine (Y1138) functions as 
bait protein. Upon stimulation, the two membrane proximal tyrosines can be phosphorylated 
by JAK2. Interaction of the prey protein with the LR, which may depend on phosphorylation, 
allows STAT3 recruitment and activation via gp130 and subsequent reporter induction. (B) 
βc-variant of LR-MAPPIT. In βc-MAPPIT a βc receptor-based prey construct (inset) is used. 
The βc receptor contains six tyrosine motifs in its cytoplasmatic tail of which three are known 
STAT5 recruitment sites. A prey in the βc-MAPPIT method is fused to a part of the βc 
receptor containing all three STAT5 recruitment sites. (C) GGS-MAPPIT. The bait protein is 
attached C-terminally to a variant of the chimeric EpoR-LR receptor.  The cytosolic domain 
of the LR following the JAK2 recruitment site is replaced by 60 GGS triplets, preventing any 
background activation resulting from prey association with the LR.  (D) βc-variant of GGS-
MAPPIT. 
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of leptin 
 
 
The human body is evolutionary conditioned to endure periods of starvation. This is 
achieved principally by energy storage in adipose tissue, but also by reducing 
physical activity and lowering thermogenesis. The balanced maintenance of energy 
reserves throughout life is of vital importance. Therefore, a rigorous equilibrium 
between eating, physical activity and body metabolism exists and is strictly 
controlled by dedicated centres in the brain. The adipocyte-derived hormone leptin 
and its receptor emerged as key players in this control mechanism regulating the 
body weight. Moreover, there is a growing body of evidence that energy reserves, or 
the nutritional status, influence important physiological processes like the onset of 
puberty and reproduction, haematopoiesis and immune reactions. 
 
I. Leptin and its receptor 
 
Leptin refers to the Greek word leptos, which means ‘thin’.  It was identified by 
positional cloning as the product of the obese (ob) gene (Zhang et al., 1994).  This 
gene is truncated in the naturally occurring severely obese ob/ob mice. These mice 
display an early onset obese phenotype (figure 15) which is associated with a 
number of endocrinological disorders. Administration of recombinant leptin to ob/ob 
mice results in a reduced food intake, increased energy expenditure and weight 
loss, thereby supporting a role for leptin in the regulation of body weight (Halaas et 
al., 1995). Leptin is expressed as a 16kDa non-glycosylated protein with an intra-
molecular disulphide bond necessary for biological activity (Rock et al., 1996). Its 
structure was solved by crystallography and revealed a typical type I long chain 
cytokine structure (see chapter 1). The hormone is mainly secreted by white 
adipose tissue, and its circulating plasma levels correlate positively with body fat 
mass (Considine et al., 1996; Maffei et al., 1995). Lower levels of leptin production 
   - 95 -               
could also be shown in other tissues, such as stomach, placenta and skeletal 
muscle (Bado et al., 1998; Masuzaki et al., 1997; Wang et al., 1998).  
 
 
 
 
Figure 15: Phenotype of the ob/ob mouse 
A wild type mouse (right) and an obese ob/ob mouse (left) 
 
The leptin receptor (LR) was isolated as the product of the diabetis (db) gene using 
an expression cloning strategy (Tartaglia et al., 1995). The gene is disrupted in the 
naturally occurring db/db mice that have the same phenotype as ob/ob mice.  So 
far, six isoforms have been identified: one long form (LRlo or LRb), one soluble 
variant (LRe) and four short forms (LRsh or LRa, LRc, LRd and LRf) (figure 16). The 
different LR variants are generated through alternative splicing but a soluble LR can 
also be created by proteolytic ectodomain shedding of membrane-anchored LRs 
(Ge et al., 2002; Maamra et al., 2001).  All isoforms possess an identical N-terminal 
extracellular domain but vary in their C-terminal intracellular part. The extracellular 
domain contains the typical extracellular characteristics of the class I cytokine 
receptor family. A rather unique feature is the presence of two extracellular CRH 
(CRH1 and 2) domains. These are separated by an Ig-like domain and followed by 
two FNIII domains (reviewed in (Zabeau et al., 2003)). The LRlo is the only isoform 
capable of efficient signalling. This LR variant is highly expressed within specific 
nuclei of the hypothalamus, known to be involved in body weight regulation. 
Expression could also be observed in different peripheral tissues (Fruhbeck, 2001; 
Lam et al., 2006; Sanchez-Margalet et al., 2002; Tian et al., 2002).  The short 
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isoforms of the LR and especially the LRsh, are more abundantly expressed 
throughout the body (Fei et al., 1997). The short  variants of the LR are proposed to 
be involved in the transport of leptin across the blood-brain barrier, leptin clearance 
or leptin signal transduction  (Hileman et al., 2002; Murakami et al., 1997; Uotani et 
al., 1999). The secreted LRe is likely involved in the modulation of the plasma levels 
of circulating free leptin (Huang et al., 2001; Yang et al., 2004).  
 
 
 
 
Figure 16: Schematic representations of the murine LR isoforms 
The extracellular domain of all isoforms consists of a CRH domain, an Ig-like domain, a 
second CRH domain and two FNIII domains. The number of AA in each isoform is 
indicated. The box1 domain represents the proline rich region necessary for JAK binding. 
 
 
II. Leptin: function and importance 
Body weight regulation 
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Although daily food intake as well as energy expenditure can vary considerably, an 
individual’s body weight remains remarkably constant over time.  The physiological 
system that regulates body weight by balancing energy intake and expenditure is 
very strictly controlled by a short-term and long-term strategy. The short-term 
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system mainly controls feeding via hunger and satiety signals. Satiety signals can 
be defined as rapidly released gastro-intestinal signals such as the hormone 
cholecystokinin that signals to the brain to stop an ongoing meal (Strader and 
Woods, 2005). Long-term regulation of energy balance is dependent on adiposity 
signal molecules that circulate at levels proportional to the body fat mass. Two 
cytokine-like hormones appear to be key players in this mechanism indicating 
sufficient long-term energy stores: leptin and insulin.  
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Figure 17: Leptin functions as an adipostat, signalling the body energy stores to the brain 
 
As circulating leptin levels correlate accurately with the body fat content, leptin is 
considered to function as an adipostat that communicates the status of body energy 
reserves to the brain (Friedman and Halaas, 1998; Maffei et al., 1995). 
Administration of leptin to rodents decreases food intake and increases energy 
expenditure (Campfield et al., 1996; Halaas et al., 1995). This demonstrates that 
leptin acts as an afferent satiety signal in a negative feedback mechanism that 
maintains the body weight at a constant level. Starvation leads to a decrease in fat 
ADIPOSE TISSUE
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weight gainweight loss
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stores and concomitant drop in leptin levels, resulting in a reduction in energy 
expenditure and allows a longer survival.  On the other hand, higher energy 
reserves will correlate with elevated leptin levels, reducing the food intake and 
augmenting the energy expenditure (figure 17). To enter the CNS, the adipocyte-
derived leptin must pass the blood-brain-barrier (BBB), via a specific and saturable 
transport system that might engage the short isoform of the LR (Banks, 2004; Banks 
et al., 1996; Bjorbaek et al., 1998b). Once in the brain, leptin binds and activates its 
receptor expressed by neurons in certain nuclei of the hypothalamus. The 
importance of the brain and especially the hypothalamus as a direct target of the 
leptin is demonstrated by neural specific deletion of the LR which leads to obesity in 
mice (Cohen et al., 2001). LR activation will alter expression and release of 
neuropeptides, which then activate pathways that engage other brain regions, 
ultimately leading to a satiated feeling (Broberger, 2005; Friedman and Halaas, 
1998). Leptin regulates two different populations of primary target neurons in the 
hypothalamus: anorexigenic and orexigenic neurons. Increased leptin levels will 
stimulate the anorexigenic (appetite-suppressive) neurons to express the satiety-
related molecules cocaine-amphetamine-regulated transcript (CART) and pro-
opionmelanocortin (POMC), the precursor of the α-melanocyte-stimulating hormone 
(α-MSH). The orexigenic (appetite-stimulating) neurons are responsive to absence 
or low concentrations of leptin and express neuropeptide Y (NPY) and agouti-
related protein (AgRP). The abundant NPY is a very potent orexigenic peptide that 
stimulates food consumption while AgRP antagonizes α-MSH action. Secondary 
target neurons process the NPY/AgRP and POMC/CART signals they receive. The 
orexigenic and anorexigenic systems act together and ultimately determine the 
response to peripheral signals (Friedman and Halaas, 1998). 
 
A broader role for leptin 
A growing body of evidence has qualified leptin as a pleiotropic molecule that is 
involved in a wide range of functions in the CNS and in the periphery. This is well 
illustrated by the phenotype of ob/ob and db/db mice: besides obesity, these mice 
display many defects in haematopoiesis, reproduction, angiogenesis, immune 
responsiveness, blood pressure control, bone formation and fetal development 
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(Ducy et al., 2000; Fruhbeck, 1999; Harigaya et al., 1997; Holness et al., 1999; Lord 
et al., 1998; Sierra-Honigmann et al., 1998; Umemoto et al., 1997). The link 
between the energy status of the body and physiological processes might not be 
surprising, as adequate energy stores are crucial to support energy-demanding 
functions such as immunity and reproduction. Fasting or starvation leads to an 
attenuation of these processes, thereby prioritizing food collection and consumption. 
As mentioned before, expression of the LRlo was reported in many peripheral 
tissues and immune cells, including bone marrow, pancreatic β cells, endothelial 
cells, dendritic cells, NK cells and T lymphocytes (figure 18) (Fehmann et al., 1997; 
Gainsford et al., 1996; Lam et al., 2006; Lord et al., 1998; Sierra-Honigmann et al., 
1998; Tian et al., 2002). 
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Figure 18: Localisation of functional LRs showing the involvement of leptin in 
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Leptin has been increasingly recognized as a cytokine-like hormone with pleiotropic 
actions in modulating immune responses. Since cell-mediated immunity is an 
energy demanding process, leptin may provide an important link between the body’s 
energy status and the immune system. Leptin was characterized as a pro-
inflammatory cytokine that functions as an early-phase reactant (Fantuzzi and 
Faggioni, 2000). It operates in both innate and adaptive immunity (La Cava and 
Matarese, 2004).  In innate immunity leptin will for example affect functions of 
monocytes and macrophages including phagocytosis, release of pro-inflammatory 
cytokines and expression of adhesion molecules (Fantuzzi and Faggioni, 2000; 
Mancuso et al., 2002; Zarkesh-Esfahani et al., 2001). In adaptive immunity, leptin 
promotes the development of T cells by reducing apoptosis and it directs memory T 
cells towards a Th1 response (Howard et al., 1999; Lord et al., 1998). Given its role 
in regulating T cell-controlled immune responses, leptin may play a role in the onset 
of T cell-controlled autoimmune diseases. Indeed, studies on mouse models 
demonstrated an involvement of leptin in the pathogenesis of several autoimmune 
diseases including inflammatory bowel disease and multiple sclerosis (Matarese et 
al., 2007; Peelman et al., 2004). Leptin increase in multiple sclerosis associates with 
reduced number of CD4(+)CD25(+) immunoregulatory T cells (Tregs) (Matarese et 
al., 2005). Tregs are known to suppress autoreactive responses mediated by 
CD4+CD25– T cells and may influence the onset and progression of autoimmunity 
(Sakaguchi, 2004).  
 
As a marker of the nutritional status, leptin has an essential role in reproduction. 
Leptin and its receptor have been found in reproductive tissues like ovary, oocytes, 
uterus and endometrium (Cervero et al., 2004; Kawamura et al., 2002; Ramos et al., 
2005; Ryan et al., 2002). The hormone appears to be a permissive factor in the 
onset of puberty since leptin administration accelerates puberty in wild type mice 
and restores fertility in ob/ob mice (Chehab et al., 1996; Chehab et al., 1997; Gruaz 
et al., 1998). Leptin affects the hypothalamus-pituitary-gonadal axis, regulating 
gonadotrophin-releasing hormone and luteinising hormone secretion (Welt et al., 
2004; Yu et al., 1997).  
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The involvement of leptin in haematopoiesis is suggested by the altered amount of 
blood cells seen in ob/ob and db/db mice (Bennett et al., 1996; Faderl et al., 2003). 
A direct role for leptin in haematopoiesis is proposed based on the expression of its 
receptor in fetal liver, bone marrow stromal cells and several haematopoietic cell 
lines (Cioffi et al., 1996; Konopleva et al., 1999). The capacity of the bone marrow 
cells to produce leptin provides further evidence for leptin in promoting the 
haematopoietic stem cells. This was further supported by colony formation studies 
where leptin stimulated the proliferation of stem cells and increased the numbers of 
lymphoid, erythroid and myeloid colonies (Bennett et al., 1996). Nevertheless, a 
direct role for leptin in the regulation of hematopoietic cells remains unclear. 
 
Leptin: clinical use and beyond  
The prevalence of overweight and obesity is escalating at an alarming rate, making 
it one of the most pressing health problems in the western world. In addition to the 
aesthetic considerations, obesity is indisputably linked with a number of serious 
health threats, including cardiovascular disease, stroke, type II diabetes and certain 
types of cancer (Calle et al., 1999; Kopelman, 2000). Although environmental and 
behavioural factors caused by economic development, urbanization and the media 
have been associated to the rise in global obesity, research demonstrated that 
obesity also has a significant genetic component. Given the remarkable weight loss 
of treated ob/ob mice, leptin was initially expected to be a miracle drug for curing 
obesity. In strong contrast, trials in which recombinant leptin was administered to 
obese patients failed to live up to the expectations as only modest weight decrease 
was obtained (Heymsfield et al., 1999; Hukshorn et al., 2000). Only in a few cases 
of obesity, caused by absence of or aberrant leptin production (Montague et al., 
1997; Ozata et al., 1999), administration of the hormone led to effective decrease in 
body weight  (Farooqi et al., 1999). The majority of the obesity cases are associated 
with significantly elevated leptin levels, pointing to a failure to respond correctly to 
the leptin signal (Considine et al., 1996; El-Haschimi et al., 2000; Maffei et al., 
1995). This so-called leptin resistance is discussed in text box 3. Leptin treatment 
was found to be effective for the treatment of hyperphagia caused by low leptin 
levels in humans with low body fat content (McDuffie et al., 2004; Welt et al., 2004).  
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Text box 3: Leptin resistance 
 
Desensitization to leptin in obese individuals might result from defects in one of the three 
levels of leptin responses: 
 
(i) Decreased transport across the blood-brain-barrier (BBB) 
 
Impaired transport of leptin through the BBB has been demonstrated in rodents with diet-
induced obesity (DIO), a model of obesity and leptin resistance in which rodents become 
obese by eating a high-fat diet. These DIO animals are resistant to peripheral leptin 
administration but lose weight when leptin was injected directly into the brain (El-Haschimi 
et al., 2000; Halaas et al., 1997).  
 
(ii) Defects in LR activation and signal transduction 
 
Impaired receptor expression results in a marked obese phenotype (e.g. db/db mice). In 
addition, aberrant signalling inhibition can cause central leptin insensitivity. SOCS3 and 
PTP1B are the two molecules that are most associated with attenuation of LR signalling and 
their enhanced activity can contribute to leptin resistance. Supportive of this, SOCS3 
haploinsufficient or neural cell-specific deficient mice and PTP1B knock-out mice show 
hypersensitivity to leptin which protects them from high fat diet obesity (Cheng et al., 2002; 
Elchebly et al., 1999; Howard et al., 2004; Mori et al., 2004). However, neural PTP1B 
expression or activity is not altered by leptin or adiposity, suggesting that PTP1B may not 
underlie tempered leptin signalling in obesity. Conversely, SOCS3 expression increases in 
response to leptin and is elevated in the hypothalami of obese animals (Bjorbaek et al., 
1998a; Munzberg et al., 2005; Tups et al., 2004). At present, most data confirm that 
alterations in cellular LR signalling, with a major role for SOCS3, have a major contribution 
in leptin resistance (El-Haschimi et al., 2000; Munzberg et al., 2005; Munzberg et al., 2004). 
 
(iii) Impaired secondary leptin signalling 
 
Defects in downstream effects of leptin in the neuronal circuit may also underlie leptin 
resistance. This comprises mutations in the genes encoding components of the neural 
circuit activated by leptin such as NPY, AgRP, POMC or CART. This is well illustrated by 
the obese phenotype observed for mice with loss-of-function mutations in the POMC 
encoding gene (Challis et al., 2004). 
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Accumulating evidence points to leptin as a potential link between obesity and 
cancer, especially in the development of breast, colorectal and prostate cancers 
(Garofalo and Surmacz, 2006). Leptin has been shown to act as a proliferative, 
mitogenic and pro-angiogenic agent promoting tumorigenesis of certain cancer cells 
(Bouloumie et al., 1998; Dieudonne et al., 2002; Horiguchi et al., 2006; Hu et al., 
2002; Iversen et al., 2002; Sierra-Honigmann et al., 1998). The relevance of leptin 
signalling in cancer is reinforced by the fact that the LR is (over)expressed in 
several cancer cells (Garofalo et al., 2006; Hardwick et al., 2001; Ishikawa et al., 
2004; Stattin et al., 2001). Until now, the association between circulating leptin 
levels and cancer risk has not been clear. Anyhow, recent studies suggest that for 
example breast carcinogenesis could also be induced by overabundance of locally 
produced leptin (Garofalo et al., 2006; Ishikawa et al., 2004). 
 
In respect to its diverse functions in immunity, leptin has been explored as a 
potential target for therapeutic application in treating autoimmune diseases. 
Modulation of the hormone has been shown to target autoimmune disease in some 
mice models and further studies are on the way to test if antagonizing leptin activity 
can affect the pathogenesis of these immunological disorders in humans.  
 
 
 
III. Signalling via the leptin receptor 
 
The LR appears as pre-assembled dimers at the plasma membrane (Biener et al., 
2005; Couturier and Jockers, 2003; White and Tartaglia, 1999). Leptin binding 
induces further clustering and conformational reorganisation of LR chains, thereby 
reorienting the intracellular domains in such a way that the associated JAKs become 
activated (Peelman et al., 2006; Zabeau et al., 2005; Zabeau et al., 2004). Three 
conserved tyrosine residues in the LR (Y985, Y1077 and Y1138, murine numbering) 
act as docking sites for downstream signalling molecules upon phosphorylation 
(figure 19) (Banks et al., 2000; Gong et al., 2007). 
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The LR can associate and activate both JAK1 and JAK2, but it is generally accepted 
that JAK2 is the main player under physiological conditions (Bjorbaek et al., 1997; 
Kloek et al., 2002; Muraoka et al., 2003). Interaction with JAK2 is mediated by the 
conserved box 1 motif, while the less conserved box 2, dispensable for JAK2 
activation, likely functions in JAK2 selectivity (Bahrenberg et al., 2002; Kloek et al., 
2002). Leptin stimulation was found to principally activate STAT3 in different in vivo 
studies (El-Hefnawy et al., 2000; Martin-Romero et al., 2000; McCowen et al., 
1998).  
 
 
 
Figure 19: Overview of the leptin signalling pathways 
 
The Y1138 of the LR is embedded in an YXXQ motif and is responsible for the 
recruitment of STAT3 (Banks et al., 2000; Haan et al., 1999). Replacement of this 
residue by a serine in mice abolished STAT3 activation and as a result these knock-
in mice became extremely obese (Bates et al., 2003), suggesting that STAT3 is a 
Chapter 5: Biological functions and signal transduction of leptin 
   - 105 -               
Chapter 5: Biological functions and signal transduction of leptin 
major intracellular mediator of leptin signalling. Nonetheless, these mice do not 
show the infertility and reduced size that is seen in db/db mice, indicatory for the 
involvement of other signal transducers.  Experiments with mutant LR constructs 
showed that deletion of the last tyrosine of the LR leads to a complete loss of 
STAT3 activation while STAT5 activity was still possible (Hekerman et al., 2005; 
White et al., 1997). Furthermore, leptin can stimulate proliferation of pancreatic β-
cells and this effect may be mediated by activation of STAT5 (Islam et al., 2000). 
Convincingly, phosphorylation of STAT5 was recently demonstrated to regulate 
leptin signalling pathways in hypothalamic nuclei of mice (Gong et al., 2007). 
Phosporylated Y1077 and Y1138 were identified as major docking sites for STAT5 
(Gong et al., 2007; Hekerman et al., 2005). 
 
The PI3K pathway  
Leptin binding to its receptor also activates some components of the insulin 
signalling cascade including IRS1/2 through phophorylated JAK2 (Elbatarny and 
Maurice, 2005). The IRS proteins bind to the regulatory unit p85 of PI3K to stimulate 
the catalytic domain. Recently, it was demonstrated that the association of the IRS4 
adaptor to the P-Y1077 motif of the LR could also mediate PI3K recruitment 
(Wauman et al., 2007). Activated PI3K transforms PIP2 into PIP3, which stimulates 
PDK1 for the phosphorylation and activation of Akt. This will ultimately result in the 
induction of cAMP phosphodiesterase PDE3B and a reduction of cAMP levels. In 
the hypothalamus, regulation of cAMP has been shown to play a critical role in 
feeding and body weight, making the PI3K pathway an important component of 
leptin signalling in energy homeostasis (Gillard et al., 1998; Minokoshi et al., 2004; 
Shimizu-Albergine et al., 2001).  
 
The MAPK pathway  
Tyrosine 985 of the LR plays an important role in leptin-induced MAPK activation by 
acting as a docking site for the protein tyrosine phosphatase, SHP-2 (Li and 
Friedman, 1999). Since SHP-2 can also negatively regulate leptin-induced 
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JAK/STAT signalling, it appears that this phosphatase can have opposite functions 
(Carpenter et al., 1998; Li and Friedman, 1999; Zhang et al., 2004). SHP-2 is 
phosphorylated by JAK2 and forms a docking site for the adaptor protein Grb2 
leading to activation of the ERK signalling cascade (Banks et al., 2000). 
Alternatively, ERK can also be activated by direct binding of SHP-2 to JAK2 
(Bjorbaek et al., 2001). Leptin-triggered activation of MAPK was observed both 
centrally and peripherally.  Regulation of calcium influxes involving MAPK activity 
was shown in hypothalamic neurons upon leptin stimulation (Jo et al., 2005). In 
peripheral tissues, leptin influences adipogenesis in preadipocytes and induces 
production of nitric oxide (NO) in white adipocytes via MAPK activation (Machinal-
Quelin et al., 2002; Mehebik et al., 2005). Furthermore, leptin-induced MAPK is 
involved in full activation of the DNA binding of STAT3 by mediating serine 
phosphorylation at position S727 of STAT3 (O'Rourke and Shepherd, 2002). 
 
 
IV. Negative regulation of leptin receptor signalling  
 
LR signal modulation is reviewed in chapter 8. 
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Scope of the thesis 
 
 
Since the discovery of the SOCS family only a decade ago, important advances 
have been made in understanding the mode of action by which these regulators 
attenuate cytokine signalling. However, unresolved issues include the involvement 
of SOCS in the modulation of specific pathways and the mechanisms controlling 
stability and regulation of these proteins. The importance of this is underscored by 
the contribution of inappropriately regulated SOCS activity to several pathologies 
including growth related diseases, cancer and inflammatory diseases. In this thesis, 
we aimed at further elucidating the mechanisms underlying SOCS regulation, 
thereby making extensive use of the mammalian two-hybrid MAPPIT technique. 
MAPPIT allows analysis of protein-protein interactions in a physiological context and 
is well suited for examining signal transduction pathways since it is capable of 
identifying interactions that are transient and weak or that depend on tyrosine 
phosphorylation. Throughout this thesis, several adaptations of the MAPPIT strategy 
were developed and applied in order to increase the sensitivity of the system and to 
expand the technology to different cellular backgrounds. 
 
The pivotal role of leptin in body weight regulation is demonstrated by the extreme 
obese phenotypes observed in mice containing defects in either leptin or its 
receptor. The importance of a strict control of leptin activity is underscored by the 
state of leptin resistance commonly found in obesity which may be caused by 
aberrant attenuation of hypothalamic leptin signalling.  A first part of this work 
focuses on the role of SOCS proteins in the modulation of LR signal transduction. 
SOCS3 is considered as a major inhibitor of leptin signalling and is proposed to be 
involved in the development of this leptin resistance. Still, expression of other SOCS 
members is induced upon leptin stimulation. A first objective was to define if other 
SOCS proteins are recruited to the activated LR and thereby contribute to 
modulation of leptin responses. Using MAPPIT and peptide affinity chromatography 
we studied interactions between the LR and SOCS in greater detail and identified 
two novel interactions of SOCS with phosphorylated tyrosine motifs. We further 
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analysed the differential binding mode of these interaction partners and the 
functionality of the interactions (chapter 6). 
Beside its effect on hypothalamic body weight regulation, leptin is also involved in a 
broad range of peripheral functions including immunity, haematopoiesis and 
reproduction and may also contribute to the development of disorders like auto-
immune diseases. The role of leptin in these peripheral effects is far from clear. 
Since different inconsistencies concerning leptin signalling in haematopoietic cells 
remain, we investigated signalling events mediated by the LR using a novel MAPPIT 
variant, βc-MAPPIT, which allows analysis in a haematopoietic background. This 
way, we characterised several interactions (including SOCS proteins) with the LR 
that are likely relevant for haematopoietic leptin signalling (chapter 7). 
 
The essential role of the SOCS box was demonstrated by the defective phenotypes 
of transgenic mice expressing SOCS box deletion mutants of SOCS1 and SOCS3 
(Boyle et al., 2007; Zhang et al., 2001). Via Elongin B/C recruitment, the SOCS box 
links associated molecules to E3 ligase activity and subsequent proteasomal 
degradation (Kamura et al., 1998; Zhang et al., 1999). The SOCS box can also 
function as an adaptor, coupling SOCS actions to other downstream signalling 
pathways including the MAPK pathway.  Furthermore, this domain was found to be 
involved in the regulation of SOCS protein levels. The second part of this thesis 
deals with the versatile effects of the SOCS box on SOCS functions and cytokine 
signalling. Increasing evidence makes clear that SOCS proteins not only act as 
inhibitors of cytokine responses but exert broader regulatory mechanisms. In 
particular for SOCS2, data indicate that it can have both inhibitory and stimulatory 
effects on cytokine responses. This dual effect led to the speculation that SOCS2 
interferes with the inhibition of other SOCS proteins. We investigated this hypothesis 
in the context of different cytokine pathways by using functional assays. MAPPIT 
and co-immunoprecipitation experiments were performed to study the interactions 
between SOCS2 and other SOCS proteins. The contribution of the SOCS box 
domain and the involvement of proteasomal degradation in this SOCS cross-
modulation were also examined. Finally, we tested whether, in analogy to SOCS2, 
other SOCS members exerted comparable interfering characteristics (chapter 9).  
As previous studies reported that the SOCS box of CIS is essential for interaction 
with receptor motifs (Lavens et al., 2007), we aimed to clarify the role of the SOCS 
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box in substrate interaction of SOCS proteins. More specifically, we evaluated the 
involvement of Elongin B/C recruitment on substrate binding and functionality of 
CIS. We pursued by testing if this SOCS box-dependency is unique for CIS. Based 
on models of CIS, a structural basis was provided for this regulatory mechanism 
controlling SH2 domain function (chapter 10). 
Taken together, the SOCS box domain emerges as a versatile regulatory module 
controlling SOCS activity and cytokine signal transduction pathways at multiple 
levels (reviewed in chapter 11).     
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CHAPTER 6: Interaction pattern of CIS and SOCS2 with 
the leptin receptor 
 
 
I. Introduction 
 
SOCS3 is considered to be one of the main players in the attenuation of leptin 
signalling and is suggested to underlie the development of leptin resistance 
commonly found in obesity (Bjorbaek et al., 1999; Bjorbaek et al., 1998).  Yet, 
expression of other SOCS members, including SOCS1, SOCS2 and CIS, is also 
induced in response to leptin (Emilsson et al., 1999; Lavens et al., 2006; Motta et 
al., 2004). Within the context of this PhD project, the MAPPIT data set 
demonstrating the interaction of CIS and SOCS2 with the LR was generated and the 
interactions were confirmed with biochemical methods. Surprisingly, the closely 
related proteins CIS and SOCS2 display differential binding capacities: both 
molecules bind to phospho (P)-Y1077, but only CIS appears to interact with the P-
Y985 of the LR. CIS and SOCS2 are believed to mainly inhibit STAT5 signalling. 
Recently, phosporylated Y1077 of the LR was revealed as a major docking site for 
STAT5 (Gong et al., 2007). We report here that SOCS2 can block the binding of the 
SH2 domain of STAT5a at this tyrosine. Surprisingly, we observed that SOCS2 
interferes with CIS association at P-Y1077 but also at the Y985 position, although 
SOCS2 itself does not interact with this tyrosine. We further examined this 
observation and found that SOCS2 could interact with CIS and that the interfering 
effect depends on Elongin B/C recruitment to SOCS2. This suggests that 
proteasomal degradation of CIS might be involved in this inhibitory mechanism. 
Besides the well-established inhibitory effect of SOCS3 on hypothalamic leptin 
signalling, other SOCS proteins bind the LR and most probably are involved in the 
modulation of leptin signalling in other cell types. 
 
 
 
   - 121 -               
Chapter 6: Interaction pattern of CIS and SOCS2 with the leptin receptor 
 
II. Article: A complex interaction pattern of CIS and SOCS2 with the leptin 
receptor. 
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Introduction
Leptin plays a major role in the regulation of energy
homeostasis and food intake. Produced mainly in white
adipose tissue (Zhang et al., 1994), it translocates through the
blood-brain-barrier to target the leptin receptor (LR) in the
hypothalamus. Although six LR splice variants can exist, the
LR isoform with an extended cytoplasmic domain (LRlo) is the
predominant signalling variant (Ghilardi et al., 1996). A short
variant (LRsh) is abundantly expressed in the choroid plexus,
brain microvessels, lung and kidney and may participate in
leptin transport across the blood-brain barrier (Bjorbaek et al.,
1998b; Boado et al., 1998). Next to its effect in weight
regulation, leptin is also involved in a broad range of other
functions including reproduction, bone formation, growth,
immune regulation, angiogenesis and glucose and insulin
metabolism.
The LR was addressed to the type I cytokine receptor family
based on sequence homology (Tartaglia et al., 1995). It is
closely related to the gp130 receptor family, especially gp130,
oncostatin M (OSM) and leukaemia inhibitory factor (LIF)
receptors, and to the G-CSF receptor (granulocyte-colony
stimulating factor) (Zabeau et al., 2003). Leptin typically
signals through the JAK-STAT pathway. An overview of LR
signalling events is shown in Fig. 1A. The LR carries three
conserved tyrosines in its cytoplasmic tail (positions Y985,
Y1077 and Y1138 in the murine LR), whereby the membrane
distal tyrosine Y1138 is embedded in a STAT3 (signal
transducer and activator of transcription) recruitment motif.
The activated receptor recruits STAT3 molecules through their
SH2 domain (Baumann et al., 1996; Vaisse et al., 1996), and,
after tyrosine phosphorylation, they translocate as homodimers
to the nucleus to induce specific gene expression.
Knock-in mice containing a Y1138S mutation reveal a
severe obese phenotype but do not show the infertility and
reduced size that occurs in db/db mice (Bates et al., 2003).
This observation, together with the wide range of leptin-
responsive cell types, suggests that alternative signalling
pathways must exist. Leptin-dependent activation of STAT1
and STAT5 was demonstrated in vitro (Baumann et al., 1996;
Hekerman et al., 2005). In addition, recruitment of SH2-
containing phosphatase SHP-2 to the phosphorylated Y985
position is responsible for leptin-induced MAPK signalling,
although an additional pathway for activation of this signalling
cascade directly by JAK2 has been suggested (Bjorbaek et al.,
2001). Leptin also induces phosphorylation of IRS-1 and IRS-
2 (Duan et al., 2004) and activates phosphatidylinositol 3-
kinase (PI-3K), as demonstrated in several cell lines (Cohen
et al., 1996; Kim et al., 2000). A role for JAK2 in activation
of the PI-3K pathway through the JAK2-interacting protein
SH2-B and recruitment of IRS-1 or IRS-2 was also reported
(Duan et al., 2004). SH2-B and leptin-activated hypothalamic
PI-3K both appear essential for weight regulation (Niswender
et al., 2001; Ren et al., 2005). Recently, an inhibitory effect
of leptin on hypothalamic AMPK (AMP-activated protein
kinase) activity was reported. AMPK is proposed to act as a
‘fuel gauge’ to an intracellular energy sensor cascade and
Hypothalamic leptin receptor signalling plays a central role
in weight regulation by controlling fat storage and energy
expenditure. In addition, leptin also has direct effects on
peripheral cell types involved in regulation of diverse body
functions including immune response, bone formation and
reproduction. Previous studies have demonstrated the
important role of SOCS3 (suppressor of cytokine signalling
3) in leptin physiology. Here, we show that CIS (cytokine-
inducible SH2 protein) and SOCS2 can also interact with
the leptin receptor. Using MAPPIT (mammalian protein-
protein interaction trap), a cytokine receptor-based two-
hybrid method operating in intact cells, we show specific
binding of CIS with the conserved Y985 and Y1077 motifs
in the cytosolic domain of the leptin receptor. SOCS2 only
interacts with the Y1077 motif, but with higher binding
affinity and can interfere with CIS and STAT5a prey
recruitment at this site. Furthermore, although SOCS2
does not associate with Y985 of the leptin receptor, we find
that SOCS2 can block interaction of CIS with this position.
This unexpected interference can be explained by the direct
binding of SOCS2 on the CIS SOCS box, whereby elongin
B/C recruitment is crucial to suppress CIS activity.
Key words: Leptin receptor, SOCS proteins, Signalling, Cross-
regulation
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2215Leptin receptor and SOCS interactions
its activation in the hypothalamus promotes food intake
(Minokoshi et al., 2004).
CIS (cytokine-inducible SH2 protein) was the founding
member of the SOCS (suppressor of cytokine signalling)
family, now consisting of eight proteins: SOCS1-7 and CIS.
SOCS proteins typically have an SH2-domain, an N-terminal
A
C
B
D
Fig. 1. (A) Overview of LR signalling and its interaction partners. The murine LR carries three conserved tyrosines in its cytoplasmic tail at
positions Y985, Y1077 and Y1138. JAK2 is constitutively associated with the LR at the conserved Box 1 and 2 motifs. Upon leptin stimulation,
the JAKs become fully activated through cross-phosphorylation and phosphorylate the tyrosine residues in the receptor. STAT3 is recruited to
the phosphorylated Y1138 docking site. Upon phosphorylation, STAT3 translocates as dimers to the nucleus, and induces specific gene
expression. SHP2 is recruited to the Y985 docking site and couples to the Ras/Raf signalling cascade. The PI-3K pathway is also involved in
LR signalling. Tyrosines Y985 and Y1077 take part in negative regulation of the leptin signal by binding SOCS3. PTP-1B is involved in
negative regulation by dephosphorylation of JAK2 after internalisation of the LR complex. (B) MAPPIT principle. A particular bait protein is
linked C-terminally to the chimeric receptor consisting of the extracellular part of the EpoR and the intracellular part of the LR with all three
tyrosines mutated to phenylalanine, whereas the prey protein is fused to the STAT3 recruitment sites of the gp130 chain. The bait-receptor is
incapable of recruiting STAT3 upon stimulation. However, when bait and prey proteins interact, the C-terminal part of the gp130 chain is
brought in close proximity to the JAK kinases allowing its tyrosine phosphorylation and subsequent STAT3 activation. Read-out is based on a
STAT3-responsive reporter construct. (C) GGS-MAPPIT. For GGS-MAPPIT the bait protein is attached C-terminally to a variant of the
chimeric EpoR-LR receptor. The cytosolic domain of the LR following the JAK2 association domain is replaced by a GGS-array, preventing
any background activation resulting from prey association with the LR-F3. (D) LR-MAPPIT. Here, the LR itself functions as bait protein.
Owing to the Y1138F mutation, no STAT3 recruitment or activation can occur. Upon stimulation, the two membrane proximal tyrosines can
nevertheless be phosphorylated by JAK2. Interaction of the prey protein with the LR, which may depend on phosphorylation, allows STAT3
activation and subsequent reporter induction.
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preSH2-domain and a C-terminal SOCS box (Starr et al.,
1997). The SOCS box targets signalling proteins to the
proteasome for degradation by recruitment of an ubiquitin-
transferase system (Kile et al., 2002). Elongin B or C of the
E3 ligase complex is recruited to the BC box in the SOCS box
(Kamura et al., 1998). SOCS1 and 3 also carry a KIR (kinase
inhibitory region) domain that may act as a pseudosubstrate for
direct inhibition of JAK kinase activity. Although SOCS1
associates with JAK2, SOCS3 binds the receptor in close
proximity to the kinase and shows only weak affinity for JAK2
(Kubo et al., 2003). Competition for binding to shared
recruitment sites can also contribute to the negative regulation
of signalling pathways, as exemplified for CIS and SOCS2 in
case of STAT5 recruitment at the growth hormone receptor
(Greenhalgh et al., 2002a; Ram and Waxman, 1999).
SOCS3 was identified as a potent inhibitor of LR signalling.
It associates predominantly with the pY985 motif in the LR.
Weak interaction at position pY1077 may explain its additive
effect on inhibition of LR signalling (Bjorbaek et al., 2000;
Eyckerman et al., 2000). SOCS3 is rapidly expressed in the
hypothalamus upon leptin stimulation making it part of a
STAT3-mediated negative feedback system (Bjorbaek et al.,
1998a; Dunn et al., 2005). Recently, PTP-1B was also
identified as a negative mediator of LR signalling, targeting
both the JAK-STAT and the MAPK pathway (Kaszubska et al.,
2002).
It is well established that in many cytokine receptor systems
multiple SOCS proteins can be involved in regulation. In the
case of the growth hormone, erythropoietin and prolactin
receptors, this includes CIS, SOCS2 and SOCS3. Since leptin
can activate STAT5 (Baumann et al., 1996; Hekerman et al.,
2005) and since CIS and SOCS2 are known regulators of
STAT5 recruitment (Ram et al., 1999; Greenhalgh et al.,
2002a), we questioned whether CIS or SOCS2 could be
involved in LR signalling. Consistent with this, highly
conserved tyrosine-based motifs compatible with CIS and
SOCS2 association are present in the LR. Also, leptin can
induce CIS and SOCS3 expression, and to a lesser extent
SOCS2 in insulinoma cells (data not shown). To analyse these
interactions with the LR we used two alternative versions of
the MAPPIT (mammalian protein-protein interaction trap)
strategy (Fig. 1). We observed differential binding of CIS and
SOCS2 with the LR and demonstrate two distinct mechanisms
for functional interference by SOCS2.
Results
Cytokine receptor signalling and design of MAPPIT
experiments
An overview of signalling through the leptin receptor (LR) is
shown in Fig. 1A, and is described in more detail in the
introductory section. With MAPPIT we developed a new
method to analyse protein interactions in mammalian cells
(Eyckerman et al., 2001). MAPPIT bait constructs were
originally designed as chimeric receptors, consisting of the
extracellular part of the erythropoietin receptor (EpoR) fused
to the transmembrane and intracellular regions of a STAT3
recruitment-deficient LR, with a C-terminally attached bait.
MAPPIT prey constructs are composed of a prey polypeptide
fused to a part of the gp130 chain carrying 4 STAT3
recruitment sites. Co-expression of interacting bait and prey
leads to functional complementation of STAT3 activity that can
Journal of Cell Science 119 (11)
be measured with the STAT3-responsive rat pancreatitis-
associated protein I (rPAPI) promoter-luciferase reporter (Fig.
1B). Intrinsic to this strategy, both modification-independent
and tyrosine phosphorylation-dependent interactions can be
detected.
To monitor interactions with isolated tyrosine motifs of the
LR, we developed a MAPPIT configuration whereby the
cytosolic domain of the LR is replaced by a large array of Gly-
Gly-Ser (GGS) repeats (Fig. 1C). The MAPPIT technique also
allows the analysis of interactions with the LR itself by simple
mutation of the Y1138 STAT3-recruitment motif to
phenylalanine (Fig. 1D). LRs with different combinations of Y
to F mutations of the two other conserved tyrosine motifs
(located at positions Y985 and Y1077) were used. This allows
the study of protein associations with the LR in its normal
oligomeric configuration.
MAPPIT analysis of CIS and SOCS2 interactions with
the LR
To determine interaction with the LR, the CISprey fusion
protein was transiently co-expressed with the LR(YYF) mutant
and the luciferase reporter construct (Fig. 2A). Clear induction
of luciferase activity indicated that CIS interacts with the LR.
MAPPIT experiments using LR(YFF), LR(FYF) or LR(F3)
showed that CIS can interact with both Y985 and Y1077
motifs, whereas no interaction was detected with the LR
lacking tyrosines. In a similar way we also tested the SOCS2-
LR interaction (Fig. 2A). SOCS2 clearly associates with the
LR, but only at position Y1077. Expression of the LR mutants
was analysed using a leptin-SEAP binding assay (Fig. 2B), and
expression of the FLAG-tagged CIS and SOCS2 preys was
revealed by immunoblotting using an anti-FLAG antibody
(Fig. 2C).
Phosphopeptide binding analysis
We confirmed the specific interaction of SOCS2 with pY1077
of the LR using a biochemical strategy (Fig. 3). FLAG-tagged
SOCS2 or CIS proteins were expressed in HEK293T cells and
total cell lysates were incubated with the biotinylated peptides
encompassing the LR phosphorylated or non-phosphorylated
Y1077 or Y985 motifs to verify (phospho)tyrosine-specific
association. SOCS2 clearly interacted with the phosphorylated
Y1077 motif but not with the phosphorylated Y985 motif,
confirming its specific phosphorylation-dependent interaction
with the LR at position Y1077. Association of CIS was found
with neither pY985 nor pY1077 indicating that these
interactions may be to weak or short-lived to be detected by
phosphopeptide affinity chromatography (data not shown).
Relative binding affinities of the CIS and SOCS2
interactions with the LR
To gain further insight into their relative binding affinities for
the LR, the CISprey or SOCS2prey were co-expressed with
wild-type CIS. Although CIS expression markedly reduced the
CISprey signal through both LR(YFF) and LR(FYF), it did not
lead to any inhibition of the SOCS2prey signal through Y1077.
Conversely, co-expression of wild-type SOCS2 with the
CISprey protein clearly diminished the MAPPIT signal at the
Y1077 position in the LR whereas the SOCS2prey signal is
only partially reduced (Fig. 4A). These results confirm that CIS
interactions with Y985 and Y1077 of the LR are weak or
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transient, whereas the association of SOCS2 with Y1077 is
more stable and therefore not easy to compete. It is quite
surprising that SOCS2 can inhibit the MAPPIT signal of the
CISprey protein through Y985 since SOCS2 is not interacting
with this position. Expression levels of the FLAG-tagged
proteins were confirmed by immunoblotting using an anti-
FLAG antibody (Fig. 4B).
Analysis of CIS and SOCS2 interactions with the LR
using GGS-MAPPIT
A new adaptation of the classic MAPPIT method, called GGS-
MAPPIT (Fig. 1C), was used to confirm the interaction of CIS
and SOCS2 with the LR. In this configuration the cytosolic
domain of the LR, following the JAK2 interaction site, is
replaced by 60 GGS repeats. GGS triplet repeats are often used
as hinge sequences for their known structural flexibility. By
using this GGS-MAPPIT strategy any background prey
association with the LR-F3 is prevented. The bait constructs
containing the LR motifs surrounding Y985 or Y1077 were
transiently co-transfected with the prey construct and the rPAP
Fig. 2. Differential association of CIS and SOCS2 with the LR.
(A) HEK293T cells were transiently co-transfected with plasmids
encoding different pMET7-LR variants and the pMG2-CIS and
pMG2-SOCS2 prey constructs, or with mock vector, combined with
the pXP2d2-rPAP1-luci. The transfected cells were either stimulated
for 24 hours with leptin or were left untreated (NS, not stimulated).
Luciferase measurements were performed in triplicate. Data are
expressed as mean fold induction (leptin stimulated/NS) + s.d.
(B) LR expression levels were measured on the same transfected
cells by incubation for 2 hours with leptin-SEAP fusion protein with
or without a 100-fold excess of unlabelled leptin. Mean bound SEAP
activity + s.d. of triplicate measurements is plotted. (C) Western blot
analysis of CISprey and SOCS2prey expression. Expression of the
FLAG-tagged fusion prey proteins in the same transfected cells was
verified on lysates using anti-FLAG antibody.
Fig. 3. SOCS2 interaction with the peptide matching the Y1077
motif of the LR is phosphorylation dependent. FLAG-tagged SOCS2
was expressed in HEK293T cells and lysates were incubated with
phosphorylated or non-phosphorylated peptides corresponding to the
Y1077 or Y985 motif. Immunoblotting with anti-FLAG antibody
revealed specific interaction of SOCS2 with the tyrosine-
phosphorylated Y1077 motif. 
Fig. 4. Stability of the CIS and SOCS2 interactions with the LR.
(A) HEK293T cells were transiently co-transfected with plasmids
encoding different pMET7-LR variants, the pMG2-CIS or pMG2-
SOCS2 prey construct, pEF-FLAG-I/mCIS or pEF-FLAG-
I/mSOCS2, or the appropriate amount of mock vector together with
the pXP2d2-rPAP1-luci. The transfected cells were either stimulated
for 24 hours with leptin or were left untreated (NS, not stimulated).
Luciferase measurements were performed in triplicate. Data are
expressed as mean fold induction (leptin stimulated/NS) + s.d.
(B) Western blot analysis of CISprey, SOCS2prey, CIS and SOCS2
expression. Expression of the FLAG-tagged fusion proteins, CIS and
SOCS2 was verified on lysates of transfected cells using anti-FLAG
antibody.
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luciferase reporter construct in HEK293T cells. Using GGS
MAPPIT we were again able to detect the interaction of CIS
with both the Y985 and Y1077 motifs, whereas SOCS2 only
interacts with the Y1077 motif, but not with the pY985 motif
(Fig. 5A). We tested this GGS-MAPPIT strategy further in
erythroleukaemic TF-1 cells and obtained similar results as
those found in HEK293T cells (Fig. 5B). A full-length
FKBP12 bait was used to evaluate non-specific binding of the
CIS and SOCS2 preys. FACS analysis, using antibodies against
the extracellular domain of the EpoR, allowed monitoring of
the expression of the different GGS baits (Fig. 5C).
SOCS2 interferes with STAT5a recruitment
We previously showed that STAT5 can be activated by the LR
upon recruitment to the LR Y1077 and Y1138 motifs
Journal of Cell Science 119 (11)
(Hekerman et al., 2005). Given the strong interaction of
SOCS2 at position Y1077 we examined whether SOCS2 can
interfere with STAT5 association at this position. The SH2
domain of STAT5a was inserted in a prey construct and used
in MAPPIT experiments using the Y1077 motif as bait in GGS-
MAPPIT. In HEK293T cells, co-expression of SOCS2 or a
SOCS2 mutant lacking the entire SOCS box completely
abolished the MAPPIT signal. Similarly, co-expression of
SOCS2 box in TF-1 cells also abrogated the MAPPIT signal,
thus excluding a role for elongin B/C recruitment in this
suppressive effect (Fig. 6A,B). Similar data were obtained
using the LR(FYF) as bait (data not shown). We conclude that
SOCS2 can compete with STAT5a association at the pY1077
motif.
SOCS2 interacts with the SOCS box of CIS
Given the discrepancy between binding experiments at position
Y985, i.e. SOCS2 interferes with CIS binding without
Fig. 5. GGS-MAPPIT analysis of CIS and SOCS2 interactions with
the LR. (A,B) HEK293T cells (A) or TF-1 cells (B) were transiently
co-transfected with plasmids encoding the chimeric bait constructs
with the different LR motifs or with the FKBP12 control bait, and
the pMG2-CIS, pMG2-SOCS2 prey constructs, combined with the
pXP2d2-rPAP1-luci. The transfected cells were either stimulated for
24 hours with Epo or were left untreated (NS, not stimulated).
Luciferase measurements were performed in triplicate. Data are
expressed as mean fold induction (Epo stimulated/NS) + s.e.m.
(C) FACS analysis shows the expression of the different chimeric
GGS bait receptors in TF-1 cells. The grey filled curves represent the
parental TF-1 cells; open lines, the transiently transfected TF-1 cells.
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Fig. 6. SOCS2 interferes with the association of a STAT5a prey at
Y1077. (A,B) HEK293T cells (A) or TF-1 cells (B) were transiently
co-transfected with the plasmid encoding the GGS bait construct
with the Y1077 LR motif, the pMG2-STAT5aSH2 prey construct, the
pMET7-FLAG-SOCS2 or pMET7-FLAG-SOCS2 box, or the
appropriate amount of mock vector together with the pXP2d2-
rPAP1-luci. The transfected cells were either stimulated for 24 hours
with leptin or were left untreated (NS, not stimulated). Luciferase
measurements were performed in triplicate. Data are expressed as
mean fold induction (Epo stimulated/NS) + s.d.
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interacting with this recruitment motif itself, we examined
whether SOCS2 can directly associate with CIS. We first used
a MAPPIT configuration with CIS as bait. Here, SOCS2
clearly interacted specifically with full-length CIS (Fig. 7A).
In Fig. 7B, we confirmed this interaction by co-
immunoprecipitation. Next we looked at association of SOCS2
with the SOCS box of CIS in a MAPPIT experiment and also
observed clear interaction (Fig. 7C).
Elongin B/C recruitment is involved in SOCS2
interference with receptor-binding of CIS
We developed a mutant of SOCS2, SOCS2(LC-QQ), in which
elongin B/C recruitment is abrogated by mutating leucine 163
and cysteine 167, analogous to an elongin B/C recruitment-
deficient SOCS1 mutant reported before (Kamura et al., 1998).
We mutated both residues to glutamines to minimise structural
alterations. Elongin B/C association was analysed using a two-
step purification method, TAP2, based on the classic TAP
method (Puig et al., 2001). This sequential purification
procedure involves a first protein A tag-based step, followed
by TEV protease cleavage to remove the protein A part of the
tag and followed by a FLAG-tag-based immunoprecipitation
step. Clearly, this SOCS2(LC-QQ) mutant no longer interacted
with elongin B or C (Fig. 8A). Furthermore, this SOCS2
mutant as a prey protein still bound CIS in a MAPPIT
experiment (Fig. 8B).
We next examined the interference of SOCS2 with CIS
binding in more detail. At position Y985, the inhibitory effect
by co-expression of SOCS2 was completely lost when using
the SOCS2(LC-QQ) mutant. Recruitment of elongin B/C to the
SOCS box of SOCS2 thus appeared essential for interference
with CIS interaction at this position. By contrast, no difference
was observed for the SOCS2(LC-QQ) mutant at the Y1077
position, clearly in line with a direct competition with CIS
binding at this site (Fig. 8C).
Discussion
MAPPIT allows the study of protein-protein interactions in the
physiologically highly relevant context of intact human cells.
Here we used several variations of the MAPPIT concept to
study the interactions of two members of the SOCS protein
family, CIS and SOCS2, with the murine LR long isoform. CIS
and SOCS2 preys were shown to interact with specific tyrosine
motifs, either within the full LR configuration or as isolated
baits. Interactions were demonstrated in two different cell
types: epithelial HEK293T cells as well as the haemopoietic
TF-1 cell line.
CIS binding was observed with the conserved mLR Y985 and
Y1077 tyrosine-based motifs. By contrast, SOCS2 interacted
only at the Y1077 position. In all cases, a Y to F mutation
abrogated signalling, indicative of the phosphorylation-
dependent nature of the interactions. We compared MAPPIT-
based interaction analysis with a biochemical approach using
Fig. 7. SOCS2 interacts with CIS. (A) MAPPIT analysis. HEK293T
cells were transiently co-transfected with plasmids encoding the
chimeric EpoR-LR(F3) construct as a negative control or with the
full-length (FL) CIS bait, and the pMG2-SOCS2 prey constructs,
combined with the pXP2d2-rPAP1-luci reporter. The transfected
cells were either stimulated for 24 hours with Epo or were left
untreated (NS, not stimulated). Luciferase measurements were
performed in triplicate. Data are expressed as mean fold induction
(Epo stimulated/NS) + s.d. (B) Co-immunoprecipitation. HEK293T
cells were transiently co-transfected with pMET7-Flag-SOCS2 and
pMET7-Etag-CIS. Cell lysates were immunoprecipitated (IP) with
anti-FLAG and subsequently immunoblotted (IB) with anti-E.
(C) SOCS2 interacts with the SOCS box of CIS. HEK293T cells
were transiently co-transfected with plasmids encoding the chimeric
EpoR-LR(F3) construct as a negative control or with the CIS SOCS
box bait, and the pMG2-SOCS2 prey construct or the appropriate
amount of mock vector, combined with the pXP2d2-rPAP1-luci. The
transfected cells were either stimulated for 24 hours with Epo or
were left untreated (NS, not stimulated). Luciferase measurements
were performed in triplicate. Data are expressed as mean fold
induction (Epo stimulated/NS) + s.d.
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Fig. 8. (A) Generation of a SOCS2 mutant deficient in elongin B/C binding. HEK293T cells were transiently transfected with the
pMET7TAP2-SOCS2 and pMET7TAP2-SOCS2(LC-QQ) constructs. Cell lysates were purified using the TAP2 tag and loaded on a
polyacrylamide gel and silverstained. From a parallel experiment, the indicated bands were identified as cullin 5, elongin B and elongin C by
mass spectrometry. (B) The SOCS2(LC-QQ) mutant still binds CIS. HEK293T cells were transiently co-transfected with plasmids encoding the
chimeric EpoR-LR(F3) construct as a negative control or with the CIS SOCS box bait, and the pMG2-SOCS2 or pMG2-SOCS2 (LC-QQ) prey
constructs, combined with the pXP2d2-rPAP1-luci. The transfected cells were either stimulated for 24 hours with Epo or were left untreated
(NS, not stimulated). Luciferase measurements were performed in triplicate. Data are expressed as mean fold induction (Epo stimulated/NS) +
s.d. (C) Differential effects of the SOCS2(LC-QQ) mutant on CIS interaction with the LR recruitment motifs. HEK293T cells were transiently
co-transfected with plasmids encoding different pMet7-LR variants, the pMG2-CIS prey construct, pMet7-FLAG-SOCS2 or pMet7-FLAG-
SOCS2(LC-QQ), or the appropriate amount of mock vector together with the pXP2d2-rPAP1-luci. The transfected cells were either stimulated
for 24 hours with leptin or were left untreated (NS, not stimulated). Luciferase measurements were performed in triplicate. Data are expressed
as mean fold induction (leptin stimulated/NS) + s.d.
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affinity chromatography with phosphorylated and non-
phosphorylated peptides matching the Y1077 or the Y985
motifs. The interaction between SOCS2 and the pY1077 motif
was readily demonstrated, in contrast to CIS and its matching
phosphopeptides. This is probably due to the more transient or
weak nature of the latter interactions. In line with this proposal,
competition experiments showed that whereas CIS over-
expression could clearly interfere with CISprey binding to
either motif, no cross-competition with the SOCS2prey
occurred. Conversely, SOCS2 could easily interfere with
CISprey binding to pY1077.
Previous reports indicated that the tyrosine at position
Y1077 of the receptor was not phosphorylated and was not
involved in LR signalling (Banks et al., 2000; Li and Friedman,
1999). However, several observations contradict this
supposition. We reported earlier that SOCS3 can interact with
the Y1077 domain, although in a rather weak manner, and that
this interaction was dependent on tyrosine phosphorylation
(Eyckerman et al., 2000). More recently, Y1077 was also
reported to induce STAT5 activation (Hekerman et al., 2005).
Consistent with a functional role, Y1077 is present in a highly
conserved motif, with great similarity to the conserved Y985
domain (Eyckerman et al., 2000). Our findings now lend
further support for the important role of the pY1077 motif in
LR signalling with two more members of the SOCS protein
family interacting at this position, whereby SOCS2 can
interfere with CIS and STAT5a prey recruitment.
Very surprisingly, SOCS2 not only interfered with CIS-prey
interaction at position Y1077, but also at the Y985 motif
without binding this site itself. We provided an explanation for
this unexpected finding by showing that SOCS2 directly binds
to the SOCS box of CIS. Abrogation of the elongin B/C
recruitment ability of SOCS2 had no influence on its
association with CIS, but its ability to eliminate CIS receptor
binding at position Y985 was completely lost, implying that
ubiquitylation and proteasomal degradation of CIS is
involved. Very recently, it was reported that SOCS2 also
interferes with SOCS3-dependent inhibition of IL-2 and IL-3
signalling (Tannahill et al., 2005). Together, these findings
point to an additional, new level of SOCS-mediated signalling
control. Reminiscent of this, both mice lacking SOCS2 and
SOCS2 transgenic mice exhibit increased growth due to
prolonged growth-hormone-dependent STAT5 activity
(Greenhalgh et al., 2002b; Metcalf et al., 2000). This dual
effect of SOCS2 was also observed in vitro because low
SOCS2 doses moderately inhibit GH signalling whereas
higher levels positively regulate signalling, probably through
interference with SOCS1 function (Favre et al., 1999;
Greenhalgh et al., 2005). Our interaction analysis clearly
implicates a complex biological role for SOCS2 and suggests
an explanation for the abovementioned duality: SOCS2 can
interfere with cytokine signalling through direct interaction
with receptors, but can also enhance signalling by eliminating
other SOCS proteins through proteasomal degradation. This
latter effect may reflect a crucial physiological role of SOCS2
in restoring cellular responsiveness after cytokine activation.
In line with this, SOCS2 is usually induced at later time points
compared with CIS, SOCS1 and SOCS3 (Adams et al., 1998;
Pezet et al., 1999; Tannahill et al., 2005). Detailed quantitative
analyses will be required to understand this balancing act in
full.
Leptin resistance, which occurs in a majority of obese
individuals, may be situated at different levels, e.g. saturation
of leptin transport through the blood-brain barrier or
aberrations in LR signalling in hypothalamic neurons (El-
Haschimi et al., 2000). LR Y1138S knock-in mice are severely
obese and fail to activate STAT3, implying a dominant role for
STAT3 in leptin-mediated regulation of the energy balance
(Bates et al., 2003). Aberrant negative feedback control of LR
signalling may contribute to leptin resistance and obesity,
because augmented leptin sensitivity and resistance to diet-
induced obesity was observed in neural-cell-specific SOCS3
conditional-knockout mice or in SOCS3-haploinsufficient
mice (Howard et al., 2004; Mori et al., 2004). In contrast to
SOCS3, a negative regulatory role for CIS and SOCS2 on the
hypothalamic LR STAT3 pathway is questionable. Bjorbaek
and colleagues reported that JAK2 phosphorylation is
inhibited by SOCS3 upon leptin stimulation in COS cells but
not by SOCS2 or CIS, which both lack a KIR domain at the
N-terminus (Bjorbaek et al., 1999). Similarly, we did not
observe any clear inhibitory effect on LR signalling through
STAT3 by either CIS or SOCS2 (data not shown). This is not
unexpected because STAT3 recruitment occurs at the Y1138
motif. Since expression of SOCS2 or CIS is also not up-
regulated in the hypothalamus upon leptin administration in
mice, a role in LR STAT3 signalling is thus unlikely (Bjorbaek
et al., 1998a).
CIS and SOCS2 can function through competition with
STAT binding at the receptor recruitment site. This
mechanism, for example, underlies down-modulation of
STAT5 activation by both CIS and SOCS2 upon growth
hormone receptor (GHR) activation (Greenhalgh et al., 2002a;
Ram and Waxman, 1999). Likewise, the physiological role for
CIS and SOCS2 on LR signalling through the Y985 and
Y1077 motifs may involve inhibition of recruitment of
downstream signalling moieties. This may be particularly
relevant in peripheral cell types, known to respond to leptin.
Experiments on MLR (mixed-lymphocyte reaction), resulting
from the culture of T cells with major histocompatibility
complex (MHC)-incompatible stimulator cells, indicated that
leptin promotes proliferation of CD4+ T cells (helper T cells,
Th) and induces a shifts to activation of Th1 cells, associated
with elevated secretion of pro-inflammatory cytokines
including interleukin-2 (IL-2) and interferon- (IFN-) (Lord
et al., 1998). Intriguingly, CIS transgenic mice show altered
helper T-cell development with a switch toward Th2 cell
response, accompanied by increased IL-4 levels (Matsumoto
et al., 1999). CIS may thus be involved in the leptin-dependent
modulation of the Th1/Th2 balance. SOCS2 knock-out mice
showed a remarkable increase in size whereas growth
retardation was observed in CIS transgenic mice. Both SOCS
proteins were identified as negative regulators of GHR
signalling, presumably through STAT5 (Matsumoto et al.,
1999; Metcalf et al., 2000). Considering the decreased linear
growth observed in db/db mice and humans with truncated LR
(Bates et al., 2003; Clement et al., 1998), SOCS2 and CIS may
also exert their influence on growth through regulation of LR
signalling. Since LR Y1138S knock-in mice are not reduced
in size (Bates et al., 2003) and since, in addition, no clear
effect of CIS or SOCS2 was observed on leptin-dependent
STAT3 signalling, this effect of SOCS2 and CIS probably
occurs independently of STAT3. A good candidate is STAT5,
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since it is activated in different cell types upon leptin
stimulation in vitro through the Y1077 and Y1138 positions
in the LR (Baumann et al., 1996; Hekerman et al., 2005). We
here showed that SOCS2 can inhibit STAT5a prey association
at the LR Y1077 position.
In conclusion, the MAPPIT approach was shown to be a
sensitive and flexible system for analysing interactions
between proteins in a cellular context. We identified two SOCS
proteins, CIS and SOCS2, as new interaction partners of the
LR, and identified a novel regulatory role for SOCS2. Full
understanding of the biological implications of cross-
regulation between SOCS proteins on the different cytokine
receptor systems will require detailed, quantitative analysis of
all members of this protein family.
Materials and Methods
Constructs
Generation of the mutant mouse LR(YYF), LR(FYF), LR(YFF), LR(F3) in the
pMET7 expression vector was described elsewhere (Eyckerman et al., 1999). A
pSEL-hEpoR-Y480 bait vector was derived from the described pSEL-hEpoR-Y402
bait (Eyckerman et al., 2001). In this pSEL-hEpoR-Y480 bait construct most of the
intracellular part of the LR was replaced by a flexible GGSN linker. An unique
EcoRI restriction site was introduced immediately following the JAK2 binding site
through site-directed mutagenesis (Stratagene) using the primer pair 5-GCTT-
GGAAAAATAAAGATGAATTCGTCCCAGCAGCTATGGTC-3 and 5-GACC-
ATAGCTGCTGGGACGAATTCATCTTTATTTTTCCAAGC-3. Phosphorylated
oligonucleotides encoding two GGS repeats (5-TCTGGTGGCAGTGGAGGG-3
and 5-AGACCCTCCACTGCCACC-3) were annealed and head to tail ligated.
Ligation was stopped by addition of two other annealed oligonucleotide couples:
5-AATTCGGAGGGAGTGGTGGC-3 and 5-AGAGCCACCACTCCCTCCG-3;
5-TCTGGAGGGAGTGGTGGGAGCT-3 and 5-CCCACCACTCCCTCC-3.
Annealing of these oligonucleotide couples generated respectively an EcoRI and a
SacII (both underlined) sticky end. The final product was ligated in EcoRI-SacII
opened pSEL-hEpoR-Y480 vector. Sequence analysis showed that using this
procedure 20 GGS repeats were introduced in the bait construct. The linker was
further amplified using oligonucletides 5-CTTCTTCTGGAGCCTGAACC-3 and
5-CGCCGCCAATTGCGAACTCCCACCACTCCC-3. The product was digested
with EcoRI-MfeI and ligated in the EcoRI digested pSEL-20GGS-hEpoR-Y480
vector yielding the pSEL-40GGS-hEpoR-Y480 vector. This ligation step was
repeated once more to generate pSEL-60GGS-hEpoR-Y480 vector. The
pSEL(+2L)60GGS-Y480 construct was generated by site-directed mutagenesis on
the pSEL-60GGS-hEpoR-Y480 vector using primers 5-CCCATAATTATTTCC-
AGCTGTCTCCTCGTCCTACTGCTCGGAAC-3 and 5-GTTCCGAGCAGTAG-
GACGAGGAGACAGCTGGAAATAATTATGGG-3 and Y480 was removed by
SacI-NotI. The mLR Y985 motif was amplified with forward primer 5-
GCCGAGCTCATGGAAAAATAAAGATGAG-3 containing a SacI site and
reverse primer 5-CGGGCGGCCGCTCAACAGACAGACTTCTCCCTGTG-3
containing a NotI site and a stop codon, allowing in-frame coupling to the hEpoR-
60GGS chimeric receptor. The same strategy was used for the mLR Y1077 motif,
using primers 5-GCCGAGCTCAGCAACTCTGGTCAGCAAC-3 and 5-GGG-
CGGCCGCTCAAGGTACAAAGTTCTCACC-3. The final constructs were called
pSEL(+2L)60GGS-mLR-Y985 and pSEL(+2L)60GGS-mLR Y1077, respectively.
For the pSEL(+2L)60GGS-FKBP12 construct, FKPB12 was cut from the
pSELFFY-FKBP12 construct described earlier (Eyckerman et al., 2005) using SacI
and NotI, and cloned in the pSEL(+2L)60GGS vector.
The pXP2d2-rPAPI-luciferase reporter, originating from the rPAPI (rat
pancreatitis-associated protein I) promoter, is used as previously described
(Eyckerman et al., 2001). Expression plasmid vectors pEF-FLAG-I/mSOCS2 and
pEF-FLAG-I/mCIS were a gift from R. Starr (The Walter and Eliza Hall Institute
of Medical Research, Parkville, Australia). Generation of the prey constructs pMG2-
CIS and pMG2-SOCS2 both containing part of the gp130 chain (aa 905-918) in
duplicate was described elsewhere (Montoye et al., 2005).
The pMET7-FLAG-CIS construct was created by a three-point ligation. The N-
terminal FLAG-tag of CIS was cut from the pEF-FLAG-I/mCIS construct using
EcoRI-PvuII and the C-terminal part of CIS was cut from the pMG1-CIS construct
using KpnI-PvuII as described elsewhere (Eyckerman et al., 2001). Both parts were
ligated in the pMet7 vector digested with EcoRI-PvuII. To create the pMET7-Etag-
CIS construct, CIS was amplified from the pMET7-FLAG-CIS using primers
5-CGTCCGCGGCCGCGGTCCTCTGCGTACAGGGATC-3 and 5-GCTGGCT-
CGAGTCAGAGTTGGAAGGGGTACTGTC-3 and was ligated in the NotI-XhoI
digested pCAGGSE-mMyD88 construct, which was a gift from Rudy Beyaert
(Ghent University, Ghent, Belgium). Etag-CIS was then digested with EcoRI-XhoI
and ligated in the pMET7 vector.
pMET7-FLAG-SOCS2 was created by cutting SOCS2 from the pMG2-SOCS2
construct using EcoRI-XbaI and ligating it into the EcoRI-XbaI digested pMET7-
FLAG-SOCS3 expression vector which was described elsewhere (Eyckerman et al.,
2000). SOCS2 box was amplified using primers 5-TGCCTTTACTTCTAGGC-
CTG-3 and 5-GCAGGTCTAGATTATGATGTATACAGAGGTTTG-3 from the
templates pMET7-FLAG-SOCS2 cloned in the NotI-XbaI opened pMET7-FLAG-
SOCS2 to create pMET7-FLAG-SOCS2 box. The pMET7-FLAG-SOCS2(LC-
QQ) mutant was created by site-directed mutagenesis of the pMET7-FLAG-SOCS2
construct using primers 5-GTATACATCAGCACCCACTCAGCAGCATTTCCA-
ACGACTCGCCATTAAC-3 and 5-GTTAATGGCGAGTCGTTGGAAATGCTG-
CTGAGTGGGTGCTGATGTATAC-3.
Generation of the chimeric receptors containing the extracellular part of the EpoR
and the transmembrane and intracellular parts of the leptin receptor, such as EpoR-
LR(F3), were described elsewhere (Eyckerman et al., 2001). A full-length CIS bait
construct was generated by digesting the pCEL(2L)-Y480 bait construct with SstI
and NotI and swapping the EpoR Y402 motif with a PCR product containing full-
length CIS and the cloning sites SstI and NotI (primers 5-GCGCGAGCTC-
AATGGTCCTCTGCGTACAGGG-3 and 5-GCTCGCGGCCGCTCAGAGTTG-
GAAGGGGTACTGTCGG-3). The CIS SOCS box bait was made using the same
strategy and the PCR amplification of the CIS SOCS box was done with primers
5 GCGAGAGCTCCGGATCCGCCCGCAGCTTACAACATC and 5 CGCTG-
CGGCCGCTTAGAGTTGGAAGGGGTACTG. The SOCS2 (LC-QQ) prey was
generated by mutating L163 and C167 of the Wild Type SOCS2 prey using primers
5-GTATACATCAGCACCCACTCAGCAGCATTTCCAACGACTCGCCATTAAC-
3 and 5-GTTAATGGCGAGTCGTTGGAAATGCTGCTGAGTGGGTGCTG-
ATGTATAC-3. pMG2-STAT5aSH2 was created by amplifying the SH2 domain of
STAT5a using primers 5-GCGAGAATTCTCCGGACCCCACTGGAATGATGG-
GGC-3 and 5-CGCTTCTAGATTAACTCGAGGAGAAGACCTCATCCTTGG-3
and EcoRI-XbaI cloning in the pMG2 vector.
To generate the pMET7TAP2 construct we used the primers 5-GCGAG-
GGCCCGCCACCATGGCCCAGCACGACGAGATCTC-3 and 5-CGCTCTCG-
AGGCCCTGGAAGTACAGGTTCTCGCTGGCGGTGGTGGGGATGTCGCTGT-
TGGCGTCCACGCTG-3 to amplify the proteinA domain from the pMA-SpaI
construct obtained from the BCCM/LMBP plasmid collection and to add a TEV
cleavage site and we cloned the PCR product in the pMET7 vector using ApaI-XhoI.
The FLAGtag was introduced using primers 5-GCGAGGGCCCGCCACCAT-
GGCCCAGCACGACGAGATCTC-3 and 5-GCGAGAATTCCCCGCTGCCCT-
TGTCATCGTCGTCCTTGTAGTCCTGGCGCGCGCCCTGGAAGTACAGGTTC-
3 and cloned in the same vector using ApaI-EcoRI.
pMET7TAP2-SOCS2 was constructed by cutting SOCS2 from the pMG2-SOCS2
construct using EcoRI-NotI and ligating it in the pMET7TAP2 construct.
This construct was then used to create the pMET7TAP2-SOCS2(LC-QQ) by site-
directed mutagenesis using the primers 5-GTATACATCAGCACCCACTCAGC-
AGCATTTCCAACGACTCGCCATTAAC-3 and 5-GTTAATGGCGAGTCGTT-
GGAAATGCTGCTGAGTGGGTGCTGATGTATAC-3. All constructs were
verified by DNA sequence analysis.
Cell culture, transfection and reporter assays
Culture conditions, transfection procedures and luciferase assays for HEK293T cells
were as previously described (Eyckerman et al., 2000). For a typical luciferase
experiment, HEK293T cells were seeded in six-well plates 24 hours before
overnight transfection with the desired constructs together with the luciferase
reporter gene. Two days after transfection cells were left untreated (not stimulated
NS) or were stimulated with 100 ng/ml leptin overnight. The luciferase activity of
the transfected cells were measured by chemiluminescence. The factor-dependent
TF-1 erythroleukaemia cell line was grown in RPMI medium supplemented with
10% foetal calf serum and 1 ng/ml GM-CSF. After electroporation (300 V, 1500
F), cells were starved (removal of GM-CSF) for 24 hours and were subsequently
stimulated with 5 ng/ml hEpo overnight. After 24 hours, luciferase activity was
measured as described before.
Leptin binding assay
LR expression on the surface of HEK293T cells was measured using a binding assay
with a mouse leptin-secreted alkaline phosphatase (SEAP) chimeric protein
(Tartaglia et al., 1995). 48 hours after transfection, cells were incubated for 2 hours
with a 1:50 dilution of conditioned Cos1 medium containing the chimeric protein
with or without an excess of leptin. After two washing steps, cells were lysed in a
buffer (1% Triton X-100, 20 mM Tris-HCl pH 7.4) and alkaline phosphatase activity
was measured by chemiluminescence, using CSPD substrate (PhosphaLight,
Tropix) according to the protocol provided by the manufacturer.
FACS analysis
The expression of the chimeric hEpoR-mLR GGS baits was monitored using goat
anti-human EpoR polyclonal IgG (R&D Systems) at 2 g/ml and Alexa Fluor 488-
conjugated donkey anti-goat IgG (Molecular Probes) at 4 g/ml. Fluorescence-
activated cell sorting (FACS) was performed on a FACSCalibur (Becton Dickinson).
Western blot analysis
Expression of the gp130-fusion proteins, CIS and SOCS2, all flag-tagged, were
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verified by western blot analysis. Transfected HEK293T or TF-1 cells were lysed
in RIPA buffer: 200 mM NaCl, 50 mM Tris-HCl pH 8, 0.05% SDS, 2 mM EDTA,
1% NP40, 0.5% DOC, Complete™ Protease Inhibitor Cocktail (Roche). 4 loading
buffer (125 mM Tris-HCl pH 6.8, 6% SDS, 20% glycerol, 0.02% BFB, 10% -
mercaptoethanol) was added to the lysates which were then loaded on a 10%
polyacrylamide gel and blotted overnight. Blotting efficiency was checked using
PonceauS staining (Sigma). Flag-tagged proteins were revealed using monoclonal
anti-Flag antibody M2 (Sigma) and anti-mouse-HRP (horseradish peroxidase)
(Amersham Biosciences).
(Phospho)peptide affinity chromatography
Approximately 35106 HEK293T cells were transfected with either pEF-FLAG-
1/mSOCS2 or pEF-FLAG-1/mCIS and were lysed in lysis buffer (20 mM HEPES
pH 7, 1 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 150 mM NaCl, 0.5% NP40, 20%
glycerol, 1 mM NaVO4, Complete™ Protease Inhibitor Cocktail). The lysates were
centrifuged for 5 minutes at 10,000 g and loaded on a pre-column with Sepharose
4B beads and streptavidin-agarose to prevent nonspecific interactions. Pre-cleared
lysates were then incubated for 2 hours at 4°C with the (phospho)-tyrosine peptides
as indicated coupled to streptavidin-agarose beads through their biotin group. The
beads were then washed twice with lysis buffer and resuspended in 2 loading
buffer (62.5 mM Tris-HCl pH 6.8, 3% SDS, 10% glycerol, 0.01% BFB, 5% -
mercaptoethanol). Specific protein binding was revealed by SDS-PAGE and
immunoblotting using the anti-flag antibody and anti-mouse-HRP. The sequences
of the used peptides were biotin-QRQPSVK(P)Y985ATLVSNDK and biotin-
NHREKSVC(P)Y1077LGVTSVNR. Synthesis and purification of the biotinylated
(phospho)tyrosine peptides and coupling to streptavidin-agarose beads was
described before (Eyckerman et al., 2000).
Co-immunoprecipitation
Approximately 2106 HEK293T cells were transfected with pMet7-Flag-SOCS2
and pMet7-Etag-CIS. Cleared lysates (modified RIPA lysis buffer) were incubated
with 4 g/ml anti-FLAG mouse monoclonal antibody (Sigma) and protein-G-
Sepharose (Amersham Biosciences). After immunoprecipitation, SDS-PAGE and
western blotting, interactions were detected using anti-E-Tag antibody (Amersham
Biosciences).
TAP2 purification and mass spectrometry
HEK293T cells were transfected with the appropriate constructs and lysed in cell
lysis buffer (50 mM Tris-HCl pH 8, 10% glycerol, 1% NP40, 150 mM NaCl, 5 mM
NaF, 5 M ZnCl2, 1 mM Na3VO4, 10 mM EGTA, Complete™ Protease Inhibitor
Cocktail). The insoluble fraction was centrifuged and the supernatant was incubated
with IgG Sepharose (Amersham Biosciences) overnight. The beads were washed
three times with washing buffer (20 mM Tris-HCl pH 7.5, 5% glycerol, 0.1% NP40,
150 mM NaCl) and twice with TEV (Tobacco Etch Virus) protease cleavage buffer
1 (10 mM Tris-HCl pH 8, 150 mM NaCl, 0.1% NP40, 0.5 mM EDTA) and were
then incubated with TEV protease in TEV protease cleavage buffer 1 for 2 to 4
hours. The beads were then centrifuged and the supernatant was incubated with anti-
FLAG agarose (Sigma) in TEV protease cleavage buffer 2 (10 mM Tris-HCl pH 8,
150 mM NaCl, 0.1% NP40) for 2 to 4 hours. The anti-FLAG agarose beads were
washed three times with washing buffer and incubated with FLAG peptide for 10
minutes. The beads were spun down and 4 loading buffer was added to the
supernatants before loading on a polyacrylamide gel. Proteins were either visualised
by silver staining, or for mass spectrometry analysis with Sypro Ruby protein gel
stain according to the manufacturer’s instructions (Molecular Probes). Proteins of
interest were excised and in-gel digested with trypsin as described. The resulting
peptide mixture was dried, re-dissolved in 20 l of 0.1% formic acid in 2/98 (v/v)
acetonitrile/water and half of it was applied for nano-LC-MS/MS analysis on an
Ultimate (Dionex, Amsterdam, The Netherlands) in-line connected to an Esquire
HCT ion trap (Bruker Daltonics, Bremen, Germany). The sample was first trapped
on a trapping column (PepMapTM C18 column, 0.3 mm ID 5 mm, Dionex) and
after back-flushing, the sample was loaded on a 75 m ID 150 mm reverse-phase
column (PepMapTM C18, Dionex). The peptides were eluted with a linear solvent
gradient over 50 minutes of 0.1% formic acid in acetonitrile/water (7/3, v/v). Using
data-dependent acquisition, only multiple charged ions with intensities above
threshold 100,000 were selected for fragmentation. For MS/MS analysis, an MS/MS
fragmentation amplitude of 0.7 V and a scan time of 40 milliseconds was used. The
fragmentation spectra were converted to Mascot generic files (mgf) using the
Automation Engine software (version 3.2, Bruker) and searched using the MASCOT
database search engine (http://www.matrixscience.com) against the SwissProt and
the NCBInr Database (taxonomy mammalia). Only spectra that exceeded Mascot’s
threshold score for identify (set at the 95% confidence level) were retained for
further manual validation.
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CHAPTER 7: Leptin signalling in haematopoietic cells  
 
 
I.  Introduction  
 
Leptin research was initially focused on its effects on hypothalamic weight 
regulation. During the last years however, leptin has been increasingly recognized 
as a cytokine-like hormone with pleiotropic actions on different physiological 
processes and in many peripheral tissues. Conceivably, leptin may function as a link 
between energy homeostasis and these physiological processes, since adequate 
energy stores are required to maintain certain energy-demanding processes. At 
present, the role of leptin in haematopoiesis is still a subject of much research and 
discussion. The functional long isoform of the LR is expressed in haematopoietic 
stem cells and in bone marrow stromal cells (Bennett et al., 1996; Cioffi et al., 1996; 
Konopleva et al., 1999). Involvement of leptin in modulation of haematopoiesis was 
demonstrated by colony formation studies where leptin stimulated the proliferation of 
stem cells and increased the numbers of lymphoid, erythroid and myeloid colonies 
(Bennett et al., 1996). Both ob/ob and db/db mice show a deficit in lymphopoietic 
progenitors and have defective erythrocyte production in the spleen, suggesting a 
role for leptin in the proliferation and expansion of haematopoietic stem cells and 
lymphoid progenitors (Bennett et al., 1996; Fantuzzi and Faggioni, 2000; Howard et 
al., 1999). Studies on signalling events induced by leptin in haematopoietic 
progenitor cells are very limited. Induction of the MAPK and PI3K pathways by leptin 
has been shown in peripheral blood mononuclear cells (Martin-Romero et al., 2000) 
and leptin was reported to prevent apoptosis of leukemia cells through STAT3 and 
MAPK activation (Tabe et al., 2004). 
 
In order to gain more insight in the function of leptin as a modulator of 
haematopoiesis, we analysed leptin-mediated signalling events in haematopoietic 
cell lines using the MAPPIT technology. In preliminary experiments, no clear signals 
could be obtained with the classical STAT3-based MAPPIT set-up in several 
haematopoietic cell lines including erythroleukemic TF1, promyelocytic FDC-P1 and 
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prolymphocytic Ba/F3 cells. Since haematopoietic signalling depends predominantly 
on STAT5, we designed a variant of the MAPPIT method relying on functional 
complementation of STAT5 signalling. A novel prey construct was generated in 
which the gp130 domain is replaced by a STAT5 interaction sites-containing part of 
the βc-receptor. We used this novel βc-adaptation of the MAPPIT technology to 
examine leptin signalling in the TF1 and Ba/F3 haematopoietic cell lines. Several 
reported as well as novel interactions with the LR were identified. Our findings 
provide a basis for more detailed functional analysis of leptin signalling in 
haematopoiesis. Furthermore, MAPPIT proves to be a flexible method that can be 
adapted to other cell types like here for haematopoietic cell lines. 
 
 
II. Article: Analysis of leptin signalling in haematopoietic cells using an 
adapted MAPPIT strategy.  
Published in FEBS letters, 2006. 
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Edited by Robert BaroukiAbstract The adipocyte-secreted hormone leptin participates in
the regulation of hematopoiesis and enhances proliferation of
hematopoietic cells. We used an adaptation of the MAPPIT
mammalian two-hybrid method to study leptin signalling in a
hematopoietic setting. We conﬁrmed the known interactions of
suppressor of cytokine signalling 3 (SOCS3) and STAT5 with
the Y985 and Y1077 motifs of the leptin receptor, respectively.
We also provide evidence for novel interactions at the Y1077 mo-
tif, including phospholipase C gamma and several members of
the SOCS protein family, further underscoring the important
role of the Y1077 motif in leptin signalling.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: MAPPIT; Leptin receptor; Signal transduction1. Introduction
Leptins’ role has been studied most extensively in the central
nervous system, where it regulates food intake and energy bal-
ance. Recent research revealed a wider spectrum of biological
actions of this adipokine in other vital processes. Leptin-deﬁ-
cient (ob/ob) and leptin-receptor (LR)-deﬁcient (db/db) mice
develop a complex syndrome characterized not only by obesity
but also abnormal reproduction, hormonal imbalances and
dysregulation of the hematopoietic and immune system [1]. Al-
tered amounts of lymphopoietic progenitors, circulating lym-
phocytes, and leukocytes are observed in ob/ob and db/db
mice, and correlation studies between plasma leptin concentra-
tion and leukocyte counts in humans led to the notion that lep-
tin participates in the regulation of hematopoiesis [2–4]. In line
with this, expression of the signalling-competent leptin receptor
long isoform (LRlo) is observed in fetal liver, bone marrow,
CD34+ progenitor cells as well as in several hematopoietic cell
lines, such as TF1 and MO7E [5,6].
The LR, a member of the class I cytokine receptor family, is
expressed as multiple alternatively spliced isoforms, of whichAbbreviations: LR, leptin receptor; SOCS, suppressor of cytokine si-
gnalling; CIS, cytokine inducible SH2 containing protein; STAT, sig-
nal transducer and activator of transcription; PLCc, phospholipase C
gamma
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   - 137 only the LRlo can activate the JAK-STAT signalling pathway
[7]. This LRlo form has three conserved tyrosine (Y) motifs in
the intracellular domain, being Y985, Y1077 and Y1138 in the
mouse LR. These sites become phosphorylated upon leptin
treatment and are used as docking sites for several signalling
or inhibitory molecules. Examples include recruitment of
STAT3 (signalling transducer and activator of transcription)
via the Y1138 motif of the LR, STAT5 via the Y1077 and
Y1138 motif of the LR [8] and binding of the SH2-containing
phosphatase SHP-2 on the Y985 motif leading to activation of
the Ras-MAPK pathway [9]. In addition, several members of
the SOCS (suppressor of cytokine signalling) protein family
can interact with the LR. SOCS3 associates predominantly
with the pY985 motif [10,11] and was identiﬁed as a potent
inhibitor of LR signalling. SOCS2 interacts with Y1077 and
cytokine inducible SH2 containing protein (CIS) with both
Y985 and Y1077 motifs (Lavens et al., in press).
In this report, we used the human premyeloid TF1 and the
murine Ba/F3 pro-B cell lines asmodels to study protein interac-
tions with the LR in a hematopoietic environment. To this end,
we adapted the MAPPIT (mammalian protein–protein interac-
tion trap) method [12] to operate in hematopoietic cell types.2. Materials and methods
2.1. Constructs
Generation of the mutant mouse LR(YYF) in the pMET7
expression vector was described elsewhere [13]. Construction of the
pSEL-60GGS-mLR-Y985 and pSEL-60GGS-mLR-Y1077 baits was
described in Lavens et al. (in press). A fragment of the intracellular
part of the hbc receptor, containing 4 tyrosine motifs, was ampliﬁed
by PCR on the pSV532-hbc plasmid using primer 1 and primer 2
(see Table 1). The PCR fragment was digested with ApoI and was li-
gated into the pMG2-SVT plasmid [12] which was digested with EcoRI
leading to replacement of the gp130 part of the pMG2-construct. This
prey-construct was called pMbc-SVT. This construct was further di-
gested with EcoRI and NotI, allowing exchange of the SVT part by
a full-length rat SOCS3 F25A PCR fragment (primers 3 and 4). The
KIR domain of SOCS3 was rendered inactive by a F25A mutation that
was introduced using primers 5 and 6. All other members of the SOCS
family were cloned as pMbc-prey fusion proteins. Murine CIS and
SOCS2 were already cloned as pMG2-preys [14], and were transferred
as EcoRI–XbaI fragments. Murine SOCS1 was ampliﬁed by PCR
using primers 7 and 8 and was ligated into EcoRI–NotI opened pMbc
vector. Inactivation of the KIR domain of SOCS1 was done with prim-
ers 9 and 10 leading to a F59A mutation. The pMbc-mSOCS4 con-
struct was obtained by PCR on cDNA prepared from mouse thymus
(gift from Dr. Peter Brouckaert) with primers 11 and 12 and insertion
in the EcoRI–NotI opened pMbc vector. The pMbc-mSOCS5 and
-mSOCS6 prey constructs were generated by ampliﬁcation from theblished by Elsevier B.V. All rights reserved.
-               
Table 1
Overview of primers used in this study
Primer 1 Forward 5 0-CGCAAATTTTCCCACACACCTGAGAAACA
Primer 2 Reverse 5 0-CGCGAATTCAGGATTGTTCCTTGGTGACC
Primer 3 Forward 5 0-GCGAGATCTCAGAATTCGTCACCCACAGCAAGTTTCC
Primer 4 Reverse 5 0-GGTGCGGCCGCTCCACCGGTCGACGAAAGTGGAGCATCATACTGG
Primer 5 Forward 5 0-CGCCTCAAGACCGCTAGCTCCAAGAGC
Primer 6 Reverse 5 0-GCTCTTGGAGCTAGCGGTCTTGAGGCG
Primer 7 Forward 5 0-CCAGCGAATTCATGGCGCGCCAGGACTACAAGGAC
Primer 8 Reverse 5 0-GCTTGCGGCCGCTTAGATCTGGAAGGGGAAGGA
Primer 9 Forward 5 0-CACTTCCGCACCGCGCGCTCCCACTCC
Primer 10 Reverse 5 0-GGAGTGGGAGCGCGCGGTGCGGAAGTG
Primer 11 Forward 5 0-GCGGAATTCGCTGAAAACAATAGT
Primer 12 Reverse 5 0-CGCGCGGCCGCTCACTGCTGCTCTGGCA
Primer 13 Forward 5 0-GCGGAATTCGATAAAGTGGGGAAAATGTG
Primer 14 Reverse 5 0-CGCGCGGCCGCTTACTTTGCTTTGACTG
Primer 15 Forward 5 0-GCGGAATTCAAGAAAATCAGTCTG
Primer 16 Reverse 5 0-CGCGCGGCCGCTCAGTAGTGCTTCTCC
Primer 17 Forward 5 0-GCGGAATTCGTGTTCCGCAACGTG
Primer 18 Reverse 5 0-CGCTCTAGAGACTACGTGGAAGGCTCCA
3302 T. Montoye et al. / FEBS Letters 580 (2006) 3301–3307RZPD clones IRAV p968 D11111D6 (mSOCS5) and IRAV p968
E0635 D6 (mSOCS6) using, respectively, primers 13 and 14, and 15
and 16, again allowing insertion in the EcoRI–NotI opened pMbc vec-
tor. A splice variant lacking exon 4 of murine SOCS7 (Dr. Martens N,
personal communication) was ampliﬁed by PCRwith primers 17 and 18
on cDNA of mouse hypothalamic N-38 cells (gift from Dr. Belsham)
and inserted in the EcoRI–XbaI opened pMbc vector. pMbc-prey vec-
tors carrying hPLCc(2· SH2) and hSTAT5a(F694) were obtained by
EcoRI–XbaI insert swaps from the parental pMG2-based vectors
[14]. The hPLCc(2· SH2) insert was also cloned in the pMET7-expres-
sion vector [13] by exchanging EcoRI–XbaI digested inserts.
2.2. Cell lines, electroporation conditions, reporter assays, expression
analysis and phospho-peptide aﬃnity chromatography
Culture conditions for Hek293T cells were as described [11]. The
TF1-M1-16 cell line is a hIL5-responsive derivative of TF1 cells [15]
[16]. Cells were grown in RPMI medium supplemented with 10% fetal
calf serum and 1 ng/ml hIL5. Ba/F3 cells were grown in RPMI medium
supplemented with 10% fetal calf serum and 1 ng/ml mIL3 (Biogen).
Transfections of both cell lines were done by electroporation (300 V,
1500 lF). Cells were simultaneously starved (removal of serum and
hIL5 or mIL3) for 24 h and stimulated with 5 ng/ml hEpo or 100 ng/
ml leptin. Activation of the pGL2-SPI2.1-luciferase reporter (gift by
Dr. Walter Becker [17]) was measured as described before [14]. All
MAPPIT data in this manuscript are expressed as fold induction (stim-
ulated/non-stimulated or NS) and are representative of at least three
independent experiments.
Expression analysis of the FLAG-tagged bc-fusion proteins was done
by Western blot analysis with anti-FLAG mouse monoclonal antibody
(Sigma), using lysates of electroporated cells. Expression of the GGS
baits was veriﬁed using goat anti-human EpoR polyclonal IgG (R&D
Systems) at 2 lg/ml and Alexa 488-conjugated donkey anti-goat IgG
(Molecular Probes) at 4 lg/ml. Fluorescence-activated cell sorting
(FACS) was performed on a FACSCalibur (Becton Dickinson).
Phospho-peptide aﬃnity chromatography experiments were per-
formed using the biotin-QRQPSVK(P)Y985ATLVSNDK and biotin-
NHREKSVC(P)Y1077LGVTSVNR peptides and lysates from Hek293T
cells transfected with the pMET7-PLCc(2· SH2) expression plasmid as
described in Lavens et al. (in press).3. Results
3.1. bc-MAPPIT: design and proof of principle
The MAPPIT concept is based on JAK-STAT signalling and
is shown in Fig. 1. We here designed a variant of the MAPPIT
method that enables us to detect protein interactions in hema-
topoietic cells. Since cytokines predominantly activate STAT5
in hematopoietic cells, we designed novel prey constructs,   - 138 wherein the gp130 moiety is swapped for a part of the bc-
receptor, containing several STAT5 interaction sites. In the
MAPPIT bait constructs, we replaced the cytosolic domain
of the LR following the JAK2 interaction site, by a large array
of Gly-Gly-Ser (GGS) repeats (Fig. 1B) in order to prevent any
background prey association with the LR-F3 (Lavens et al., in
press). Interaction of co-transfected GGS-bait and bc-prey will
lead in this setting to activation of the STAT5-dependent
SPI2.1-luciferase reporter. The MAPPIT technique also allows
the analysis of interactions with the LR itself. A mutant
LR(YYF) [13] was used to avoid possible background by acti-
vation of STAT3 and 5 via Y1138 (Fig. 1C). Binding of
STAT5 to the Y1077 motif [18], did not interfere with the
read-out in the hematopoietic cell systems used.
We initially tested the concept using a SOCS3(F25A)-prey.
SOCS3 strongly binds to the LR pY985-motif and negatively
regulates LR signalling [18]. To suppress its inhibitory eﬀect
on JAK2 activation, we inactivated the Kinase Inhibitory Re-
gion (KIR domain) in the SOCS3 prey by introducing a F25A
mutation. SV40 large T protein (SVT) was used as negative
prey control. As shown in Fig. 2, clear, speciﬁc signals were
obtained in both Ba/F3 and TF1-M1-16 cells with either the
LR(YYF) lacking the Y1138 STAT recruitment motif or with
a GGS-bait construct containing only the LR Y985 motif. A
slight activation was observed in case of the negative control
in Ba/F3 cells, when stimulated with leptin and in TF1-M1-
16 cells when stimulated with Epo. This is probably due to
the presence of the endogenous LR or EpoR on Ba/F3 and
TF1-M1-16 cells, respectively. The data shown in Figs. 2 and
3A are corrected for this low background. In these, and the
experiments described below, expression of the FLAG-tagged
bc-preys in TF1-M1-16 or Hek293-T cells was revealed by
immunoblotting using an anti-FLAG antibody (data not
shown). Expression analysis of the GGS baits in TF1-M1-16
cells was performed using FACS analysis with antibodies
against the extracellular domain of the EpoR as described
before [18] (data not shown).3.2. Interaction of signalling molecules with the LR
Since the LR can trigger several signalling pathways, we next
checked interaction of distinct signalling molecules with the
LR(YYF) in both Ba/F3 and TF1-M1-16 cells. The bc-preys-               
Fig. 1. (A) MAPPIT principle: A bait protein is C-terminally linked to a chimeric receptor consisting of the extracellular part of the EpoR and the
transmembrane and intracellular parts of a STAT3 recruitment-deﬁcient LRF3, while the prey protein is fused to functional STAT3 recruitment sites
of gp130. Co-expression of interacting bait and prey can lead to functional complementation of STAT3 activity that can be measured with a STAT3-
responsive luciferase reporter. (B) GGS-MAPPIT: A bait protein is attached C-terminally to a variant of the chimeric EpoR-LR receptor. The
cytosolic domain of the LR following the JAK2 association domain is replaced by a GGS-array, preventing any background activation due to prey
association with the LR-F3. In this paper we use a bc-receptor based prey construct (inset). The bc receptor contains six tyrosine motifs in its
cytoplasmatic tail of which three are known STAT5 recruitment sites. A prey in the bc-MAPPIT concept is fused to a part of the bc receptor
containing all three STAT5 recruitment sites. (C) LR MAPPIT: Here, the LR itself functions as bait protein. Due to the Y1138F mutation, no
detectable STAT recruitment occurs in our hematopoietic cell types. Upon stimulation, the two membrane proximal tyrosines become
phosphorylated by JAK2. Interaction of the bc-based prey protein with the LR allows eﬃcient STAT5 activation and subsequent reporter induction.
T. Montoye et al. / FEBS Letters 580 (2006) 3301–3307 3303used in this study were full-length STAT5a and part of PLCc
encompassing its two SH2-domains. The STAT5a prey was
made signalling-deﬁcient by introducing an Y694F mutation.   - 139 Strong luciferase signals were detected with the PLCc-prey,
and a weaker interaction was seen with the STAT5a-prey
(Fig. 3A). Analysis using the GGS-LR Y985 and GGS-LR-               
Fig. 2. bc-MAPPIT: proof of principle. (Bars 1–4) Ba/F3 cells were transiently electroporated with plasmids encoding the non-speciﬁc prey bc-SVT
used as negative control, and the speciﬁc prey bc-SOCS3F25A with, respectively, the LR(YYF) mutant (Bars 1 and 2) or the EpoR-LR-60xGGS-
Y985 bait (Bars 3 and 4), combined with the pGL2-SPI2.1-luciferase reporter. After 48 h of electroporation, the cells were either stimulated overnight
with leptin/Epo as indicated or were left untreated. Data are expressed as fold induction (stimulated/NS). (Bars 5–8) Similar experimental set-up as
above, but performed in TF1-M1-16 cells. The values obtained with the bc-SVT prey in Ba/F3 cells, when stimulated with leptin and in TF1-M1-16
cells when stimulated with Epo were, respectively, 5- and 2-fold, possibly due to endogenous expression of the LR and EpoR. The values shown are
normalized for this background.
3304 T. Montoye et al. / FEBS Letters 580 (2006) 3301–3307Y1077 baits revealed that both preys only interact with the
Y1077 motif (Fig. 3B). We conﬁrmed the PLCc dataset with
(phospho)peptide aﬃnity chromatography using lysates from
Hek293T cells containing a FLAG-tagged PLCc-derived poly-
peptide encompassing both SH2 domains. Clear binding was
observed with the pY1077 phospho-peptide, with only minor
binding to the pY985 motif. No detectable binding was ob-
served with the non-phosphorylated peptides (Fig. 4B).
3.3. Interaction map of SOCS proteins with the LR
To determine their interaction with the LR, all members of
the SOCS family were cloned as bc-preys and were tested for
interaction with LR(YYF) in Ba/F3 or TF1-M1-16 cells
(Fig. 4A and B). The inhibitory eﬀect by SOCS1 was sup-
pressed by a F59A mutation in its KIR domain, similar to
SOCS3 (see above). In Ba/F3 cells, clear induction of lucifer-
ase activity indicated that CIS, SOCS2 and SOCS3 interact
with the LR(YYF), consistent previous reports [11] (Lavens
et al., in press). In addition, reproducible induction of lucifer-
ase activity was also seen with SOCS6 and SOCS7. Similar re-
sults were obtained in TF1-M1-16 cells. No signal was
obtained in the case of the bc-SOCS1 F59A, SOCS4 and
SOCS5 preys.
A detailed binding analysis of SOCS preys showed that
SOCS3 interacted with the Y985 motif, while SOCS2 and -6
bind to the Y1077 motif. CIS and SOCS7 can interact with
both motifs (Fig. 4C). These bc-preys bind speciﬁcally with
the tyrosine motifs of the LR, since no interaction could be
found with an irrelevant GGS-FKBP12 bait and replacement
of preys by a wild-type SOCS protein (SOCS7) did not lead
to luciferase activity (data not shown).4. Discussion
Although a role of leptin in hematopoiesis is now well doc-
umented, studies on the intracellular pathways used by the LR   - 140 in hematopoietic cells are limited. Leptin can prevent apopto-
sis of leukaemia cells through STAT3 and mitogen-activated
protein kinase (MAPK) phosphorylation [19] and activation
of the MAPK and PI3-K pathways by leptin has been shown
in peripheral blood mononuclear cells [20]. Here, we adapted
the MAPPIT mammalian two-hybrid method to a hematopoi-
etic setting and studied protein interactions with the LR in
TF1-M1-16 and Ba/F3 cells. The basic MAPPIT set-up using
STAT3 did not function in these cell lines, presumably due
to low amounts of endogenous STAT3. We therefore swapped
the gp130 moiety in the prey constructs for part of the cyto-
solic domain of bc capable of recruiting and activating STAT5,
which is highly expressed in hematopoietic cell types. Our
experiments illustrate the ﬂexibility of the MAPPIT strategy,
which can be adapted to operate in diﬀerent types of human
cells by simple adjustment to diﬀerent reporter systems.
The murine LR cytoplasmic tail contains three conserved
tyrosine motifs at positions Y985, Y1077 and Y1138. With
the bc-MAPPIT approach we conﬁrmed the interaction of
SOCS3 with the LR Y985 motif in hematopoietic cells, whilst
only a very weak eﬀect was seen with Y1077, consistent with
the weak interaction with this motif (Figs. 2 and 4C) (10).
The role of the Y1077 motif in leptin signalling is still some-
what controversial since its tyrosine phosphorylation is diﬃ-
cult to demonstrate. However, the Y1077 motif was shown
to interact with SOCS3 and STAT5 in a phosphorylation-
dependent modus [8,11]. Here, we provide further evidence
for an important role of the Y1077 motif in leptin signalling
with several additional signalling proteins interacting at this
site. Although there is evidence suggesting involvement of
the phospholipase C–phosphokinase C (PLC–PKC) pathway
in leptin signalling [21–23], no proof for interaction of PLC
proteins with the LR was obtained so far. We here show that
PLCc can interact via its SH2 domains with the LR(YYF) and
more detailed analysis using both bc-MAPPIT and peptide
aﬃnity chromatography revealed that PLCc interacts with
the phosphorylated Y1077 motif.-               
Fig. 3. Interaction of STAT5 and PLCc with the LR. (A) Ba/F3 (Bars 1–3) or TF1-M1-16 cells (Bars 4–6) were transiently electroporated with
plasmids encoding pMet7-LR(YYF) and a bc-prey as indicated or an empty vector, combined with the pGL2-SPI2.1-luciferase reporter.
Experimental set-up was as in Fig. 2. The values were normalized for background as mentioned in Fig. 2. (B) Ba/F3 were transiently electroporated
with plasmids encoding the pSEL60GGS-LR Y985 or pSEL-60GGS-LR Y1077 bait and a bc-prey as indicated or an empty vector, combined with
the pGL2-SPI2.1-luciferase reporter. Experimental set-up was as in Fig. 2. (C) The FLAG-tagged PLCc(2· SH2) protein was expressed in Hek293T
cells and total cell lysates were incubated with biotinylated peptides encompassing the LR (phosphorylated) Y1077 or Y985 motifs. Immunoblotting
with anti-FLAG antibody revealed speciﬁc interaction of PLCc with the phosphorylated Y1077 motif.
T. Montoye et al. / FEBS Letters 580 (2006) 3301–3307 3305Since SOCS3 and SOCS7 were reported to inhibit leptin sig-
nalling in diﬀerent ways [24], we performed a MAPPIT scan to
monitor the binding capacity of all SOCS proteins with the LR.
We were able to detect binding of SOCS3 as expected, but also
of CIS, SOCS2, SOCS6 and SOCS7. SOCS4- and SOCS5-preys
do not induce reporter activity, indicating that no interaction
occurs, although direct inhibition of STAT5 activation cannot
be completely ruled out. Also, no interaction of SOCS1 is de-   - 141 tected, which is somewhat surprising since SOCS1 is known
to bind JAK2 [25] and can inhibit leptin signalling in cell-based
assays (Piessevaux et al., submitted for publication). Possibly,
certain preys that directly interact with JAK2 may be subject
to a topological restraint whereby phosphorylation of the prey
tyrosines by the JAK is sterically impossible. Interestingly, the
closely related SOCS proteins CIS and SOCS2 both bind to the
Y1077 motif, but only CIS appears to interact with the Y985-               
Fig. 4. Interaction of SOCS proteins with the LR. (A, B) Ba/F3 (Panel A) or TF1-M1-16 cells (Panel B) were transiently electroporated with
plasmids encoding pMet7-LR(YYF) and a bc-SOCS prey or an empty vector, combined with the pGL2-SPI2.1-luciferase reporter. Experimental set-
up was as in Fig. 2. (C) Ba/F3 cells were transiently electroporated with plasmids encoding the pSEL60GGS-LR Y985 or pSEL-60GGS-LR Y1077
bait and a bc-SOCS prey as indicated or an empty vector, combined with the pGL2-SPI2.1-luciferase reporter. Experimental set-up was as in Fig. 2.
3306 T. Montoye et al. / FEBS Letters 580 (2006) 3301–3307motif. Similar data were obtained in non-haematopoietic cell
types (Lavens et al., in press). Similarly, SOCS7 can interact
with both the Y985 and the Y1077 motifs, whilst SOCS6 only
binds Y1077. Inhibition or binding of SOCS6 on the LR has
not been reported so far, although both can be expressed in
hematopoietic cells [26]. Inhibition of leptin signalling by
SOCS7 has been shown through binding and inhibition of
STAT3 by SOCS7 [24]. However, binding of SOCS7 on the
LR itself was not demonstrated before. Our ﬁndings suggest   - 142 that besides the well-established inhibitory eﬀect of SOCS3
on hypothalamic leptin signalling, other SOCS proteins can
bind to the LR and possibly may modulate leptin signalling
in other, e.g., peripheral cell types.
Together, our ﬁndings illustrate that the MAPPIT strategy
can easily be adapted to hematopoietic cell types. Our ﬁndings
identify several novel interactions with the LR and provide a
rationale for more detailed functional analysis of leptin signal-
ling in hematopoiesis.-               
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ABSTRACT. Leptin was discovered as an adipostat, regulating body weight by balancing food intake and energy
expenditure. Recently, leptin emerged as a pleiotropic cytokine. It plays a substantial role in a wide spectrum of
other functions including immune regulation, bone formation and fertility. Leptin signalling is under tight control.
Aberrations of this stringent control system may be implicated in a variety of pathologies. Here, we review the
various mechanisms that control cellular leptin receptor signalling.
Keywords: leptin receptor signalling, negative regulation, SHP-2, PTP1B, SOCS proteins
Leptin plays a major role in the regulation of energy
homeostasis and food intake. It is mainly produced in
white adipose tissue and, to a lesser degree, in the stomach
and in some other tissues [1, 2]. Leptin is released into the
circulation and is translocated through the blood-brain-
barrier (BBB) to target the leptin receptor (LR) in the
hypothalamus. Functioning as an adipostat, it signals the
state of body fat reserves to the brain. Aberrations in leptin
signalling are often associated with obesity, but only a
minority of obese individuals show a deficiency in leptin or
its receptor. Instead, most cases of human obesity show a
state of relative leptin resistance, as reflected in high serum
leptin levels [3, 4]. This resistance may be situated at
different levels in the leptin pathway, including saturation
of transport through the blood-brain barrier, aberrations in
LR signal transduction or downstream effects on neural
networks in the hypothalamus [5, 6].
Leptin is a pleiotropic cytokine. Apart from its role in
energy homeostasis, it is also implicated in a range of
other, often peripheral processes, including immune re-
sponse, bone formation, angiogenesis and reproduction.
Recent findings suggest that leptin is involved in a variety
of pathological processes, including cardiovascular and
autoimmune diseases [7, 8].
Given leptin’s wide range of important functions, its ac-
tivities must be under stringent control. In this review we
discuss the molecular mechanisms that are responsible for
the modulation of signal transduction via the LR. A sche-
matic representation of LR signalling and modulation is
shown in figure 1.
JAK-STAT SIGNALLING
At least 5 different LR isoforms exist, but the main player
responsible for signal transduction is the long isoform of
the LR [9]. Canonical leptin signalling occurs through the
JAK-STAT pathway. Ligand binding results in LR cluster-
ing, bringing the associated JAKs (janus kinase) into close
proximity. This allows them to activate each other by
cross-phosphorylating tyrosines in their activation loop.
These activated JAK kinases then phosphorylate tyrosines
in the cytoplasmic tail of the receptor and on the JAKs,
forming docking sites for signalling proteins. Amongst
these, the STATs (signal transducers and activators of
transcription) associate with the phosphotyrosines in the
receptor via their SH2 domain and become activated by
JAK2 mediated tyrosine phosphorylation. The activated
STATs then dissociate from the receptor and translocate to
the nucleus as dimers to induce specific target genes.
JAK2 is constitutively associated with the membrane
proximal box1 in the cytoplasmatic tail of the LR [10, 11].
The intracellular part of the receptor also carries three
conserved tyrosines at positions Y985, Y1077 and Y1138
(murine numbering). The membrane distal tyrosine is em-
bedded in aYXXQ motif and is responsible for the recruit-
ment of STAT3 [12, 13]. STAT3 activation was demon-
strated after leptin stimulation in the hypothalamus of mice
[14]. Knock-in mice containing an Y1138S mutation are
incapable of STAT3 activation and reveal a severely obese
phenotype. They do not show the infertility and reduced
size that is seen in db/db mice that are truncated in the long
LR, indicative of the involvement of other signal transduc-
ers [15]. Leptin-induced activation of STAT1 and
STAT5B, in addition to STAT3, was shown in COS cells
and in HIT-T15 cells [16, 17]. In the latter cell line, STAT1
was activated via Y1138 while STAT5B activation oc-
curred via both Y1138 and Y1077 [17].
Next to JAK-STAT signalling, leptin also activates other
pathways. A number of adaptor molecules can associate
with the receptor and link to several signalling pathways,
including the mitogen-activated protein kinase (MAPK)
pathway (see below) and the phosphoinositol 3-kinasedoi
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(PI3K) pathway. In the latter, the JAK2-interacting protein,
SH2-B, mediates binding of IRS (insulin receptor sub-
strate) proteins that function as adaptors for PI3K [18, 19].
PI3K transforms phosphatidylinositol4,5-biphosphate
(PIP2) into phosphatidylinositol3,4,5-triphosphate (PIP3)
eventually resulting in reduced levels of cAMP. It was also
demonstrated that leptin has an inhibitory role on hypotha-
lamic AMPK (AMP-activated protein kinase) activity
which contributes to body weight regulation [20].
MODULATION OF FUNCTIONAL RECEPTOR
EXPRESSION
Obviously, receptor internalisation is an effective mecha-
nism for rapidly turning off cytokine signalling. Upon
ligand binding, cytokine receptors can be internalized via
the clathrin-coated pit pathway into early endosomes.
Trafficking dynamics of the LR with receptor internalisa-
tion and subsequent degradation or recycling back to the
cell surface clearly are involved in the regulation of leptin
signalling. In steady-state conditions, no more than 25% of
the LR is located at the cell surface, whilst the majority of
the LR are found in intracellular pools [21]. This distribu-
tion of the LR may be explained by its tendency to consti-
tutive endocytosis resulting in short-lived membrane ex-
pression. In addition, some of the newly-synthesized LRs
are retained intracellularly based on a retention signal in
the transmembrane domain [22]. Whether external stimuli
modulate this LR localisation throughout the cell and in
this way regulate leptin sensitivity remains to be deter-
mined.
125I-labeled leptin uptake experiments demonstrated that
LRs are also internalized upon ligand binding via clathrin-
mediated endocytosis leading to leptin degradation in the
lysosomes [21, 23]. An internalisation signal was identi-
fied in the intracellular part of the receptor in immediate
proximity to the membrane [23]. Compared with other LR
splice variants, the long LR isoform seemed to be depleted
relatively quickly from the cell surface upon leptin expo-
sure, suggesting it is most sensitive to leptin-induced
down-regulation while its limited recycling to the cell
membrane was slow [21-24]. This favoured down-
modulation of LR signalling may be implicated in leptin
resistance [25, 26].
Recently, it was demonstrated that both the long LR and
the short LR, a membrane-anchored isoform with a short
cytoplasmic tail, become ubiquitinated. Unlike for the
long LR, this ubiquitination is essential for clathrin-
mediated endocytosis of the short LR [27]. Many aspects
of the mechanisms underlying LR cell surface expression
and internalisation remain to be elucidated. It is likely that
additional proteins involved in ubiquitination of the (acti-
vated) LR complex remain to be identified.
A soluble form of the LR associates with circulating leptin
[28]. Secreted cytokine receptors can protect their ligands
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Schematic representation of LR signalling and negative regulation. For abbreviations, refer to the main text.
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from either degradation or clearance and thus significantly
extend their half-life or they can act as antagonists, captur-
ing their ligand and thus preventing signalling by their
membrane-spanning counterparts. In mice, the soluble LR
is generated by alternative mRNA splicing. In contrast, no
such mRNA splice variant has been discovered in humans;
a secreted human LR is generated by ectodomain shedding
of membrane-anchored LRs including the signalling long
form, by a hitherto unknown protease [29-31]. Although
the soluble LR appears important for keeping leptin avail-
able in circulation, it is at the same time, capable of
competing with the long LR isoform for leptin binding and
may suppress leptin action in that way [32-35]. This could
indicate that the secreted LR plays an important role in
determining leptin levels available for signal transduction.
It is of note that the relative concentrations of the soluble
LR and free leptin are similar, while in obese individuals
concentrations of free leptin exceed by far the concentra-
tions of secreted LR [36].
PHOSPHATASES
SH2 domain-containing phosphatase-2 (SHP-2) is a con-
stitutively expressed protein tyrosine phosphatase known
to be involved in the dephosphorylation of the JAKs. It
carries two tandem SH2 domains followed by a tyrosine
phosphatase catalytic domain and associates directly with
the LR at position Y985 [37]. The exact role of SHP-2 in
LR signalling has been a long standing matter of debate.
Despite its initial identification as an inhibitor of LR sig-
nalling (see below), it also appeared as a strong activator of
the MAPK pathway. ERK activation occurs predominantly
via SHP-2 recruitment at tyrosine Y985 via its C-terminal
SH2 domain. SHP-2 is phosphorylated by JAK2 and forms
a docking site for the adaptor protein growth factor recep-
tor binding 2 (Grb2) leading to the activation of the ERK
signalling cascade [12]. Alternatively, ERK is also directly
activated by JAK2, but still requires the intervention of
SHP-2 [38]. Leptin-triggered activation of MAPK was
observed both peripherally and centrally. Recently, regu-
lation of calcium fluxes involving MAPK activity was
shown in lateral hypothalamic neurons upon leptin stimu-
lation [39]. Also, NO (nitric oxide) production induced by
leptin via MAPK activation was observed in white adipo-
cytes [40]. Moreover, leptin induced MAPK is involved in
full activation of the DNA binding of STAT3 by mediating
serine phosphorylation at position S727 of STAT3 [41].
On the other hand, many reports have also attributed an
inhibitory role to the SHP-2 phosphatase in LR signalling.
Mutation of the Y986 position in the human LR led to
augmented STAT3 signalling, and inhibitory properties
associated with this position were ascribed to the negative
regulatory function of SHP-2 [42]. However, suppressor of
cytokine signalling 3 (SOCS3), identified as a strong in-
hibitor of LR signalling (see below), was found to interact
with the corresponding Y985 position in the murine LR
[43-45]. SOCS3 is part of the SOCS family and its inhibi-
tory mechanism is discussed below. SHP-2 and SOCS3
have very similar binding specificities, and overlapping
binding sites were also observed for the gp130 chain
[46-49]. Thus, the negative regulation associated with the
membrane proximal tyrosine position is partly attributed
to SOCS3. However, SHP-2-mediated dephosphorylation
of JAK2 was demonstrated in vitro [37]. Recently,
forebrain-specific SHP-2-deficient mice revealed that
SHP-2 moderately down-modulates JAK2 and STAT3 ac-
tivation in vivo [50]. Although SHP-2 has a modest role in
terminating leptin signal transduction, its dominant induc-
tion of the ERK pathway makes it overall an enhancer of
leptin signalling, whereby it may function as a switch
towards MAPK signalling.
Protein tyrosine phosphatase 1B (PTP1B) is a crucial
protein tyrosine phosphatase implicated in the negative
regulation of leptin receptor signalling. PTP1B deficiency
results in hypersensitivity to insulin and leptin in mice, and
leads to protection from high fat diet obesity [51]. PTP1B
harbours two phosphotyrosine binding pockets in its cata-
lytic domain that determine its intrinsic specificity. A con-
sensus substrate recognition motif was found in the kinase
activation loop of the insulin receptor and in JAK2 [52-54].
Both in vivo and in vitro data demonstrate that PTP1B
targets LR signalling predominantly by dephosphorylating
JAK2 [55-58]. PTP1B is a negative mediator of both the
JAK-STAT and MAPK pathway in leptin receptor signal-
ling. PTP1B-mediated hypophosphorylation of JAK2 in a
mouse hypothalamic neuronal cell line abrogated the
leptin-dependent induction of the STAT3 and MAPK in-
ducible SOCS3 and c-fos genes, respectively [56]. Re-
cently, leptin induced PTP1B was observed in liver, raising
the possibility that PTP1B may also function in a negative
feedback loop [59]. Diet-induced obesity is associated
with increased hepatic PTP1B levels. Aberrant PTP1B
activity is implicated in leptin resistance and PTP1B is
currently being investigated as a drug target in obesity
[60-63].
PTP1B is localized predominantly on the ER (endoplas-
mic reticulum) via its C-terminal hydrophobic targeting
sequence [64]. How PTP1B acts on its substrates remains
unclear. It was demonstrated that the platelet-derived
growth factor (PDGF) receptor becomes dephosphoryl-
ized by PTP1B at the ER after internalization [65]. Re-
cently, direct interaction of PTP1B with the insulin recep-
tor was observed in a perinuclear endosome compartment
[66]. On the other hand, it has been demonstrated that
internalisation of the insulin receptor is not essential for
interaction with PTP1B and subsequent dephosphoryla-
tion [67]. In line with this, proteolytic cleavage of PTP1B
can lead to the relocalization of the catalytic domain of
PTP1B to the cytosol [68].
The ubiquitously expressed phosphatase and tensin homo-
logue deleted on chromosome ten (PTEN) is a tumour
suppressor protein and its mutation is linked with several
human cancer types [69]. It belongs to the family of protein
tyrosine phosphatases but also possesses lipid phosphatase
activity. PTEN suppresses the PI3K pathway by hydrolyz-
ing the secondary messenger PIP3 back to PIP2. [70]. It
was demonstrated that hypothalamic PI3K is involved in
leptin-induced reduction in food intake [19]. Surprisingly,
specific disruption of PTEN restricted to the hypothalamic
neurons expressing the anorexigenic proopiomelanocortin
(POMC) neuropeptide results in an obese phenotype asso-
ciated with leptin resistance [71].
SUPPRESSORS OF CYTOKINE SIGNALLING
The family of SOCS proteins consists of 8 members:
cytokine inducible SH2 protein (CIS) and SOCS1 through
SOCS7. SOCS proteins have a characteristic domain
Review: negative regulation of leptin receptor signalling 213
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structure which is represented in figure 2. They carry a
central SH2 domain, an N-terminal preSH2 domain with
an ESS (extended SH2 subdomain) region and in some
cases a kinase inhibitory region (KIR) domain and a
C-terminal SOCS-box [72]. The N-terminal domain varies
in length and composition while the SH2 domain and the
SOCS-box are more conserved. They also carry one or two
conserved tyrosines in the C-terminus of their SOCS-box.
SOCS proteins can interfere with cytokine signalling at
different levels. They can interact with phosphotyrosine
motifs in activated cytokine receptor complexes by means
of their SH2 domain, thereby hindering association of
signalling molecules. The SOCS-box of SOCS proteins is
identified as a key mediator in targeting associated proteins
for proteasomal degradation. It associates with elonginB/C
via its BC-box and takes part in a multi-protein complex
that acts as an E3 ligase known to link ubiquitin to the
substrate. Finally, the kinase activity of the JAKs can be
abolished through the KIR domain.
SOCS proteins are typically part of a negative feedback
loop. They are induced upon cytokine stimulation and
attenuate signalling by various cytokine receptors, allow-
ing possible cross-regulation among cytokine systems.
Leptin induces SOCS3 expression in a rapid and transient
manner while CIS expression accumulates over a longer
period of time [43, 73, 74]. A role for leptin has also been
implicated in the expression of SOCS1 and, to a lesser
extent of SOCS2 [74, 75].
SOCS3 was identified as a potent inhibitor of LR signal-
ling [43]. Its STAT3-mediated expression is induced in the
hypothalamus and liver after peripheral leptin administra-
tion in leptin-deficient ob/ob mice [12, 43, 76]. SOCS3 is a
functional marker for identification of leptin-sensitive neu-
rons in the hypothalamus [77]. In these hypothalamic
neurons of the leptin-resistant lethal yellow (Ay/a) mouse
model, elevated levels of SOCS3 were found [43]. Unlike
SOCS3-deficient mice that die in utero, SOCS3 haploin-
sufficient or neural-cell specific-deficient mice are viable
and show augmented leptin sensitivity in the hypothala-
mus and a remarkable attenuation of diet-induced obesity
[78, 79]. It was demonstrated that SOCS3 action is in-
volved in rendering the LR refractory to reactivation after
chronic leptin stimulation [80]. These observations show
SOCS3 up as a key mediator of negative regulation of
leptin signalling and suggest a prominent role in leptin
resistance.
Only SOCS1 and 3 carry a KIR domain in their N-terminal
region involved in direct inhibition of the JAK kinase
activity. They both inhibit leptin receptor signalling, using
a slightly different mechanism. SOCS1 directly interacts
with the kinase domain of JAK2 by targeting the phospho-
tyrosine at position Y1007 in the activation loop of JAK2
[81, 82]. The KIR domain is essential for the inhibitory
function of the SOCS protein [82]. It associates with the
catalytic groove of JAK2 and is suggested to act as a
pseudosubstrate which mimics the activation loop that
regulates access to the catalytic groove [81, 82]. It may
obstruct the ATP binding pocket and hinder accessibility
for substrates [81, 82]. Unlike SOCS1, SOCS3 has only
weak affinity for JAK2. It is thought to inhibit the kinase
activity through its KIR domain after binding via its SH2
domain with phosphotyrosine motifs in the receptor in
close proximity to the JAKs [83]. Indeed, SOCS3 associ-
ates with the LR at the membrane proximal tyrosine Y985
domain [44, 84]. It also weakly binds the highly similar
Y1077 interaction site, with an accessory effect on LR
signalling inhibition [84].
Using the MAPPIT technique, a two-hybrid method based
on cytokine signalling, we recently demonstrated the inter-
action of CIS and SOCS2, two other members of the SOCS
protein family, with the LR [45, 74]. We showed that CIS
interacts with the two membrane proximal tyrosine motifs
at positions Y985 and Y1077, while SOCS2 only associ-
ated with the latter of the two. Phosphotyrosine specific
interaction of SOCS2 with the LR Y1077 motif was con-
firmed by peptide affinity chromatography (PAC). Using
this method, we also demonstrated that SOCS2 binds
specifically to the phosphotyrosine Y1138 peptide. An
overview of LR/SOCS interactions is given in table 1.
Interactions with the LR Y1138 motif and those involving
SOCS1 were only analysed using PAC since in these cases
interference occurs with the MAPPIT read-out. Of note,
MAPPIT proved to be a highly sensitive technique that can
detect weak or transient (but functionally relevant) inter-
actions that could not be detected by PAC.
CIS and SOCS2 are known inhibitors of STAT5 activation.
Although negative regulation of a leptin-induced STAT3
binding reporter gene by CIS was suggested, we did not
CIS
SOCS1
SOCS2
SOCS3
SOCS4
SOCS5
SOCS6
SOCS7
Pre SH2 SH2 SOCS box
Figure 2
Schematic overview of SOCS protein structure. The KIR domain is indicated with a black box, the C-terminal, conserved tyrosines are
represented by a black line.
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observe any inhibitory effect on STAT3-mediated LR sig-
nalling by either CIS or SOCS2 [73, 74]. Instead, we
suggest an inhibitory role in leptin-induced STAT5 signal-
ling through interference with STAT5a recruitment to the
Y1077 tyrosine motif in a MAPPIT based experiment [74].
Supporting this notion, SOCS2 binding completely over-
laps with STAT5 association at the LR. CIS and SOCS2
may be implicated in preventing recruitment of down-
stream signalling moieties to the LR. Both SOCS2 knock-
outs and CIS transgenes show growth abnormalities, the
former being larger and the latter smaller than normal [85,
86]. Although both SOCS proteins are negative regulators
of GH signalling, growth retardation in people with a
truncated LR as well as in LR null db/db mice suggests
these SOCS proteins may additionally influence growth
via the LR [15, 87]. Leptin has been identified as a pro-
inflammatory cytokine [88]. It is implicated in the patho-
genesis of several autoimmune diseases including rheuma-
toid arthritis, multiple sclerosis and inflammatory bowel
disease [7, 8]. A role for leptin was described in T-cell
proliferation and switching towards a Th1 response [89].
CIS transgenic mice exhibit a shift to activation of Th2
cells [85], an effect that may, in part, be explained by its
effect on leptin signalling in T-cells. More detailed analy-
sis in cell-type specific expression and function will be
needed to elucidate the specific roles of SOCS proteins in
leptin signalling. Possibly, different physiological func-
tions of leptin may be under the control of different SOCS
proteins.
More detailed examination of the binding modalities of
SOCS proteins with the LR reveals that the SOCS-box of
CIS is implicated in the association with the LR (Lavens et
al., in press). The conserved C-terminal tyrosine at posi-
tionY253 is essential for binding to both membrane proxi-
mal tyrosines. The same phenomenon is also observed for
interaction with other cytokine receptors such as the EpoR
but not for association with the unrelated MyD88 protein,
an adaptor protein involved in toll-like receptor (TLR)
signalling [74, 90]. In contrast, the corresponding
C-terminal tyrosine or even the entire SOCS-box of the
highly related SOCS2 protein are not essential for interac-
tion with the LR, and deletion of the SOCS-box also,
hardly influenced the inhibitory capacity of SOCS1 or
SOCS3 on LR signalling [74]. This indispensable role of
the SOCS-box for binding with the LR (and likely other
cytokine receptors as well), is probably an exclusive char-
acteristic of CIS. The exact functional role of the
C-terminus of CIS is still unclear. This observation is very
reminiscent of the Von Hippel-Lindau protein whereby the
C-terminus of its SOCS-box is also involved in substrate
recognition [91, 92].
Recently, it has become clear that regulation by certain
SOCS proteins can be more complex than a mere negative
feedback loop. It has been demonstrated that, apart from its
negative regulatory effects, SOCS2 can also have positive
effects on cytokine signalling, as was clearly observed in
vivo and in vitro for GHR signalling [93, 94]. SOCS2
interference with other SOCS proteins has been observed
in several cytokine receptor systems including LR signal-
ling [74, 93, 95, 96, 97]. We recently demonstrated that
SOCS2 interferes with the association of CIS to the mem-
brane proximal tyrosine of the LR, although no direct
binding of SOCS2 with this tyrosine position was demon-
strated [74]. In addition, SOCS2 can impair the inhibitory
effect of SOCS1 or SOCS3 on leptin-induced signalling.
This effect strictly relied on the presence of the SOCS-box
of both SOCS-proteins, since deletion of the SOCS-box of
either SOCS2 or SOCS1 and SOCS3 abolished complete
SOCS2 interference [97]. SOCS2 is demonstrated to asso-
ciate with all members of the SOCS protein family [74, 96,
97]. Abolishing the elonginB/C recruitment potential of
SOCS2 has no effect on its SOCS interaction capacity but
leads to complete loss of its functional interfering charac-
teristics [74, 97]. SOCS2 influences the stability of target
SOCS proteins and this effect is sensitive to proteasome
inhibitors and clearly relies on the presence of its BC-box
[96, 97]. Together, these data strongly suggest that SOCS2
can target SOCS proteins for degradation and regulate
SOCS protein turnover. In addition, we demonstrated that
SOCS6 and SOCS7 are also capable of interacting with the
SOCS protein family members. Similar potentiating ef-
fects as with SOCS2 are observed for SOCS6 in LR
signalling as well as other cytokine receptor systems [97].
This cross-regulatory effect of SOCS proteins may be of
great importance in restoring cellular sensitivity after cy-
tokine stimulation. Indeed, it has been reported that the
expression of SOCS2 is in many cases more prolonged
than that seen for other SOCS proteins [96-100].
Using the MAPPIT methodology, we recently demon-
strated that SOCS6 and SOCS7 also interact with the LR.
Both associate with the Y1077 motif whilst only SOCS7
interacts with the more membrane proximal tyrosine
[101]. It was reported that SOCS7 is implicated in LR
signalling termination. It can inhibit STAT3 activation
which we speculate may involve LR association, but it can
also interact with activated STAT3 molecules to prevent
them from translocating to the nucleus [102].
Table 1
Binding of the SOCS proteins, CIS and SOCS1 through SOCS3, with the tyrosines of the LR based
on peptide affinity chromatography (PAC) with corresponding phosphorylated and
non-phosphorylated tyrosine motifs and based on mammalian protein-protein interaction trap
(MAPPIT) [74, 84, 100]
PY985 PY1077 PY1138
MAPPIT PAC MAPPIT PAC PAC
CIS + - + - -
SOCS1 - - -
SOCS2 - - + + +
SOCS3 + + - /+ + -
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CONCLUSION
Leptin is involved in a variety of crucial processes includ-
ing adipocyte metabolism and immune responses, and
aberrant leptin signalling has been implicated in several
pathophysiological processes. Tight control mechanisms
exist that regulate leptin receptor signal transduction. To-
day, SOCS3 and PTP1B are the two molecules that are
most associated with modulation of LR signalling. How-
ever, the involvement of other mechanisms and molecules,
especially other SOCS proteins is emerging. It is likely that
the different inhibitory molecules may be implicated in the
regulation of leptin functions in different cell types. Fur-
ther investigation will be needed to clarify the complex
regulatory mechanisms that control leptin receptor signal-
ling in many vital processes.
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CHAPTER 9: Enhanced cytokine signalling by SOCS box-
dependent cross-regulation between SOCS proteins. 
 
 
I. Introduction 
 
Increasing evidence indicates that SOCS molecules not only act as inhibitors of 
cytokine responses but also play an essential role in determining cell fate by 
exerting broader regulatory mechanisms.  SOCS proteins were for example shown 
to exert a stimulating effect on signal transduction of the RAS/MAPK pathway. In 
this respect, CIS increases ERK- and JNK-mediated MAPK signalling in activated T 
cells (Li et al., 2000). Tyrosine phosphorylation of the SOCS box of SOCS3 allows 
interaction with the Ras inhibitor p120RasGAP, resulting in sustained ERK 
activation (Cacalano et al., 2001).  SOCS2 expression enhances ERK (and STAT) 
phoshorylation following cytokine treatment (Johnston, 2004). Also the Drosophila 
SOCS44A protein can have a stimulatory action on the EGFR/MAPK pathway 
(Rawlings et al., 2004). Additionally, positive effects were reported for SOCS2 and 
SOCS6 in other signalling cascades. SOCS6 increases AKT activation upon insulin 
stimulation possibly by interacting with the p85 monomer which is an attenuator of 
PI-3K dependent pathways.  Accordingly, an improvement in glucose metabolism 
was observed in SOCS6 transgenic mice (Li et al., 2004).  In vitro data 
demonstrated a dual effect of SOCS2 on GH responses with low concentrations 
having a suppressive effect while signalling is restored and even enhanced at 
higher concentrations (Favre et al., 1999). This paradoxal effect of SOCS2 is 
supported by in vivo data since deficiency and overexpression of SOCS2 in mice 
causes a similar phenotype characterized by enhanced growth (Greenhalgh et al., 
2002; Metcalf et al., 2000).  
 
In this paper we examined the molecular mechanisms underlying the positive effect 
of SOCS2 on cytokine signalling and show that SOCS2 can interfere with the 
inhibitory functions of SOCS1 and SOCS3 in GH, type I IFN and leptin signalling. 
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The modalities of this interfering effect were studied in greater detail. Using MAPPIT 
we found that SOCS2 (and SOCS6 and -7) can bind with all members of the SOCS 
protein family and the SOCS box of the targeted SOCS appears to be implicated. In 
analogy to the SOCS2 interference with CIS interaction at the LR described in 
chapter 6, this regulatory capacity of SOCS2 depends on Elongin B/C recruitment to 
its SOCS box. We observed SOCS2 mediated degradation of SOCS1 but not by its 
Elongin B/C recruitment-deficient mutant, suggesting that SOCS2 targets other 
SOCS proteins for proteasomal degradation. The cross-regulatory mechanism 
between SOCS molecules may be important for the restoration of cellular 
responsiveness for subsequent stimulation by eliminating excess SOCS levels. 
 
II. Article: Functional cross-modulation between SOCS proteins can 
stimulate cytokine signalling. 
Published in Journal of Biological Chemistry, 2006 
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SOCS (suppressors of cytokine signaling) proteins are nega-
tive regulators of cytokine signaling that function primarily at
the receptor level. Remarkably, in vitro and in vivo observations
revealed both inhibitory and stimulatory effects of SOCS2 on
growth hormone signaling, suggesting an additional regulatory
level. In this study, we examined the possibility of direct cross-
modulation between SOCS proteins and found that SOCS2
could interfere with the inhibitory actions of other SOCS pro-
teins in growth hormone, interferon, and leptin signaling. This
SOCS2 effect was SOCS box-dependent, required recruitment
of the elongin BC complex, and coincided with degradation of
target SOCS proteins. Detailed mammalian protein-protein
interaction trap (MAPPIT) analysis indicated that SOCS2 can
interact with all members of the SOCS family. SOCS2 may thus
function as a molecular bridge between a ubiquitin-protein
isopeptide ligase complex and SOCS proteins, targeting them
for proteasomal turnover. We furthermore extended these
observations to SOCS6 and SOCS7. Our findings point to a
unique regulatory role for SOCS2, SOCS6, and SOCS7 within
the SOCS family and provide an explanation for the unexpected
phenotypes observed in SOCS2 and SOCS6 transgenic mice.
Cytokine signaling is typically a transient event, implying
rapid and finely tuned attenuation. Receptor binding leads to
rapid activation of receptor-associated members of the JAK3
family. Subsequent phosphorylation of tyrosine residues in the
receptor tails enables recruitment of downstream signaling
molecules whereby STATs play a prominent role. Activated
STATs translocate to the nucleus, where they control cytokine-
regulated gene transcription. Negative control occurs at many
levels and involves receptor down-regulation, protein-tyrosine
phosphatases, protein inhibitors of activated STATs, andmem-
bers of the SOCS (suppressors of cytokine signaling) protein
family.
The SOCS family consists of eight different members
(SOCS1–7 and CIS (cytokine-inducible SH2 domain-contain-
ing protein)) characterized by conserved structural features. All
SOCS proteins consist of a central SH2 domain flanked by a
variable N-terminal region and a conserved C-terminal SOCS
box (1, 2). The SH2 domain can inhibit STAT activation by
direct competition for the phosphorylated receptor recruit-
ment sites (3–8). SOCS1 and SOCS3 carry an additional kinase
inhibitory region (KIR) in their N-terminal domains that acts as
a pseudosubstrate for the JAK kinase, thereby blocking signal-
ing (5). The SOCS box was shown to act as an interaction
domain for the elongin BC complex (9, 10), which, in turn, is a
component of an ubiquitin-protein isopeptide ligase (E3) com-
plex (11). This way, the SOCS box can control protein turnover
by marking target proteins for proteasomal degradation (12).
However, the significance of the interaction between SOCS
proteins and the elongin BC complex is not totally clarified, as
some reports propose that elongin association targets SOCS
molecules for proteasomal degradation (10, 12–15), whereas
other data suggest that elonginBCbinding stabilizes SOCSpro-
tein expression (9, 16, 17).
Deletion studies of SOCS genes in mice have underscored
their importance in specific restricted cytokine signaling path-
ways, e.g. SOCS1-deficient mice suffer from deregulated inter-
feron (IFN)- signaling characterized by malfunctioning of the
immune system at several levels (18–20), and SOCS3 haplo-
insufficient mice or mice with a specific deletion of SOCS3 in
hypothalamic neurons show augmented central leptin sensitiv-
ity (21, 22), suggesting a key role for SOCS3 in leptin resistance.
A special case concerns SOCS2, which can have opposing
effects on growth hormone (GH) signaling: SOCS2 knock-out
mice exhibit an overgrowth phenotype because of prolonged
GH-dependent STAT5 activity (23, 24), and paradoxically,
overexpression of SOCS2 in a transgenic mouse model also
leads to gigantism (25). This dual effect of SOCS2 is also
observed in vitro, where low SOCS2 doses moderately inhibit
GH signaling, and higher levels positively regulate signaling
(25–27). A similar phenomenon is observed for the effect of
SOCS2 on prolactin (PRL) (28) and interleukin-3 (29) signaling.
The role of SOCS2 in regulating cytokine-induced signals is
obviously complex because increasing SOCS2 levels can over-
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THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 281, NO. 44, pp. 32953–32966, November 3, 2006
© 2006 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
NOVEMBER 3, 2006•VOLUME 281•NUMBER 44 JOURNAL OF BIOLOGICAL CHEMISTRY 32953
 at BIO
M
EDISCHE BIBLIO
THEEK on February 12, 2008 
w
w
w
.jbc.org
D
ow
nloaded from
 
   - 159 -               
come the negative effect of SOCS1 on GH receptor (GHR) and
PRL signaling and can partially restore the SOCS3 down-regu-
lated PRL function (26, 28, 30). Of note, SOCS6 overexpression
also confers an enhanced phenotype because SOCS6 transgenic
mice display increased insulin sensitivity and enhanced glucose
metabolism (31).
GH, PRL, IFN, and others induce SOCS2 expression (27, 28,
32). Unlike SOCS1 and SOCS3 expression, which is typically
induced in a rapid and transient manner, SOCS2 expression
usually occurs later after cytokine stimulation and is more pro-
longed (28, 32). Consequently, it is tempting to speculate that
SOCS2may be involved in restoring cellular sensitivity by over-
coming the inhibitory effect of other SOCS proteins. However,
to date, no report concerning the precisemolecularmechanismof
action of SOCS2 in signal enhancement of GH response has been
published.
This study was conducted to clarify the stimulatory effect of
SOCS2 observed inGH signaling.We demonstrate that SOCS2
can interfere with the negative regulatory effects of SOCS1 and
SOCS3 via direct interaction. This effect requires the C-termi-
nal SOCS box of the targeted SOCS protein as well as the elon-
gin BC-bindingmotif in the SOCS2 SOCS box, supporting pro-
teasomal degradation of the targeted SOCS proteins. We also
show that this inter-SOCS cross-modulation can be extended
to other cytokine receptor systems and to othermembers of the
SOCS protein family.
EXPERIMENTAL PROCEDURES
Constructs—All constructs used in this study were generated
by standard PCR- or restriction-based cloning procedures and
are represented in Table 1. The pEF-FLAG-I/mSOCS1, pEF-
FLAG-I/mCIS, andpEF-FLAG-I/mSOCS2constructswerekindly
provided by Dr. R. Starr. pMET7-mLR (mouse leptin receptor
(LR) long form) was a gift from Dr. L. Tartaglia, and the pcb6-
rbGHR vector was a gift fromDr. G. Strous. Themouse thymus
cDNA was kindly provided by Dr. P. Brouckaert. The pMET7-
FLAG rat SOCS3 expression vector was described elsewhere
(33). The pMET7-FLAG-CIS, pMET7-Etag-CIS, and pMET7-
FLAG rat SOCS2 expression vectors have been described pre-
viously (34). Generation of the chimeric bait receptors contain-
ing the extracellular part of the erythropoietin receptor (EpoR)
and the transmembrane and intracellular parts of the LR, such
as pCEL, was described elsewhere (35, 36). Generation of the
prey constructs pMG2-CIS and pMG2-SOCS2, both contain-
ing part of the gp130 chain (amino acids 905–918) in duplicate,
was as described (37). The EpoR Tyr402 bait and pMET7-SVT
(SV40 large T antigen) expression vectors were obtained as
described previously (36).
Cell Culture, Transfection Procedures, andReagents—HEK293-
T, 3T3-F442A, and N38 cells were cultured in a 10% CO2
humidified atmosphere at 37 °C and grown in Dulbecco’s mod-
ified Eagle’s medium (Invitrogen) with 10% fetal calf serum
(Cambrex Corp.). For transfection experiments, cells were
freshly seeded in 6-well plates. HEK293-T cells were trans-
fected overnightwith2.5g of plasmidDNAusing a standard
calcium phosphate precipitation procedure. The pMET7-SVT
construct was used to normalize for the amount of transfected
DNA and load of the transcriptional and translational machin-
ery. N38 cells were transfected using Lipofectamine 2000
(Invitrogen) following the manufacturer’s guidelines. One day
after transfection, cells were washed with phosphate-buffed
saline without calcium, magnesium, and sodium bicarbonate
and cultured until used. Recombinantmouse leptin and human
erythropoietinwere purchased fromR&DSystems.HumanGH
was purchased from ImmunoTools, and human IFN- was
generated in the laboratory.
Luciferase and Secreted Alkaline Phosphatase (SEAP) Assays—
For a typical luciferase experiment, HEK293-T or N38 cells
were transfected with the desired constructs together with a
luciferase reporter gene. For STAT5-dependent luciferase
assays, we used a STAT5-responsive -casein-derived lucifer-
ase reporter plasmid (38). For STAT3-dependent luciferase
experiments, we used the pXP2d2-rPAP1-luciferase reporter,
originating from the rat pancreatitis-associated protein 1 pro-
moter, as described previously (36). 24 h after transfection, cells
were left untreated or were stimulated with ligand. After
another 24 h, luciferase activity from triplicate samples was
measured by chemiluminescence in a TopCount luminometer
(Canberra Packard). For IFN-stimulated gene factor 3-depend-
ent SEAP assays, we used the 6-16 SEAP reporter construct,
which was constructed as described previously (39). The
amount of SEAP was determined with a Phospha-Light kit
(Tropix, Inc., Bedford, MA) using disodium 3-(4-meth-
oxyspiro-(1,2-dioxetane-3,2-(5-chloro)tricycloneo[3.3.1.1]de-
can)-4-yl)phenyl phosphate as the luminogen substrate. Assays
were performed in a 96-well microtiter plate following the
manufacturer’s guidelines. Cells were lysed in 1% Triton X-100
and 20 mM Tris (pH 7.4), and alkaline phosphatase activity in
triplicate samples was measured by chemiluminescence in the
TopCount luminometer.
WesternBlotAnalysis andCo-immunoprecipitation—Trans-
fected HEK293-T or N38 cells were lysed in modified radioim-
mune precipitation assay buffer (200 mM NaCl, 50 mM Tris-
HCl (pH 8), 0.05% SDS, 2 mM EDTA, 1% Nonidet P-40, 0.5%
deoxycholic acid, 1 mM Na3VO4, 1 mM NaF, 20 mM -glycero-
phosphate, andCompleteTMprotease inhibitormixture (Roche
Applied Science)). 5 loading buffer (156 mM Tris-HCl (pH
6.8), 2% SDS, 25% glycerol, 0.01% bromphenol blue sodium salt,
and 5%-mercaptoethanol) was added to the cell lysates, which
were then resolved by SDS-PAGE and transferred to nitrocel-
lulosemembranes (AmershamBiosciences). Blotting efficiency
was checked by Ponceau S staining (Sigma). Blocking, washing,
and incubation with antibodies were carried out in Tris-buff-
ered saline supplemented with 5% dried skimmed milk and
0.1% Tween 20. FLAG-tagged (corresponding to the peptide
tag DYKDDDDK) and E-tagged (corresponding to the peptide
tag GAPVPYPDPLEPR) proteins were revealed using anti-
FLAG monoclonal antibody M2 (Sigma) and anti-E tag mono-
clonal antibody (Amersham Biosciences), respectively. Rabbit
anti-SOCS2 polyclonal antibody was a gift fromDr. J. Johnston,
and anti-mouse -actin antibody was supplied by Sigma.
Immunoblots were then revealed by incubation with horserad-
ish peroxidase-conjugated anti-mouse or anti-rabbit secondary
antibodies (AmershamBiosciences) and SuperSignalWest Pico
chemiluminescent substrate (Pierce). For co-immunoprecipi-
tation experiments,2 106HEK293-T cells were transfected
SOCS Cross-regulation
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with FLAG- or E-tagged pMET7-
SOCS expression vectors. Cleared
lysates (modified radioimmune
precipitation assay lysis buffer) were
incubated with 4.0 g/ml mouse
anti-FLAG or anti-E tag monoclonal
antibody and protein G-Sepharose
(Amersham Biosciences). After
immunoprecipitation, SDS-PAGE,
and Western blotting, interactions
were detected using anti-FLAG or
anti-E tag antibody as described
above.
RESULTS
Essential Role for the SOCS2
SOCS Box in Antagonizing SOCS1
and SOCS3 Inhibition of Cytokine
Signaling—SOCS2 exerts a dual
action onGHand PRL signaling and
impairs the inhibitory effect of other
SOCS proteins (26, 30). To gain
more detailed insight in the under-
lying mechanism, we first analyzed
the role of the different SOCS
protein subdomains. The effect of
constitutive expression of SOCS
proteins on GH signaling was inves-
tigated in HEK293-T cells using
the STAT5-responsive -casein-
derived luciferase reporter. Fig. 1A
shows dose-response curves dem-
onstrating complete inhibition of
GHsignaling by SOCS1 and SOCS3.
GH-inducible activity was fully
inhibited by low concentrations of
either SOCS1 or SOCS3, i.e. con-
centrations below the level of
antibody detection as judged by
Western blot analysis of the
FLAG-tagged SOCS constructs
using anti-FLAG antibody. After
removal of the SOCS boxes of
SOCS1 (SOCS1box) and SOCS3
(SOCS3box), inhibition was
slightly reduced but not abolished in
this assay system. Coexpression of
SOCS2 completely suppressed the
SOCS1- and SOCS3-dependent
inhibition of GH signaling (Fig. 1, B
and C), whereby SOCS1 inhibition
appeared to bemore sensitive to the
counteracting effect of SOCS2 com-
pared with SOCS3. Of note, the
amounts of SOCS1 used in this
experiment could not be visualized
by Western blot analysis, indicating
that the working concentrations
FIGURE 1. Essential role for the SOCS box in interference of SOCS2 with SOCS1 and SOCS3 inhibition of
GH signaling. HEK293-T cells were transfected with a rabbit GHR expression vector (40 ng) and a -casein-
derived luciferase reporter gene (200 ng). 24 h after transfection, the cells were deprived of serum and then
treatedwith human GH (200 ng/ml) for 15 h before the luciferase activity from the -casein reporter genewas
measured. Luciferasemeasurements were performed in triplicate. -Fold induction represents the ratio of lucif-
erase activity determined in the presence or absence of ligand. A, SOCS1, SOCS3, or their SOCS box deletion
mutant plasmids (SOCS1box (S1box) and SOCS3box (S3box)) were cotransfected at a range of concen-
trations to analyze the inhibitory effect on GH signaling. A sample of lysate from each group was Western-
blotted and probed with anti-FLAG antibody. B, SOCS1 (10 ng) or SOCS1box (60 ng) was cotransfected
with SOCS2 or SOCS2box (S2box) at increasing concentrations. Expression of the E-tagged SOCS2 and
SOCS2box proteins in the same transfected cells was verified on lysates using anti-E tag antibody. C, SOCS3
(100 ng) or SOCS3box (100 ng) was cotransfected with SOCS2 or SOCS2box at increasing concentrations.
Expression of the E-tagged SOCS2 and SOCS2box proteins in the same transfected cells was verified on
lysates using anti-E tag antibody.D, shown is a comparisonof the ectopic andendogenous expression levels of
mouse SOCS2 in HEK293-T and 3T3-F442A cells, respectively. SOCS1 (10 ng) was cotransfected with SOCS2 at
increasing concentrations in HEK293-T cells. Expression of the E-tagged SOCS2 proteins in the same trans-
fected cells and of endogenous SOCS2 in the 3T3-F442A cells was verified on lysates using anti-SOCS2 anti-
body. 3T3-F442A cells were incubated in serum-free medium prior to stimulation with GH (200 ng/ml) for the
indicated times. The levels of loaded proteinwere normalized by determining the protein concentrationswith
the Bradford method, and this was verified by Ponceau S staining. As an additional control, the blots were
stripped and probed with anti--actin antibody to check for equal loading of lysates of the same cell type.
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were approaching the physiological concentrations of this
SOCS protein. The SOCS2 amounts were also not supra-
physiological, as the SOCS2 concentration at which a cross-
regulatory effect was observed was comparable with the
endogenous level of SOCS2 in the
GH-responsive mouse 3T3-F442A
preadipocyte cell line (Fig. 1D).
This suppressive effect on SOCS
molecules was specific for SOCS2,
as coexpression of CIS did not
interfere with SOCS1- or SOCS3-
mediated inhibition (data not
shown). Strikingly, this effect of
SOCS2 depended strictly on the
presence of its SOCS box. Of note,
the deletion of the SOCS box led to
enhanced expression in the case of
SOCS2. This effect was also
observed, albeit to a lesser extent,
with SOCS1, but was not observed
for SOCS3.
We next evaluated whether we
could extrapolate this SOCS2 regu-
lation to other receptor systems.
SOCS1 and SOCS3 have been
implicated as potent inhibitors of
IFN type I receptor signaling (40,
41); however, the role of SOCS2 is
less well elucidated. We monitored
IFN- signaling in HEK293-T cells
using the IFN-sensitive 6-16 SEAP
type I reporter gene and evaluated
the effect of expression of various
combinations of (mutant) SOCS
proteins as described above. We
found that expression of SOCS2 at
increasing concentrations resulted
in a clear dual effect on IFN signal-
ing (Fig. 2A): at low concentrations,
SOCS2 suppressed IFN signaling,
but at higher concentrations,
SOCS2 led to complete restoration
and even enhancement of the
responsiveness of the 6-16 reporter
to IFN-, suggesting a negative
effect of SOCS2 on endogenous
SOCS proteins. Quite similar to
what we observed with GH, expres-
sion of SOCS1, SOCS3, or their
mutants lacking the SOCS box
inhibited IFN- signaling (Fig. 2B).
Again, analogous to the observa-
tions made for GH, SOCS1- and
SOCS3-mediated inhibition of
IFN- signaling was completely
neutralized by coexpression of
SOCS2, and the SOCS boxes of
SOCS1 or SOCS3 and of SOCS2
were strictly required for the full effect (Fig. 2, C and D).
We finally extended these analyses of SOCSmodulation also
to LR signaling. Again, quite similar to the previous observa-
tions, expression of SOCS1, SOCS3, or their SOCS box deletion
FIGURE 2. Essential role for the SOCS box in interference of SOCS2 with SOCS1 and SOCS3 inhibition of
IFN signaling. SEAP activity was assayed in HEK293-T cells transfectedwithout SOCS or with SOCS1–3 expres-
sion vectors and the IFN-responsive 6-16 SEAP reporter (200 ng) at several ratios. After 24 h, transfected cells
were stimulated with human IFN- (100 pM); and after 48 h, the SEAP activity in the 6-16 reporter gene was
measured. SEAP measurements were performed in triplicate. -Fold induction represents the ratio of SEAP
activity determined in the presence or absence of ligand. A, SOCS2 can act as a dual effector of INF type I
signaling as assessed by transfection with SOCS2 at a range of concentrations or with empty vector in an
appropriate amount in HEK293-T cells. Expression of the E-tagged SOCS2 protein in the same transfected cells
was verified on lysates using anti-E tag antibody. B, SOCS1, SOCS3, or their SOCSbox deletionmutant plasmids
were transfected at a range of concentrations to analyze the inhibitory effect on interferon type I signaling.
C, SOCS1 (10 ng) or SOCS1box (S1box; 60 ng) was cotransfected with SOCS2 or SOCS2box (S2box) at
increasing concentrations.D, SOCS3 (20 ng) or SOCS3box (S3box; 100 ng) was cotransfectedwith SOCS2 or
SOCS2box at increasing concentrations.
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mutants blocked induction of leptin-mediated activation of a
STAT3-responsive rat pancreatitis-associated protein 1 pro-
moter-luciferase reporter in HEK293-T cells (data not shown).
Coexpression of SOCS2 restored the SOCS-dependent signal-
ing blockade. These effectswere dependent on either SOCSbox
and were less pronounced for SOCS3-mediated LR inhibition
than for SOCS1-mediated LR inhibition (data not shown). We
further verified the cross-modulatory effects of SOCS2 in
mouseN38 hypothalamic cells, which represent a physiological
context for LR signaling. This N38 cell line responds to leptin
stimulation and is a part of a collection of clonal neuronal cell
lines recently isolated by Belsham et al. (42). Similar to what we
observed in HEK293-T cells, expression of SOCS1, SOCS3, or
their mutants lacking the SOCS box inhibited leptin signaling
(Fig. 3A). Coexpression of SOCS2 with SOCS1 (Fig. 3B) or
SOCS3 (data not shown) in the N38 cells led to recovery of the
leptin-induced signaling in a SOCS box-dependent manner.
Moreover, expression of SOCS2 alone clearly stimulated
the STAT3-dependent luciferase
response (Fig. 3C), which can be
explained by a negative effect of
SOCS2 on the endogenous SOCS
proteins. This effect was again lost
with a SOCS2 mutant lacking the
SOCS box. Together, these findings
show that the cross-modulatory
effect of SOCS2 on other SOCS pro-
teins is not limited to theGH system
and likely involves similar underly-
ing mechanisms.
Recruitment of the Elongin BC
Complex by SOCS2 Is Essential for
Interference with Other SOCS Pro-
teins—Sequence alignments of SOCS
box-containing proteins reveal a sin-
gle conserved regionwith the consen-
sus sequence (T/S)(L/M)XXX(C/S)-
XXX(V/L/I) that defines an elongin
BC complex-binding site or “BC
box” (9, 10, 43). We generated a
SOCS2 mutant, SOCS2(LC-PF),
containing point mutations in the
BC box of SOCS2 that abrogate
elongin BC recruitment (9). In
another SOCS2 derivative, SOCS2-
(LC-QQ), both residues were
mutated to glutamine to minimize
structural alterations of the protein.
As shown in Fig. 4, this SOCS2(LC-
QQ) mutant completely lost its
capacity to interfere with SOCS1
and SOCS3 antagonism in GH and
IFN signaling in HEK293-T cells
and with leptin signaling in N38
cells. Similar findings were made
with the SOCS2(LC-PF) mutant
(data not shown). This indicates
that functional recruitment of the
elongin BC complex is a prerequisite for the negative regulation
by SOCS2 of other SOCS proteins.
SOCS2 Interacts with Other Members of the SOCS Family—
We next used mammalian protein-protein interaction trap
(MAPPIT), a strategy designed to analyze protein-protein
interactions in intact mammalian cells (36), to investigate
whether SOCS2 exerts its cross-modulatory function via direct
binding to other SOCS proteins. In MAPPIT, a bait protein is
C-terminally linked to a chimeric receptor consisting of the
extracellular region of the EpoR linked to the transmembrane
and the intracellular part of a signaling-deficient LR. The use of
a triple Tyr-to-Phe mutant LR (further referred to as LR-F3)
knocks out STAT3 activation and offers the added advantage
that negative feedback mechanisms are inoperative, implying
enhanced signaling.
MAPPIT prey constructs are composed of a prey protein
fused to a part of the gp130 chain carrying four STAT3
recruitment sites. Coexpression of interacting bait and prey
FIGURE 3. SOCS2 displays a SOCS box-dependent stimulatory effect on leptin signaling in N38 cells.
Mouse N38 hypothalamic cells were transiently cotransfectedwith amouse LR expression vector (250 ng) and
the pXP2d2-rPAP1-luciferase reporter (1g). The transfected cells were either left untreated or stimulated for
24 hwith leptin (100 ng/ml). Luciferasemeasurements were performed in triplicate. Data are expressed as the
leptin-stimulated/non-stimulated ratio. A, SOCS1, SOCS3, or their SOCS box deletion mutant plasmids were
cotransfected at a range of concentrations to analyze the inhibitory effect on leptin signaling. B, SOCS1 (30 ng)
or SOCS1box (S1box; 100 ng) was cotransfected with SOCS2 or SOCS2box (S2box) at increasing concen-
trations. C, SOCS2 or the SOCS2box mutant plasmid was transfected at a range of concentrations to analyze
the stimulatory effect on leptin signaling.
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leads to functional complementation of STAT3 activity and
induction of the STAT3-responsive rat pancreatitis-associ-
ated protein 1 promoter-luciferase reporter. MAPPIT per-
mits the detection of both modification-independent and
phosphorylation-dependent interactions in intact human
cells. The MAPPIT configuration used in this study is shown
in Fig. 5A.
We have shown previously that SOCS2 directly interacts
with CIS (34). This observation and the abovementioned find-
ings on cross-regulation between SOCS2 and SOCS1 or SOCS3
prompted us to investigate whether
SOCS2 can bind to these SOCS
family members. HEK293-T cells
were cotransfected with a bait plas-
mid encoding the SOCS boxes of
SOCS1, SOCS2, SOCS3, or CIS
combined with a plasmid encod-
ing the SOCS2 or CIS prey and
the STAT3-responsive luciferase
reporter construct. We always used
isolated SOCSboxes as bait proteins
because, in the case of SOCS1 and
SOCS3, the full-length baits inter-
feredwith theMAPPIT readout and
therefore could not be investigated.
Erythropoietin stimulation revealed
clear interaction of SOCS2 with all
baits examined. In contrast, the CIS
prey failed to induce any reporter
activity (Fig. 5B). The expression
levels of the FLAG-tagged prey pro-
teins were confirmed by immuno-
blotting using anti-FLAG antibody.
In Fig. 5C, we show, usingMAPPIT,
that the SOCS2(LC-QQ) mutant
lost its capacity to associate with an
elongin B prey while maintaining its
interaction with the CIS bait. A
MAPPIT bait construct containing
the Tyr402 motif of the EpoR was
used as a positive control, as this
receptor motif directly interacts
with SOCS2 (36). This association
of SOCS2 with SOCS1–3 and CIS
was confirmed by co-immunopre-
cipitation. We transiently cotrans-
fected HEK293-T cells with a plas-
mid encoding E-tagged SOCS2
together with FLAG-tagged plas-
mids encoding SOCS1, SOCS2, and
SOCS3, respectively, or we coex-
pressed FLAG-tagged SOCS2 with
E-tagged SOCS1, SOCS2, and CIS.
SOCS2 co-immunoprecipitated
SOCS1–3 (Fig. 6A) and, in the case
of CIS, both the 37- and 32-kDa
forms that correspond to mono-
and non-ubiquitinated proteins,
respectively (44). Observed interactions of SOCS2 with SOCS
proteins in HEK293-T cells depended on proteasomal inhibi-
tion with the proteasomal inhibitorMG132 (20M) for 6 h and
stimulation with IFN- (100 pM) for 30 min. SOCS1 was still
co-immunoprecipitated with the SOCS2box and SOCS2(LC-
QQ) mutants, indicating that deletion of the SOCS box or the
BC box motif did not disrupt the capacity of SOCS2 to bind
SOCS1 (Fig. 6B). Nevertheless, elimination of the SOCS box of
SOCS2weakened the interactionwith SOCS1, suggesting a role
for this domain in SOCS-SOCS interactions.
FIGURE 4. The negative effect of SOCS2 on other SOCS proteins is dependent on recruitment of the
elongin BC complex. HEK293-T or N38 cells were transiently transfected with plasmids encoding SOCS1 or
SOCS3 at fixed amounts and with wild-type SOCS2 or SOCS2BC box(LC-QQ) (S2(LC-QQ)) at increasing con-
centrations. The transfected cells were either left untreated or were stimulated with human GH (200 ng/ml),
IFN- (100pM), or leptin (100ng/ml). Luciferase and SEAPmeasurementswere performed in triplicate. Data are
expressed as -fold induction (stimulated/non-stimulated). A, HEK293-T cells were transfected with 10 ng of
SOCS1, 100 ng of SOCS3, and increasing concentrations of SOCS2 derivatives. GH signaling was assayed as
described in the legend to Fig. 1. B, HEK293-T cells were transfected with 10 ng of SOCS1, 20 ng of SOCS3, and
increasing concentrations of SOCS2 derivatives. IFN signalingwas assayed as described in the legend to Fig. 2.
C, N38 cells were transfected with 30 ng of SOCS1, 15 ng of SOCS3, and increasing concentrations of SOCS2
derivatives. Leptin signaling was assayed as described in the legend to Fig. 3.
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SOCS2 Promotes Degradation of SOCS1—The dependence
of the SOCS2 effect on an intact BC box suggests that SOCS2
can target SOCS proteins for proteasomal degradation.
HEK293-T cells were transiently transfected with SOCS1 and
increasing concentrations of SOCS2 and then treated with the
protein synthesis inhibitor cycloheximide (20 M) for 6 h. Deg-
radation of SOCS1 was observed when increasing concentra-
tions of SOCS2 were coexpressed, whereas SOCS2(LC-QQ)
had no effect (Fig. 7). This suggests a mechanism in which
SOCS2 acts as an adaptormolecule between an E3 complex and
SOCS proteins, targeting them for proteasomal turnover.
SOCS2 and Also SOCS6 and
SOCS7 Interact with All Members
of the SOCS Family—Interaction
studies performed with the other
SOCS proteins used as baits
revealed that the SOCS2 prey can
also interact with the SOCS boxes of
SOCS4–7 (Fig. 8A). Using the same
approach, we performed a matrix-
type interaction analysis of SOCS
proteins, and we found that SOCS6
and SOCS7 preys also interacted
with the SOCS box baits of all mem-
bers of the SOCS family (Fig. 8, B
and C). Of note, SOCS2, SOCS6,
and SOCS7 also displayed binding
to themselves. The MAPPIT data
with the CIS prey were included as a
negative control, and functionality
of this CIS prey was demonstrated
using the interaction with the EpoR
Tyr402 motif as a control (Fig. 8D).
The EpoR-LR-F3 bait provided a
control for aspecific binding to the
intracellular part of the LR and
JAK2. The expression of the differ-
ent bait constructs was verified by
checking the interaction with the
SH2 prey, which binds the associ-
ated JAK of LR-F3 (data not shown).
Possible complications that could
arise from interference of the SOCS
prey constructs with JAK activity or
STAT recruitment and that could
lead to false negative signals were
considered and ruled out, as their
coexpression with an established
MAPPIT interaction had no deleterious effect (data not
shown). From these experiments, we concluded that SOCS2,
SOCS6, and SOCS7 can interact with the SOCS boxes of all
SOCS family members.
SOCS6 Is aNegative Regulator of Other SOCS Proteins—Sub-
sequently, we investigated whether SOCS6 displays similar
functional SOCS cross-modulation as SOCS2. We found that
SOCS6 antagonized the inhibition of SOCS proteins in GH and
IFN (Fig. 9, A and B) and leptin (data not shown) signaling in
HEK293-T cells. In N38 cells, SOCS6 interfered with SOCS1
and SOCS3 inhibition of leptin signaling (Fig. 9C).
FIGURE 5. MAPPIT analysis of SOCS interactions. A, principle of MAPPIT. See “Results” for details. rPAP1, rat pancreatitis-associated protein 1. B, SOCS2
interacts with the SOCS boxes of SOCS1–3 and CIS. HEK293-T cells were transiently cotransfected with plasmids encoding bait variants of the SOCS boxes of
several SOCS proteins or with a mock bait lacking the SOCS motif, the pMG2-SOCS2 or pMG2-CIS prey construct, and the pXP2d2-rPAP1-luciferase reporter.
After transfection, cells were either left untreated or were stimulated with erythropoietin (Epo) for 24 h. Luciferase activities weremeasured in triplicate. -Fold
induction represents the ratio of luciferase activity determined in the presence or absence of ligand. Expression of the FLAG-tagged fusion prey proteins in the
same transfected cellswas verified on lysates using anti-FLAGantibody.C, the SOCS2(LC-QQ)mutant does not bind elongin B,whereas the interactionwithCIS
is preserved. HEK293-T cells were transiently cotransfected with plasmids encoding the chimeric EpoR-LR-F3 construct as a negative control, the EpoR Tyr402
bait as a positive control for SOCS2, the elongin B bait, or the CIS SOCS box bait and with the pMG2-SOCS2 or pMG2-SOCS2(LC-QQ) prey construct combined
with pXP2d2-rPAP1-luciferase. The transfected cells were either stimulated for 24 hwith erythropoietin or were left untreated. Luciferasemeasurements were
performed in triplicate. Data are expressed as -fold induction (stimulated/non-stimulated).
FIGURE 6. A, SOCS2 interactions demonstrated by co-immunoprecipitation experiments. Lysates from
HEK293-T cells cotransfected with FLAG- or E-tagged SOCS1 (S1), SOCS2 (S2), SOCS3 (S3), and CIS were immu-
noprecipitated (IP)with anti-E tagor anti-FLAGantibodyandWestern-blotted (WB)with anti-FLAGor anti-E tag
antibody (upper panels). The whole cell lysate was Western-blotted with anti-FLAG or anti-E tag antibody as a
loading control (middle and lower panels). B, interaction analysis of SOCS1 and SOCS2mutants. HEK293-T cells
were transiently cotransfected with FLAG-tagged SOCS2, SOCS2box (S2box), SOCS2BC box(LC-QQ)
(S2(LC-QQ)), or the appropriate amount of empty vector and E-tagged SOCS1. Cell lysates were immunopre-
cipitated with anti-FLAG antibody and subsequently immunoblotted with anti-E tag or anti-FLAG antibody.
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Like other SOCS molecules, SOCS6 was shown to bind to
elongins B and C in a SOCS box-dependent manner (45). Anal-
ogous to SOCS2, disruption of elongin BC binding in SOCS6
yielded a mutant that was not able to interfere with the inhibi-
tory effect of other SOCS proteins (Fig. 9). Also, wild-type
SOCS6, but not the BC box mutant, reduced SOCS1 expres-
sion in a dose-dependentmanner, indicating that SOCS6medi-
ated the observed inhibition by accelerating turnover of other
SOCS proteins (Fig. 10). Taken together, our data suggest that
SOCS6 can negatively regulate SOCS function in a way very
similar to SOCS2.
DISCUSSION
Protein degradation by the ubiquitin-proteasome pathway
plays an essential role in controlling the abundance of regula-
tory molecules. Key to this is the sequential action of three
protein sets: ubiquitin-activating enzymes, ubiquitin carrier
enzymes, and a large set of E3 enzymes, whereby the latter
define substrate specificity. The SCF (Skp1-Cul1-F-box) E3
complex is composed of the Cul1 scaffold protein, which binds
the Roc1/Rbx1 RING domain protein and the ubiquitin carrier
enzyme and which recruits, via the Skp1 linker protein, F-box
proteins, which in turn bind substrates for ubiquitination. This
same architecture is also found in other SCF-like complexes,
including those based on the Cul2-von Hippel-Lindau and
Cul5-SOCS box adaptor proteins, whereby elongins B and C
and SOCS or von Hippel-Lindau proteins fulfil the role of the
Skp1 and F-box proteinmoieties, respectively (1). Evidence that
SOCS proteins can mediate proteasomal turnover of target
molecules is accumulating. Examples include the GHR and
EpoR (44, 46), JAK2 (13), the Rac guanine nucleotide exchange
factor Vav (47), RasGTPase-activating protein (17), and insulin
receptor substrates 1 and 2 (48). Of note, SOCS proteins them-
selves can be targeted for ubiquitination and proteasomal deg-
radation, although contradictory reports exist regarding the
effect of elongin BC interaction on the protein stability of
SOCS1, SOCS3 and CIS. Some data suggest that elongin BC
association targets SOCS proteins for degradation by the pro-
teasome, as has been demonstrated for CIS (44, 49), SOCS1 (10,
50), and SOCS3 (10, 51). In contrast, there is also evidence that
elongin BC interaction can stabilize SOCS1 (9, 16, 52) and
SOCS3 (17) and that disruption of this interaction leads to pro-
teasome-mediated degradation of these SOCS proteins.
SOCS2 undeniably plays a role as a negative regulator of GH
signaling in vivo and in vitro (43), but can also enhance GH
signaling when expressed at higher concentrations (25, 26). It
binds to the GHR at multiple sites, some of which could also
function as recruitment sites for negative regulators such as
SHP-2 (53) and SOCS3 (54, 55). Such competition between
SOCS2 and potentiallymore potent negative regulatorswas put
forward as a potential explanation for the dual effect of SOCS2
(25). However, little direct evidence was reported in support of
such a model, and recently, Greenhalgh et al. (43) showed that
SOCS2 binds theGHRatTyr487 andTyr595, which are not usual
immunoreceptor tyrosine-based inhibitory motifs, suggesting
that competition of SOCS3 at these sites is not involved.
The key finding in this study is that a restricted set of SOCS
proteins, including SOCS2, can bind to other members of the
SOCSfamily,thuscontrollingtheiractivitythroughproteasome-
dependent degradation. We found that SOCS2 can restore and
potentiate GH signaling by antagonizing SOCS1 and SOCS3 in
a SOCS box-dependentmanner. This effect is not limited to the
GH systembecausewe found similar effects on signaling via the
endogenous IFN type I receptor and LR in HEK293-T and N38
cells, respectively.
SOCS2mutants lacking the binding site for elongin BC com-
pletely lose their inhibitory potential, providing a strong argu-
ment for proteasomal degradation of the target SOCS proteins.
Indeed, as observed for SOCS1, coexpression of SOCS2 leads to
lowered expression levels of this target SOCS protein. The crit-
ical elongin BC dependence of the inhibitory effect by SOCS2
strongly argues that SOCS2 functions as part of an E3 complex.
Alternatively, higher expression levels of SOCS2 may compete
for recruitment of the elongin BC complex, indirectly leading to
destabilization of other SOCS proteins lacking this complex
(see above). However, SOCS1 and SOCS3 proteins lacking their
entire SOCS boxes are still able, although to a lesser extent, to
inhibit cytokine signaling, but are completely refractory to the
SOCS2 effect, implying that SOCS2 binding is critical. More-
over, overexpression of CIS, which is equally well capable of
sequestering elongin BC complexes, does not lead to any effect
on other SOCS proteins. The SOCS box of the target SOCS
protein appears to be involved in SOCS2 binding. Although our
data support an involvement of the SOCS box in the interaction
between the inhibitory SOCS and targeted SOCS proteins, the
precise nature of this inter-SOCS interaction is still unclear
and, given the MAPPIT configuration, may well depend on
phosphorylation of critical tyrosine residues. Mutational anal-
ysis will be required to fully determine the binding modus
between different SOCS proteins.
Evidence that SOCS2 can act as a regulator of turnover of
other SOCS proteins was recently also reported by Tannahill
et al. (29), who demonstrated SOCS2 regulation of the SOCS3-
dependent inhibition of interleukin-2 and interleukin-3 signal-
ing, and by Lavens et al. (34), who showed elongin BC-depend-
ent interference of SOCS2 with binding of CIS to the LR at
Tyr985. In line with such a regulatory role of SOCS proteins is
the sequential induction pattern of different SOCS molecules.
Unlike expression of SOCS1 and SOCS3, which is typically
induced in a rapid and transient manner upon cytokine stimu-
lation, expression of SOCS2 usually occurs late after cytokine
FIGURE 7. Coexpression of SOCS2 accelerates SOCS1 degradation.
Increasing concentrations of E-tagged SOCS2 or SOCS2(LC-QQ) were tran-
siently coexpressed in HEK293-T cells with FLAG-tagged SOCS1. Cells were
treated with cycloheximide (20M) for up to 6 h. The lysates were blotted for
SOCS1 with anti-FLAG antibody and for SOCS2 with anti-E tag antibody.
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FIGURE 8. SOCS2, SOCS6, and SOCS7 interact with the SOCS boxes of all SOCS family members. HEK293-T cells were transiently cotransfected with
plasmids encoding bait variants of the SOCS boxes of all SOCS proteins or the chimeric EpoR-LR-F3 construct as a negative control; the pMG2-SOCS2,
pMG2-SOCS6, pMG2-SOCS7, or pMG2-CIS prey; and the pXP2d2-rPAP1-luciferase reporter. After transfection, cells were either left untreated or were stimu-
lated with erythropoietin (Epo) for 24 h. Luciferase activities were measured in triplicate. Data are expressed as -fold induction (stimulated/non-stimulated).
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FIGURE 9. The negative effect of SOCS6 on other SOCS proteins depends on recruitment of the elongin BC complex. HEK293-T or N38 cells were
transiently transfected with plasmids encoding SOCS1 or SOCS3 at fixed amounts and wild-type SOCS6 or SOCS6BC box(LC-QQ) (S6(LC-QQ)) at increasing
concentrations. The transfected cells were either left untreated or were stimulated with GH (200 ng/ml), IFN- (100 pM), or leptin (100 ng/ml). Data are
expressed as -fold induction (stimulated/non-stimulated). Luciferase and SEAPmeasurementswere performed in triplicate.A, HEK293-T cellswere transfected
with 10 ng of SOCS1, 100 ng of SOCS3, and increasing concentrations of SOCS6 derivatives. GH signaling was assayed as described in the legend to Fig. 1.
B, HEK293-T cells were transfected with 10 ng of SOCS1, 50 ng of SOCS3, and increasing concentrations of SOCS6 derivatives. IFN signaling was assayed as
described in the legend to Fig. 2.C, N38 cellswere transfectedwith 30 ngof SOCS1, 10 ngof SOCS3, and increasing concentrations of SOCS6derivatives. Leptin
signaling was assayed as described in the legend to Fig. 3.
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stimulation and is more prolonged (27, 28, 32). Accumulation
of increasing levels of SOCS2 late after induction is consistent
with a role in eliminating excess levels of SOCS proteins after
receptor activation and may be involved in restoring cellular
responsiveness for subsequent stimulation. Interestingly,
SOCS2, SOCS6, and SOCS7 can also bind to themselves, sug-
gesting the possibility of self-elimination. A full and global
insight into the precise inhibitory effects will thus require care-
full analysis of the interaction pattern at the cytokine receptor,
at the targeted SOCS protein, and at the level of self-interac-
tion, bearing in mind the effect of the differences in binding
affinities and relative expression levels of all components.
Whereas SOCS1–3 andCIS have been studied extensively, so
far little is known about the physiological role of the other four
SOCS proteins, SOCS4–7. We therefore analyzed matrix-
wise all possible inter-SOCS interactions. The interaction map
showed two characteristics: first, SOCS2 appears to bind to all
SOCSproteins, including itself; and second, SOCS6 and SOCS7
display exactly the same binding profile.
In line with a SOCS-counteracting role of SOCS6, we have
shown that its expression potentiates signaling via the GHR,
IFN type I receptor, and LR in a way quite similar to what we
observed for SOCS2. Similar data sets were also obtained for
leptin signaling in the physiologically relevant N38 hypotha-
lamic cell line. These novel findings regarding SOCS6 provide
an explanation for the significant enhancement of glucose
metabolism observed in SOCS6 transgenic mice (31). More
evidence for a positive role for SOCS6 in cytokine signaling
also comes from studies in Drosophila melanogaster, where
SOCS44A (which is similar to SOCS6) was shown to enhance
the activity of the growth factor receptor/mitogen-activated
protein kinase (MAPK) signaling cascade, in contrast to
SOCS36E (which is similar to SOCS5) (56).
Because several SOCSmolecules canmediate similar regula-
tory effects, functional redundancy is not unlikely. This may be
particularly true for (but not limited to) SOCS6 and SOCS7,
which show high homology and similarity in binding specificity
(45). Compensatory effects between cross-modulatory SOCS
molecules may perhaps have an effect on the phenotypes of
SOCS2-, SOCS6-, and SOCS7-deficient mice (23, 45, 57), war-
ranting analysis of double knock-out mice, which may uncover
additional physiological activities of particular SOCS proteins.
Of note, the SOCS box is not limited to the SOCS protein fam-
ily, but at present, 128 proteins harboring a SOCS box have
been described in the mammalian genome (according to the
Pfam Database).
In summary, our findings point to the existence of a subfam-
ily of SOCS proteins consisting of SOCS2, SOCS6, and SOCS7,
capable of controlling SOCS protein stability. This functional
cross-modulation between SOCS proteins requires the SOCS
box, probably both as an inter-SOCS-binding domain and as a
functional recruitment motif for elongin BC-containing E3
enzymes. The observation that several SOCS proteins do not
act solely as inhibitors of cytokine signaling should be taken in
consideration in the evaluation of gene knock-out studies and
may be of relevance for several human pathologies.
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CHAPTER 10: CIS functions are controlled by Elongin B/C 
binding  
 
I. Introduction 
Elongin B/C association is known to be involved in proteasomal targeting of 
substrates and regulation of protein stability. In the following study we show that 
Elongin B/C recruitment to the SOCS box of a protein can also control its substrate 
interaction.  Receptor interaction of CIS and subsequent inhibition of STAT5 activity 
were found to crucially depend on Elongin B/C binding. This Elongin B/C-
dependency for substrate interaction appears to be unique for CIS and structural 
basis for this distinct feature of CIS is provided by molecular modelling of the CIS-
Elongin B/C complex. These findings imply a new role for the SOCS box which may 
form a regulatory on/off switch acting on the SH2 domain. Increasing evidence 
indicates a key role for proteasomal activity in CIS-mediated signal suppression 
(Hunter et al., 2004; Ram and Waxman, 2000; Uyttendaele et al., 2007).  Our 
observation that Elongin B/C association cannot be uncoupled from CIS actions 
further supports a major contribution for the recruitment of E3 ligase activity in CIS-
mediated inhibition. 
 
II. Article: Elongin B/C recruitment regulates substrate binding by CIS. 
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SOCS proteins play a major role in the 
regulation of cytokine signalling.  They are 
recruited to activated receptors and can 
suppress signalling by different mechanisms 
including targeting of the receptor complex for 
proteasomal degradation.  The activity of SOCS 
proteins is regulated at different levels including 
transcriptional control and posttranslational 
modification.  We here describe a novel 
regulatory mechanism for CIS, one of the 
members of this protein family. A CIS mutant 
that is deficient in recruiting the Elongin B/C 
complex completely fails to suppress STAT5 
activation. This deficiency was not caused by 
altered turnover of CIS but by loss of cytokine 
receptor interaction. Intriguingly, no such effect 
was seen for binding to MyD88. The interaction 
between CIS and the Elongin B/C complex is 
easily disrupted and depends on the levels of 
uncomplexed Elongin B/C. This regulatory 
mechanism may be unique for CIS since similar 
mutations in SOCS1, -2, -3, -6 and -7 had no 
functional impact. Our findings indicate that the 
SOCS box not only plays a role in the formation 
of E3 ligase complexes, but, at least for CIS, can 
also regulate the binding modus of SOCS box 
containing proteins. 
 
Cytokines regulate multiple biological 
processes by activating specific cell surface 
receptor complexes.  This leads to a series of 
signalling events, including activation of the 
Janus kinase (JAK)/signal transducer and 
activator of transcription (STAT), 
phosphoinositol 3-kinase (PI3K), phospholipase 
C ɣ (PLCɣ) and mitogen activated protein kinase 
(MAPK) pathways. The magnitude and duration 
of a cellular response is determined by the 
integration of different positive and negative 
signals. Mechanisms of signal attenuation are 
diverse and involve different protein families 
including phosphatases such as protein tyrosine 
phosphatase 1B (PTP-1B) or T-cell protein 
tyrosine phosphatase (TCPTP) (1-5), members of 
the protein inhibitors of activated STATs (PIAS) 
(6-8) and suppressor of cytokine signalling 
(SOCS) families (9-11).  
SOCS proteins are induced by a broad 
range of extracellular ligands and function in a 
negative feedback loop to modulate signal 
transduction by multiple cytokine and growth 
factor receptors (12,13,14,15,16). The eight 
members of the SOCS family, SOCS1-7 and 
cytokine-inducible SH2 containing protein (CIS), 
share a common structure with a central SH2 
domain, an amino-terminal domain of variable 
length and divergent sequence, and a carboxy-
terminal 40 amino-acid module that is known as 
the SOCS box (9,17,18).  The SH2 domain is the 
main determinant of target recognition by the 
SOCS proteins as it mediates interaction with 
phosphorylated tyrosine residues on their 
specific substrates (18-20).  This way, SOCS 
proteins can suppress signalling by direct 
competition with signalling molecules for the 
phosphorylated recruitment sites.  SOCS1 and 
SOCS3 can also inhibit JAK tyrosine kinase 
activity through their kinase inhibitory region 
(KIR), which is proposed to function as a 
pseudosubstrate blocking the catalytic cleft of the 
JAK kinase (21).  Finally, SOCS proteins can 
suppress signalling through proteolytic 
degradation of the activated receptor complexes.  
Conserved motives in their SOCS box couple to 
Elongin B and C (B/C), Cullin and Rbx proteins, 
leading to the formation of an E3 ubiquitin ligase 
complex (22-25) and subsequent ubiquitin-
marking of the target protein for proteasomal 
degradation.  The functional significance of the 
association of Elongin B/C to the SOCS box is 
however complex as the SOCS box may also 
target SOCS proteins themselves for proteasomal 
degradation (23,26,27).  Conversely, Elongin 
B/C binding was also found to stabilize SOCS 
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protein expression (22,28,29). Therefore, it is 
assumed that Elongin B/C binding has a double-
edged effect on SOCS proteins: a degrading role 
by the link with the E3 ubiquitin ligase complex, 
but also a protective function by prevention of 
proteasomal turnover of the SOCS molecules 
them selves. There is also evidence that the 
SOCS box is involved in a SOCS cross-
modulatory mechanism as some SOCS members 
like SOCS2 can act as negative regulators of 
other SOCS proteins by targeting them for 
proteasomal turnover (30-32). Furthermore, we 
reported that the SOCS box of CIS is required 
for functional interaction with cytokine receptor 
motifs with a critical role for the single tyrosine 
residue at position 253 (33). 
The founding member of the family, CIS, 
can inhibit signalling by several cytokine receptors 
including the erythropoietin receptor (EpoR) and 
the growth hormone receptor (GHR). CIS 
suppresses Epo-induced cell proliferation and 
induces apoptosis of erythroid progenitor cells 
(34,35).  CIS transgenic mice exhibit growth 
retardation, suggesting a defect in GH signal 
transduction (36).  Other abnormalities of CIS 
overexpressing mice were detected in prolactin and 
IL-2 signalling pathways and these phenotypes 
resembled those found in STAT5a and/or STAT5b 
knock-out mice, lending support for CIS as a 
specific negative regulator of STAT5-mediated 
cytokine signalling (36). Direct competition with 
STAT5 for common phosphotyrosine binding sites 
is observed for the EpoR (37-40), but not for the 
GHR (41).  In addition, CIS was found to induce 
proteasome-dependent degradation of the EpoR and 
GHR (37,42,43) and in the latter case, CIS also was 
reported to play a role in GHR internalization (43).  
In this report, we investigated the effect of Elongin 
B/C binding on CIS function in greater detail.  
Notably, we found that Elongin B/C recruitment by 
CIS is crucial for interaction with its receptor 
substrates and subsequent inhibition of STAT5 
activity. 
 
Experimental Procedures 
 
Constructs- All constructs used in this study were 
generated by standard PCR- or restriction-based 
cloning procedures and are represented in table 1. 
The pXP2d2-rPAPI-luciferase reporter, originating 
from the rPAPI (rat pancreatitis associated protein 
I) promoter was described previously (44). The 
pGL3-β-casein-luciferase reporter consisting of five 
repeats of the STAT5-responsive motif of the β-
casein promoter was a gift from Dr. Ivo Touw (45) 
and the STAT5-responsive pGL2-SPI2.1-luciferase 
reporter was a gift from Dr. Walter Becker (46).   
The pRK5-mJAK2 construct was a gift from Dr. 
Yohan Royer.  Generation of the chimeric bait 
receptors containing the extracellular part of the 
EpoR and the transmembrane and intracellular parts 
of the leptin receptor, such as pCEL, were reported 
elsewhere (44,47).  The following constructs were 
described previously : mLR Y1138F (YYF) (48); 
pCEL-EpoR Y402 and pMG-SVT (44); pCEL-GHR 
Y595 (41); pSV-EpoR pMG2-CIS  and pMG2-
SOCS2 (40); pMET7-FLAG-CIS and pMET7-
FLAG-SOCS2 (49); pMG2-CISY253F and 
pCAGGS-E-mMyD88-DD (33); pMG2-
SOCS2ΔB/C, pMG2-SOCS6, pMG2-SOCS7, 
pMET7-E-SOCS1 and pMET7-FLAG-
SOCS2ΔB/C (31); pMET7-FLAG-SOCS3 (50). 
 
Cell culture, transfection procedures and reporter 
assay- HEK293-T cells were cultured in 8% CO2 
humidified atmosphere at 37°C, and grown using 
Dulbecco’s modified Eagle’s medium (Invitrogen) 
with 10% fetal calf serum (Cambrex Corp.).  For 
transfection experiments, HEK293-T cells were 
freshly seeded in 6-wells plates and transfected 
overnight with approximately 2,5 µg plasmid DNA 
using a standard calcium phosphate precipitation 
procedure. The pMET7-SVT construct was used to 
normalize for the amount of transfected DNA and 
load of the transcriptional and translational 
machinery.  The next day, cells were washed with 
phosphate-buffered saline (PBS), transferred to a 
96-well plate and left untreated or stimulated with 
ligand for at least 24 h. Recombinant mouse leptin 
and human erythropoietin (Epo) were purchased 
from R&D Systems.  Luciferase activity from 
triplicate samples was measured by 
chemiluminescence in a TopCount luminometer 
(Canberra Packard) and expressed as fold induction 
(stimulated/non-stimulated).  Ba/F3 cells were 
grown in RPMI medium (Invitrogen) supplemented 
with 10% fetal calf serum (Cambrex Corp.) and 
1 ng/ml mIL-3 (Biogen). Transfection of the cell 
line was done by electroporation (300 V, 1500 μF). 
48 h after transfection cells were simultaneously 
starved (removal of serum and mIL-3) for 24 h and 
stimulated with 1 ng/ml mIL-3 overnight.  
Activation of the pGL2-SPI2.1-luciferase reporter 
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was measured with the Topcount luminometer 
(Canberra Packard). 
 
Western blot analysis and co-immunoprecipitation-
Transfected HEK293-T cells were lysed in 
modified RIPA buffer (200 mM NaCl, 50 mM Tris-
HCl pH 8.0, 0.05% SDS, 2mM EDTA, 1% Nonidet 
P-40, 0.5% deoxycholic acid, 1mM Na3VO4, 1mM 
NaF, 20 mM β-glycerophosphate and CompleteTM 
protease inhibitor cocktail (Roche Applied 
Science)). Lysates were cleared by centrifugation at 
14,000 rpm for 10 minutes at 4°C. 5x loading 
buffer (156 mM Tris-HCl pH 6.8, 2% SDS, 25% 
glycerol, 0.01% bromophenol blue, 5% β-
mercaptoethanol) was added to the cell lysates, 
which were then resolved by SDS-PAGE and 
transferred to nitrocellulose membranes 
(Amersham Biosciences). Blotting efficiency was 
checked by Ponceau S staining (Sigma).  FLAG-
tagged (corresponding to the peptide tag 
DYKDDDDK)   and E-tagged (corresponding to 
the peptide tag GAPVPYPDPLEPR) proteins were 
revealed using respectively monoclonal anti-FLAG 
antibody M2 (Sigma) and monoclonal anti-E-tag 
antibody (GE Healthcare).  Polyclonal rabbit anti-
CIS, goat anti-Elongin C and rabbit anti-JAK2 were 
supplied by Santa Cruz Biotechnology.  Western 
blot analysis was performed using the Odyssey 
Infrared Imaging System (Li-Cor) following the 
manufacturer’s guidelines. In brief, blots were 
blocked in Odyssey blocking buffer (Li-Cor), then 
probed overnight with the appropriated antibodies 
diluted in Odyssey blocking buffer with 0.1% 
Tween 20 and finally incubated with an IRDye 700 
donkey anti-goat, IRDye 800 goat anti-mouse or 
IRDye 800 goat anti-rabbit secondary antibody (Li-
Cor).  For the co-immunoprecipitation experiments 
approximately 6 x 106 HEK293-T cells were 
transfected with FLAG-tagged or E-tagged 
expression vectors using the calcium phosphate 
transfection procedure and lysed after 48 h in 1ml 
lysis buffer (50mM NaCl, 20mM Tris-HCl pH6.6, 
1% Nonidet P-40, 2,5% glycerol, 1mM EDTA, 
1mM Na3VO4, 1mM NaF, 20 mM β-
glycerophosphate and CompleteTM protease 
inhibitor cocktail (Roche Applied Science)). 
Lysates were cleared by centrifugation at 14,000 
rpm for 10 minutes at 4°C and incubated with 4,0 
µg/ml anti-FLAG mouse monoclonal antibody 
(Sigma) or anti E-tag mouse monoclonal antibody 
(GE Healthcare) and protein G-sepharose 
(Amersham Biosciences). After 
immunoprecipitation and SDS-PAGE, interactions 
were detected by immunobloting using the 
appropriate antibody. 
(Phospho)peptide affinity chromatography-
Approximately 2×107 HEK293-T cells transiently 
transfected as indicated were lysed in 5 ml lysis 
buffer (150 mM NaCl, 20 mM HEPES pH 7.8, 
0,5% Nonidet P-40, 20% glycerol, 1 mM MgCl2, 
10 mM KCl, 0.5 mM DTT, 1 mM NaVO4, 1 mM 
NaF, Complete™ Protease Inhibitor Cocktail 
(Roche Applied Science)). Lysates were cleared by 
centrifugation at 14,000 rpm for 10 minutes at 4°C 
and loaded on a pre-column with Sepharose 4B 
beads and streptavidin-agarose to prevent 
nonspecific interactions. Pre-cleared lysates were 
then incubated for 2 h at 4°C with the 
(phospho)tyrosine peptides as indicated coupled to 
streptavidin-agarose beads through their biotin 
group. The beads were then washed twice with lysis 
buffer and resuspended in 2x loading buffer (62.5 
mM Tris-HCl pH 6.8, 3% SDS, 10% glycerol, 
0.01% bromophenol blue, 5% ß-mercaptoethanol). 
Specific protein binding was revealed by SDS-
PAGE and immunoblotting using the anti-FLAG 
antibody. The sequences of the used peptides were 
biotin-EGASAASFEY(P)TILDPSSQL for Y402 of 
the EpoR and biotin-QRQPSVKY(P)ATLVSNDK 
for Y985 of the LR. Synthesis and purification of the 
biotinylated (phospho)tyrosine peptides and 
coupling to streptavidin-agarose beads was 
described before (50). 
 
Gel filtration chromatography- Approximately 108 
Ba/F3 cells were stimulated with 10 ng/ml IL-3 for 
1h at 37 °C and lysed in 3 ml lysis buffer 
containing 150 mM NaCl, 50 mM Tris-HCl pH 8, 2 
mM EDTA, 0.875% Brij 97 (Sigma-Aldrich), 
0.125% Nonidet P-40, 1mM Pefabloc and Protease 
Inhibitor Cocktail Set III (Calbiochem). Lysates 
were cleared by centrifugation at 14,000 rpm for 10 
minutes at 4°C, quantified with the Bradford 
method and applied to a calibrated Superdex 75 
PG16/60 gel filtration column (Amersham) run by 
an Advanced Protein Purification System (APPS) 
apparatus (Waters). The running buffer consisted of 
50 mM Tris-HCl pH 7.4 and 150 mM NaCl. After 
trichloroaceticacid (TCA) precipitation of equal 
volumes of collected fractions, the samples were 
subjected to SDS−PAGE and immunoblotting 
using the indicated antibodies. 
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Modelling method- Homology models for CIS, 
based on the crystal structures of SOCS2 (51) or 
SOCS4 (52) were created as described before (41). 
 
RESULTS 
 
CIS activity depends on Elongin B/C 
binding.  To investigate the role of Elongin B/C and 
Cullin5 binding on CIS function, we generated CIS 
variants lacking their respective recruitment sites:  
CISΔB/C (L222Q,C226Q) (22)  and  CISΔCul 
(L240PLP244-AAAA) (53) (Fig. 1A).  CIS activity 
was evaluated by a STAT5-dependent reporter 
assay in HEK293-T cells that were transiently 
transfected with the human EpoR expression vector 
and CIS, SOCS2 or mutant constructs.  While wild 
type CIS clearly suppressed reporter activity as 
expected, the CISΔB/C derivative was almost 
completely unable to impair reporter induction (Fig. 
1B). In contrast, the CISΔCul variant was still fully 
functional, indicating that the effect of the 
CISΔB/C mutation was specifically due to 
abrogated Elongin B/C recruitment and not to a 
lack of formation of a larger E3 complex.  As a 
control, we also included the Y253F loss-of-
function CIS mutant (33).  Much in contrast, a 
similar B/C box mutation in the highly related 
SOCS2 protein (SOCS2ΔB/C, L163Q,C167Q) 
showed no effect on STAT5 signalling. To examine 
the function of the CIS mutants in a more 
physiological set-up, STAT5-dependent reporter 
assays measuring interleukin-3 (IL-3) signalling 
were performed in the murine Ba/F3 pro-B cell 
line.  Again, we observed that the inhibitory effect 
of CIS was completely dependent on an intact B/C 
box (Fig. 1C).   
 
Elongin B/C recruitment to CIS is required 
for receptor substrate binding. It is well established 
that the interaction of SOCS proteins with their 
receptor targets depends on their SH2 domains 
(18,20).  In case of CIS, we recently demonstrated 
that the carboxy-terminal Y253 residue is also 
required for interaction with phosphotyrosine 
motifs in cytokine receptors (33).  Since disruption 
of Elongin B/C binding abrogated CIS function, we 
next investigated the involvement of Elongin B/C 
recruitment in substrate binding.  To address this 
question we used the mammalian protein-protein 
interaction trap (MAPPIT) method, a strategy 
designed to analyse protein-protein interactions in 
mammalian cells.  In MAPPIT, a bait protein is 
carboxy-terminally linked to a chimaeric receptor 
that is deficient in STAT3 recruitment, while a prey 
protein is fused to a part of the glycoprotein 130 
(gp130) chain containing four functional STAT3 
recruitment sites. Co-expression of an interacting 
bait/prey pair leads to functional complementation 
of STAT3 activity and induction of a STAT3-
responsive luciferase reporter.  MAPPIT permits 
the detection of both modification-independent and 
phosphorylation-dependent interactions. The 
MAPPIT configurations used in this manuscript are 
described in Figure 2A.  Functional expression of 
the different bait constructs was assessed by 
measuring interaction with the JAK2-binding Ring 
Finger Protein 41 (RNF41) prey (De Ceuninck et 
al., unpublished results). The CIS Y253F prey was 
again used as a loss-of-function control.   
As examples of known interaction partners 
of CIS and SOCS2, we used the intracellular 
receptor tyrosine motifs Y402 of the EpoR (44) and 
Y595 of the GHR (41) as baits.   We also analysed 
interactions with the leptin receptor (LR) by 
mutating the STAT3-recruiting Y1138 to F (LR 
(YYF)). This way, MAPPIT analysis of interactions 
at positions Y985 and Y1077, that are known to recruit 
SOCS proteins (49,50,54) is possible using the full 
length LR.  HEK293-T cells were cotransfected 
with the aforementioned baits and prey constructs 
encoding the different CIS and SOCS2 variants, 
combined with the STAT3-responsive rPAP1 
luciferase reporter.  Figure 2B shows that 
elimination of the Elongin B/C binding site in the 
CIS prey caused complete loss of binding to all 
studied receptor motifs. In contrast, deletion of the 
conserved B/C box in the SOCS2 prey did not 
significantly affect interaction with the baits.  The 
observed interaction patterns with the EpoR Y402 
bait were confirmed by phosphopeptide affinity 
chromatography. Complete loss of binding to the 
phosphorylated Y402 of the EpoR was observed for 
the CISΔB/C or Y253F mutants, while no effect was 
seen for a similar SOCS2ΔB/C mutant (Fig. 2C).  
In analogy with the observed interaction pattern of 
the CIS Y253F mutant (33), deletion of the B/C box 
did not affect interaction with the TLR adaptor 
MyD88 (Fig. 2D). This implies that the structural 
integrity of the CIS prey is maintained upon 
deletion of the Elongin B/C recruitment site.  In 
Figure 2E we integrated binding controls for the 
CIS mutants. The top panel shows a MAPPIT 
experiment demonstrating that the CISΔB/C, but 
not the CISΔCul prey is incapable to interact with 
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an Elongin C bait.  Similar data were obtained in a 
reciprocal setting: a complete loss of binding with 
the Elongin B and C (B/C) preys and Cullin5 prey 
is seen for the CISΔB/C bait, whilst interaction of 
only the Cullin5 prey is lost for the CISΔCul 
mutation.  Finally, the bottom panels show co-
immunoprecipitation experiments demonstrating 
loss of interaction with the endogenous Elongin C 
and FLAG-tagged Cullin5 upon deletion of the B/C 
motif or the Cullin box in CIS.  
 
Loss of substrate binding by CISΔB/C is 
not due to an effect on CIS stability. Although we 
did not observe a significant effect of the CISΔB/C 
mutation on protein expression, we wanted to 
verify whether an altered protein half-life time 
could account for the loss of substrate binding. To 
this end, protein expression levels of CIS (with or 
without co-expressed Elongin B/C) and of the 
CISΔB/C mutant were monitored in the presence of 
the translation inhibitor cycloheximide and half-
lives were determined by quantification of the 
observed band intensities.   As shown in Figure 3, 
the decline of the mutant was less pronounced than 
that of wild type CIS. The estimated half-life was 
40’ for CIS and 1 h 30’ for CISΔB/C respectively, 
ruling out an effect of protein stability on the 
interaction assays.  Of note, Elongin B/C co-
expression also significantly extended CIS half-life 
time, indicating a stabilizing effect of Elongin B/C. 
 
The CIS Elongin B/C-dependency for 
substrate interaction is unique among SOCS 
proteins. We next questioned whether other SOCS 
family members also display a similar dependency 
on Elongin B/C binding for substrate recognition.  
We used MAPPIT to examine the binding of 
SOCS6 and SOCS7 or of their respective Elongin 
B/C deletion mutants on the LR (YYF) bait.  
Similar to SOCS2, the ΔB/C mutation in SOCS6 or 
SOCS7 did not alter the interaction pattern (Fig. 
4A).  Other read-outs were used for SOCS1 and 
SOCS3 since these inhibit the MAPPIT assay due 
to their JAK suppressive activity. The interaction of 
SOCS1 with JAK2 was analysed by co-
immunoprecipitation. As shown in Figure 4B, 
SOCS1 and its ΔB/C mutant bind equally well to 
JAK2.  For SOCS3, no effect was seen for the 
SOCS3ΔB/C mutant in a STAT5-dependent 
reporter assay implying normal interaction with the 
EpoR (Fig. 4C). Similarly, normal binding was 
seen for the SOCS3ΔB/C mutant in a 
phosphopeptide affinity chromatography 
experiment using the phosphorylated Y985 motif of 
the LR (Fig. 4D).   
 
CIS and SOCS2 display different binding 
properties for the Elongin B/C complex. Co-
immunoprecipitation experiments demonstrated 
that CIS coprecipitates less endogenous Elongin C 
than SOCS2 (Fig. 5A). We next compared the 
relative binding properties of CIS and SOCS2 for 
Elongin C in a MAPPIT set-up. To this end, the 
interaction of a SOCS2 or CIS prey with the 
Elongin C bait was assessed by cotransfection of 
increasing amounts of wild type CIS or SOCS2, 
respectively (Fig. 5B).  In contrast to SOCS2 that 
strongly competed with the CIS prey for binding to 
Elongin C, CIS could not interfere with the 
interaction between the SOCS2 prey and the 
Elongin C bait, suggesting a lower binding affinity 
of CIS for Elongin C, in comparison with SOCS2.  
Thus, the CIS interaction with the Elongin B/C 
complex is easily disrupted and accordingly CIS 
function may depend on the availability of a free 
Elongin B/C pool within the cell.  
 
 
Elongin B/C levels can determine CIS 
activity. To verify the concept that CIS 
functionality is regulated by the intracellular level 
of free Elongin B/C complex, we performed two 
distinct experiments.  First, we examined using 
MAPPIT whether co-expression of Elongin B/C in 
HEK293-T cells could enhance CIS substrate 
binding. As shown in Figure 6A, this is clearly the 
case using the GHR Y595 motif as bait, while 
Elongin B/C co-expression was not inducing a 
stronger binding of the SOCS2 prey to the GHR 
receptor motive. This implicates the existence of a 
pool of free CIS prey that becomes activated upon 
Elongin B/C recruitment. We therefore examined in 
a second experiment whether an unbound 
endogenous CIS fraction exists. This was evaluated 
in the physiological background of BaF/3 cells.  
Lysates of IL-3-stimulated Ba/F3 cells were 
separated by gel filtration chromatography over a 
Superdex 75 PG16/60 column and the fractions 
containing CIS and Elongin C were identified by 
immunoblotting.  As shown in Figure 6B the 
majority of CIS eluted in fractions corresponding to 
complexes of smaller molecular weight or 
monomeric CIS (< 37 kDa in mass) and only a 
subset of the total CIS pool co-eluted with Elongin 
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C (complex of > 44,6 kDa).  This provides 
evidence for the occurrence of a cellular population 
of free CIS which can thus be bound and regulated 
by Elongin B/C. 
 
DISCUSSION 
 
SOCS proteins are known to act as the 
substrate recognition part of a RING-type E3 
ubiquitin ligase complex.  Association of the 
SOCS box with the adaptor proteins Elongin B 
and C mediates further assembly with Cullin and 
Rbx proteins, resulting in the formation of a 
multiprotein E3 ligase.  This complex will 
function as a scaffold that presents bound 
substrate to an E2 ubiquitin conjugating enzyme, 
ultimately leading to ubiquitination and 
degradation of the target molecule.  Within the 
SOCS box, conserved B/C and Cullin boxes 
respectively mediate Elongin C (22,55-58) and 
Cullin2 or 5 recruitment depending on the SOCS 
family member (53).  We here report that 
deletion of the B/C box completely abrogated 
CIS function through loss of substrate binding.  
Deletion of the Cullin5 box had no impact on the 
inhibitory effects of CIS, indicating that solely 
binding of Elongin B/C, and not the association 
of a larger E3 complex, is essential for 
interaction of CIS with its cognate cytokine 
receptor motifs. 
Two mechanisms for CIS inhibition have 
been proposed: partial inhibition by direct 
competition with STAT5 for common 
phosphotyrosine binding sites on the receptor 
and proteasome-mediated degradation of the 
receptor-JAK2 signalling complex. In case of the 
GHR, this latter mechanism may be coupled to 
internalization of the activated receptor complex, 
a critical step preceding termination of receptor 
signalling (43).  SOCS-mediated inhibition of the 
GHR by competition for shared binding sites 
with STAT5 was recently ruled out based on the 
non-overlapping bindings pattern of CIS and 
SOCS2 with STAT5 (41).  Furthermore, the 
SOCS box of CIS was found to be essential for 
the apoptotic effect of CIS on erythroid 
progenitor cells (35).  Our observation that 
Elongin B/C recruitment cannot be uncoupled 
from CIS function lends further support for a 
primary role for the formation of an E3 ligase 
complex in CIS-mediated signal suppression. 
Nevertheless, we found that deletion of the 
Cullin box did not abolish completely the 
inhibitory functions of CIS in EpoR (and IL-3R, 
data not shown) signalling and this is currently 
being investigated in greater detail. 
Much in contrast, no evidence was 
obtained for a role in substrate binding by the 
Elongin B/C box of SOCS1, -2, -3, -6 and -7.  
Since none of the other examined SOCS 
members was found to depend on Elongin 
recruitment for interaction with target motifs, 
this may be a unique feature of CIS. This 
specific effect seems to parallel the effects 
observed for the Y253F mutation in the carboxy-
terminal portion of the CIS SOCS box.  We 
previously demonstrated that this mutation also 
completely abrogated functional interaction with 
most cytokine receptor-based interaction motifs 
(33,41). Again, no such role for conserved 
tyrosines in the SOCS box was observed for the 
highly related SOCS2 proteins, or for SOCS1 
and -3.  Mutation of the Elongin B/C motif or 
Y253 in CIS both lead to loss of binding to all 
substrates that were tested, except MyD88. 
Together, these data suggest that the Elongin 
B/C mutation and Y253 mutation affect receptor 
binding through a common mechanism.  
Two different homology models were 
built for CIS, with a SOCS box orientation as in 
SOCS2 (homology model 1, Fig. 7A) or SOCS4 
(homology model 2, Fig. 7B). Both models 
exclude a direct interaction of the SOCS box or 
Y253 with the phosphopeptide substrate. In the 
model, Y253 shows no direct interaction with the 
Elongins and mutation of Y253 does not impair 
Elongin B/C binding (33). In both models, Y253 
is found in the interface between the SOCS box 
and the SH2 domain, suggesting that it might 
mediate an allosteric regulation of substrate 
binding by the SOCS box domain.  We propose 
that the correct position of Y253 is critical for 
substrate binding and that this correct position is 
induced by structural changes in the SOCS box 
upon binding of Elongins.  Similar structural 
rearrangements take place in yeast Elongin C 
upon binding of a SOCS box peptide from the 
von Hippel-Lindau (VHL) protein (59).  VHL 
requires Elongin B/C binding to adopt a stable 
structure (60,61) and stable expression.  The 
deletion of the Elongin binding site in CIS 
appeared to have no drastic effects on the 
structural integrity of the SH2 domain protein, 
since B/C box independent interactions of CIS 
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were still observed with MyD88.  We verified 
whether the loss-of-function of the CISΔB/C 
mutant was not due to an altered half-life time. 
The particular CIS mutant appeared to be even 
more stable that the wild type protein.  However, 
Elongin B/C co-expression significantly 
extended the half-life time of wild type CIS, 
indicating that a stabilizing effect of Elongin B/C 
on CIS does exist.  
In co-immunoprecipitation experiments 
CIS appeared to display a lower affinity for 
Elongin C than SOCS2.  Furthermore, MAPPIT 
competition experiments showed that SOCS2 
over-expression easily interfered with the 
interaction between CIS and Elongin C, a 
phenomenon that appeared to be unidirectional.  
This sensitivity of CIS for Elongin recruitment 
suggests an underlying regulatory mechanism. 
Conceivably, CIS activity may be down-
modulated by SOCS2 in a dual way. First, 
SOCS2 is induced at later stage post receptor 
activation and may scavenge Elongin B/C from 
CIS leading to loss of substrate binding. Second, 
SOCS2 can interact with unbound CIS leading to 
degradation of the free CIS pool. We previously 
reported that this involves the SOCS box of CIS 
as interaction domain for SOCS2 and also the 
SOCS box of SOCS2 as template for building 
the E3 ligase complex (31). 
Lending further support for regulation at 
this level is our observation that CIS activity 
depends on the levels of Elongin B/C within the 
cell. Using MAPPIT we demonstrated that co-
expression of Elongin B/C increased CIS prey 
interaction with a receptor motif, while no such 
effect was seen for SOCS2 prey binding.  We 
also provided evidence for the existence of 
monomeric CIS protein in BaF/3 cells by gel 
filtration analysis.  These findings suggest that 
the activity of free CIS protein can be 
functionally modulated by Elongin B/C and that 
the availability of unbound Elongin B/C complex 
will determine CIS activity.  So far, little is 
known on the mechanisms that determine free 
Elongin B/C levels in the cell and more detailed 
studies are clearly required. Elongin B/C can be 
part of different multiprotein complexes 
including the RNA polymerase II (Pol II) (62,63) 
machinery and a large subfamily of E3 ubiquitin 
ligases. This encompasses the VHL tumor 
suppressor complex (64) and over 70 proteins 
harboring a SOCS box in the human genome 
(according to Pfam database).  As each of these 
could possibly sequester the Elongin B/C 
complex, it is clear that depending on induction 
pattern, subcellular localization and relative 
binding affinities of all these SOCS box 
containing proteins, a competition for Elongin 
B/C will occur. Of note, also viral genomes can 
encode proteins that recruit Elongin B/C, e.g. 
HIV-1 Viral infectivity factor (Vif) that 
suppresses the antiviral activity of APOBEC3G 
(65). We here also mention that inappropriately 
elevated SOCS (66-71) or Elongin C (72) levels 
can be found in several oncologic disorders.  
We can only speculate on the 
physiological reason behind this built-in 
molecular on/off switch in CIS. It is intriguing 
that different effects are observed for different 
substrates: CIS binding of several cytokine 
receptors is under tight control, whilst no effect 
is seen for the interaction with MyD88. Perhaps, 
this observed Elongin B/C dependency may 
function as a ‘safety lock’ for ensuring complete 
suppression of signalling as only the CIS 
molecules that recruit an E3 ligase complex will 
be able to participate in the inhibition. 
Conceivably, such tight control may be required 
for the vital processes that are modulated by CIS 
like the GHR mediated somatic growth and 
cellular metabolism.    The remarkable 
discrepancy observed between the lack of 
phenotype of CIS knock-out mice and the 
defective phenotype in growth, mammary gland 
development and immune effects of CIS 
transgenic mice (36,73) may also suggest the 
high risk of unrestrained CIS activity.   
In conclusion, our findings further 
underscore the functional complexity of the SOCS 
box domain. Next to its role in protein turnover, the 
SOCS box domain appears also to be involved in 
regulation of substrate binding. 
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FIGURE LEGENDS 
 
Table 1. Overview of the constructs used in the present study  
 
Fig. 1. CIS inhibition of Epo and IL-3 signalling depends on Elongin B/C recruitment. A. Domain structure 
of CIS and amino-acid sequence alignment of the SOCS boxes of mouse SOCS1, SOCS2, SOCS3 and CIS.  
Conserved residues are highlighted by different colors in the sequence alignment. The B/C box and 
IPLN/LPXP motif, which respectively confer Elongin B/C and Cullin binding, are indicated. B. HEK293-T 
cells were transfected with expression vectors for CIS, SOCS2 or their ΔB/C or ΔCul box deletion mutants, 
combined with the human EpoR and the STAT5-responsive β-casein-luciferase reporter.  24 h after 
transfection, cells were left untreated or were stimulated overnight with Epo (5 ng/ml) and luciferase 
measurements were performed in triplicate. Data are expressed as fold induction (stimulated/non stimulated 
ratio).  Expression of the FLAG-tagged CIS and SOCS2 proteins was verified on lysates using anti-FLAG 
antibody. C. Ba/F3 cells were transiently electroporated with plasmids encoding CIS or CISΔB/C, 
combined with the STAT5-responsive pGL2-SPI2.1-luciferase reporter. 48 h after electroporation, the cells 
were starved and were left untreated or were stimulated overnight with mIL-3 (1ng/ml).  Luciferase 
activities are represented as fold induction (stimulated/non stimulated ratio). 
 
Fig. 2.  Elongin B/C binding is critical for interaction of CIS with receptor motifs. A. Diagrammatic 
presentation of the MAPPIT configurations used in this study. The left panel shows the bait and prey 
chimeras. The right panel shows a variant of the MAPPIT technique wherein the LR itself functions as bait 
protein. See main text for explanation of the MAPPIT technique. B. HEK-293T cells were transiently 
cotransfected with bait plasmids encoding the LR (YYF), the EpoR Y402 or the GHR Y595 motif and prey 
plasmids encoding RNF41 as positive control, CIS, SOCS or derived mutant constructs, combined with the 
STAT3 responsive pXP2d2-rPAPI-luciferase reporter.  24 h after transfection, cells were left untreated or 
were stimulated with leptin (100 ng/ml) or Epo (5ng/ml) overnight. Luciferase data of triplicate 
measurements are expressed as fold induction (stimulated/non stimulated ratio). The expression of the 
FLAG-tagged prey proteins were evaluated by immunoblotting using anti-FLAG antibody. C. 
(Phospho)peptide affinity chromatography. HEK-293T cells were transfected with FLAG-tagged CIS, 
SOCS2 or mutant derivatives. The lysates were incubated with phosphorylated or non-phosphorylated 
peptides corresponding to the Y402 motif of the EpoR. Specific protein binding was revealed by SDS-
polyacrylamide gel electrophoresis (PAGE) and immunoblotting using the anti-FLAG antibody. D. HEK-
293T cells were transiently cotransfected with bait plasmids encoding the GHR Y595 motif or MyD88 and 
prey plasmids encoding CIS or mutants, combined with the STAT3 responsive pXP2d2-rPAPI-luciferase 
reporter.  MAPPIT signalling was assayed as described in Figure 2B. E. Verification of the interaction 
pattern of the CIS mutants. In the upper panel HEK293-T cells were transiently cotransfected with plasmids 
encoding the Simian Virus 40 large T-antigen (SVT) as a negative control, Elongin B, CIS or derived 
mutant prey constructs, combined with the indicated bait constructs and the pXP2d2-rPAP1-luciferase 
reporter. MAPPIT signalling was assayed as described in Figure 2B.  In the bottom panels the bindings 
mode of the CIS mutants are demonstrated by co-immunoprecipiation experiments. Lysates of HEK-293T 
cells transfected with FLAG-tagged CIS or CISΔB/C were immunoprecipitated (IP) with anti-FLAG and 
subsequently immunoblotted (IB) with anti-Elongin C (left panel).  HEK293-T cells were cotransfected 
with combinations of FLAG-tagged Cullin5 and E-tagged CIS, CISΔB/C or CISΔCul and the lysates were 
immunoprecipitated with anti-E and then immunoblotted with anti-FLAG (right panel). 
 
Fig. 3.  Effect of Elongin B/C on CIS half-life. HEK293-T cells were transiently transfected with 
combinations of FLAG-tagged CIS, CISΔB/C or Elongin B/C. 24 h after transfection, cells were treated 
with cycloheximide (CHX) (20µg/ml) for different time points. The lysates were revealed by SDS-PAGE 
and immunoblotting using the anti-FLAG antibody. CIS expression levels were detected and quantified 
using the Odyssey Infrared Imaging System (Li-Cor) and normalized for β-actin expression levels. The 
graph shows processed data of the degradation assay above in which the initial maximal expression was 
defined as 100%.  
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Fig. 4.  Substrate interaction of other SOCS proteins is not Elongin B/C dependent. A. MAPPIT analysis of 
the binding modus of SOCS6 and SOCS7 (ΔB/C) preys with the leptin receptor.  HEK293-T cells were 
transiently cotransfected with plasmids encoding the indicated prey constructs, combined with the 
LR(YYF) bait and the pXP2d2-rPAP1-luciferase reporter.  MAPPIT signalling was assayed as described in 
Figure 2B.  B. Co-immunoprecipitation analysis of the interaction between JAK2 and SOCS1(ΔB/C).  
HEK-293T cells were transiently transfected with combinations of JAK2 and E-tagged SOCS1, 
SOCS1ΔB/C or MyD88 as negative control. Cell lysates were immunoprecipitated with anti-E-tag and 
subsequently immunoblotted with anti-JAK2.  C. Effect of the deletion of the B/C box on SOCS3 inhibition 
of EpoR signalling. HEK293-T cells were transfected with expression vectors for SOCS3, CIS or their 
ΔB/C deletion mutants, combined with the human EpoR and the β-casein-derived luciferase reporter gene.  
EpoR signalling was assayed as described in the legend of Figure 1B. D. (Phospho)peptide affinity 
chromatography to analyse the interaction between SOCS3 or its ΔB/C mutant and the Y985 motif of the LR.  
HEK-293T cells were transfected with FLAG-tagged SOCS3 or SOCS3ΔB/C and lysates were incubated 
with phosphorylated or non-phosphorylated peptides corresponding to the Y985 motif of the LR. Specific 
protein binding was revealed by SDS-PAGE and immunoblotting using the anti-FLAG antibody.    
 
Fig. 5.  CIS displays a lower affinity for Elongin C in comparison to SOCS2. A. Co-immunoprecipitation 
analysis of the interaction between CIS or SOCS2 and endogenous Elongin C.  HEK-293T cells were 
transiently transfected with E-tagged CIS, SOCS2 or APOBEC3G as a negative control. Cell lysates were 
immunoprecipitated with anti-E-tag and subsequently immunoblotted with anti-Elongin C. B. MAPPIT 
competition assay in HEK293-T cells transiently expressing the pXP2d2-rPAP1-luciferase reporter and the 
Elongin C bait combined with the SOCS2 or CIS preys and increasing amounts of a competitor (CIS for the 
SOCS2 prey and SOCS2 for the CIS prey).  MAPPIT signalling was assayed as described in Figure 2B.  
 
Fig. 6.  Elongin B/C levels can determine CIS activity.  A. The bindings potency of the CIS prey depends 
on Elongin B/C levels in MAPPIT.  HEK-293T cells were transiently cotransfected with expression vectors 
encoding the pXP2d2-rPAP1-luci reporter, the GHR Y595 bait and CIS or SOCS2 (ΔB/C) preys, with or 
without Elongin B/C co-expression.  MAPPIT signalling was assayed as described in Figure 2B. B. 
Occurrence of uncomplexed CIS in Ba/F3 cells. Lysates of IL-3 activated Ba/F3 cells (108 cells) harboring 
endogenous CIS were size fractionated by gel filtration on a Superdex 75 PG16/60 column.  The individual 
fractions were subjected to SDS−PAGE and immunoblotting using anti-CIS and anti-Elongin C antibody.  
As a standard, a mix of proteins of defined molecular weights was also fractionated on the same column, 
allowing an estimation of the molecular weight of the different fractions.  
 
Fig. 7. Homology models for CIS. Two different homology models were built for CIS, with a SOCS box 
orientation as in SOCS2 (homology model 1, panel A) or SOCS4 (homology model 2, panel B). In 
homology model 1 for CIS, Y253 forms a hydrogen bond with the buried C-terminal carboxyl group (panel 
C).  The C-terminal residue L257 in CIS interacts with residues in the βG strand (P212) and the αB helix 
(V160, V164) of the CIS SH2 domain. In this model, mutating Y253 might lead to structure changes in the 
adjacent EF and BG loops. As these loops interact with the phosphopeptide substrate in the CIS homology 
model, this can affect substrate binding. In a model for CIS based on the SOCS4 structure (homology 
model 2), Y253 forms a hydrogen bond with D108 (panel D). R107 in CIS is the βB5 arginine, a residue that 
is critical in SH2 domain phosphopeptide binding (74). A CIS R107K mutant is dominant-negative for CIS, 
but  still associates with IL-2R  (75), reminiscent of the binding of our CIS mutants to MyD88. If the 
second model is correct, disruption of the hydrogen bond to D108 might affect the position of R107 and 
thus the affinity for phosphopeptide substrates.  
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 Table 1.  
 
Name of the construct Template Cloning 
vector 
Cloning 
sites 
Primers  
MAPPIT bait constructs     
pCEL-Elongin C pMG2-mElongin C    pCEL BamHI-NotI 5’CGCGGATCCGATGGAGAGGAGAAGACC 
5’CGCTGCGGCCGCTTAACAATCTAGGAAG 
pCEL-CIS pMG2-mCIS pCEL SacI-NotI 5’GCGCGAGCTCAATGGTCCTCTGCGTACAGGG 
5’GCTCGCGGCCGCTCAGAGTTGGAAGGGGTACTGTCGG 
pCEL-CISΔB/C pCEL-mCIS  mutagenesis 5’GAGCAGTGCCCGCAGCCAACAACATCTGCAACGACTAGTCATCAACCGTC 
5’GACGGTTGATGACTAGTCGTTGCAGATGTTGTTGGCTGCGGGCACTGCTC 
pCEL-CISΔCul pCEL-mCIS  mutagenesis 5’CGACGTGGACTGC GCCGCGGCAGCA CGGCGTATGGCCG 
5’CGGCCATACGCCGTGCTGCCGCGGCGCAGTCCACGTCG 
MAPPIT prey constructs     
pMG-RNF41 CDNA of HEK293-T (human) pMG2 EcoRI-SalI 5’GGCATGGAGGCTGCGACTG 
5’GTTACTTAAGCTAGCTTGC 
pMG2-CISΔB/C pMG2-mCIS  mutagenesis 5’GAGCAGTGCCCGCAGCCAACAACATCTGCAACGACTAGTCATCAACCGTC 
5’GACGGTTGATGACTAGTCGTTGCAGATGTTGTTGGCTGCGGGCACTGCTC 
pMG2-CISΔCul pMET7-FLAG-mCISΔCul pMG2 PvuII-SacI  
pMG2-Elongin B cDNA of N38 (mouse) pMG2 EcoRI-NotI 5’GCGAGAATTCGACGTGTTTCTCATGATCC 
5’CGCTGCGGCCGCTCACTGCACAGCTTGTTC 
pMG2-Elongin C cDNA of N38 (mouse) pMG2 EcoRI-NotI 5’GCGAGAATTCGATGGAGAGGAGAAG 
5’CGCTGCGGCCGCTTAACAATCTAGGAAG 
pMG2-Cullin5 pMET7-FLAG-mCullin5 pMG2 EcoRI-KpnI  
pMG2-SOCS6ΔB/C pMG2-mSOCS6  mutagenesis 5’TGCAGGTGCGCTCGCAACAGTACCTGCAACGCTTTGTTATCCGT 
5’ACGGATAACAAAGCGTTGCAGGTACTGTTGCGAGCGCACCTGCA 
pMG2-SOCS7ΔB/C pMG2-mSOCS7  mutagenesis 5’CAGCAATGTCAAGTCCCAACAGCATCTTCAACGTTTCCGGATCCGGCAG 
5’CTGCCGGATCCGGAAACGTTGAAGATGCTGTTGGGACTTGACATTGCTG 
Non-MAPPIT constructs     
pMET7-FLAG-CISΔB/C pMG2-mCISΔB/C pMET7-
FLAG 
EcoRI-XbaI  
pMET7-FLAG-CISΔCul pMET7-FLAG-mCIS  mutagenesis 5’CGACGTGGACTGC GCCGCGGCAGCA CGGCGTATGGCCG 
5’CGGCCATACGCCGTGCTGCCGCGGCGCAGTCCACGTCG 
pMET7-E-SOCS1ΔB/C pMET7-E-mSOCS1ΔB/C  mutagenesis 5’GCCGCGTGCGGCCGCAGCAGGAGCTGCAACGCCAGCGCATCGTG 
5’CACGATGCGCTGGCGTTGCAGCTCCTGCTGCGGCCGCACGCGGC 
pMET7-FLAG-SOCS3ΔB/C pMET7-FLAG-ratSOCS3  mutagenesis 5’CAACGTGGCTACCCAGCAGCATCTTCAGCGGAAGACTGTCAACGGCCACCTGGACT
CC 
5’GGAGTCCAGGTGGCCGTTGACAGTCTTCCGCTGAAGATGCTGCTGGGTAGCCACGTT
G 
pMET7-FLAG-Cullin5 cDNA of 3T3-F442A (mouse) 
 
pMET7 EcoRI-XhoI 5’CCGGAATTCACCATGGATTACAAGGATGACGACGATAAGGCGACGTCTAATCTGTT
AAAG 
5’CCGCTCGAGCTAGGCCATGTAGATGAAGG 
pMET7-FLAG-Elongin B pMG2-mElongin B pMET7-
FLAG 
EcoRI-XbaI  
pMET7-FLAG-Elongin C pMG2-mElongin C pMET7-
FLAG 
SacI-EcoRI  
pMET7-E-APOBEC3G pMG2-APOBEC3G pMET7-E NotI-XbaI 5’CGTACGCGGCCGCGATGAAGCCTCACTTCAG 
5’GGTCATCTAGATCAGTTTTCCTGATTCTG 
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ABSTRACT 
 
The SOCS box is a structural domain found at the C-terminus of over 200 
human proteins. It is usually coupled to a protein interaction domain such as an SH2 
domain in case of the SOCS proteins. Most insights into the role of the SOCS box 
come from studies on these important regulators of cytokine signalling. A well 
established, general function of the SOCS box is the recruitment of Elongin B/C and 
Cullin proteins leading to the formation of an E3 ligase complex. SOCS proteins 
thus can negatively regulate signalling by marking tyrosine-phosphorylated cytokine 
receptors for proteasomal degradation. A similar mechanism was more recently 
uncovered for controlling SOCS activity itself, since SOCS2 was found to enhance 
the turnover of other SOCS proteins, thus restoring cytokine responses. The SOCS 
box can add unique features to individual SOCS proteins: it can function as an 
adaptor domain coupling activated receptors to downstream signalling pathways as 
was demonstrated for SOCS3, or as modulator of substrate binding by the SH2 
domain in case of CIS.  In this review we discuss these multiple roles of the SOCS 
box, which emerges as a versatile module controlling SOCS protein activity and 
cytokine signalling via multiple mechanisms. 
 
 
INTRODUCTION 
 
Cytokines are secreted proteins that regulate a broad range of biological 
processes as diverse as haematopoiesis, immune responses, cell development 
and growth.  Binding of cytokines to cell surface receptors on target cells leads to 
multiple signalling events, including activation of the Janus kinase (JAK)/signal 
transducer and activator of transcription (STAT) pathway (figure 1) (reviewed in 
(Ihle et al., 1994; Leonard and O'Shea, 1998; Rawlings et al., 2004b)).  Cytokine-
induced signal transduction must be tightly regulated to avoid the detrimental 
consequences of excessive stimulation.  Accordingly, several mechanisms exist 
to control the kinetics and magnitude of signalling at different levels.  Three major 
classes of negative regulators are the protein tyrosine phosphatases (PTPs), 
protein inhibitors of activated STATs (PIAS) and suppressors of cytokine 
signalling (SOCS) proteins (reviewed in (Greenhalgh and Hilton, 2001)). 
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Figure 1: JAK-STAT signal transduction and SOCS inhibition. 
Cytokine binding to its receptor complex induces reorganisation of the receptor chains, 
which leads to juxtaposition and activation of the JAKs by cross-phosphorylation. JAKs 
phosphorylate the cytoplasmatic domains of receptors, creating docking sites for 
cytoplasmatic proteins such as STATs. Following phosphorylation by the action of the JAKs, 
STATs form dimers and migrate to the nucleus to induce target genes, including those that 
express the SOCS.  Acting in a negative feedback loop, SOCS will then attenuate receptor 
signalling by different mechanisms (see text). 
Chapter 11: Versatility of the SOCS box domain 
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The SOCS family consists of eights proteins, SOCS1-7 and CIS, of which the 
expression is induced in response to a wide range of cytokines, growth factors and 
hormones (Adams et al., 1998; Dogusan et al., 2000; Krebs and Hilton, 2003; 
Yasukawa et al., 2000). They were identified as inhibitors of the JAK-STAT 
signalling pathway, operating as part of a classical negative feedback loop (Fujimoto 
and Naka, 2003; Greenhalgh and Hilton, 2001; Krebs and Hilton, 2001).  SOCS 
proteins display a similar domain architecture with an N-terminal region of variable 
length, a central Src homology 2 (SH2) domain which is involved in binding of 
phosphotyrosine motifs and a conserved C-terminal domain, known as the SOCS 
box (figure 2).   
 
 
       
 
 
Figure 2: Domain structure of the SOCS protein family 
The major structural characteristics of the SOCS family are the presence of two domains 
with relatively well conserved AA sequence: a SH2 domain in the middle portion and a 
SOCS box at the C-terminus. Only SOCS1 and -3 possess a KIR immediately upstream of 
the SH2 domain. Conserved tyrosines in the SOCS box are indicated by a black line 
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SOCS proteins modulate cytokine receptor responses by different 
mechanisms (figure 1).  First, they can suppress signalling by competing with other 
signal transductors for binding to phosphorylated motifs of the activated receptor via 
their SH2 domain (Ram and Waxman, 1999; Yoshimura et al., 1995). Second, a 
small kinase inhibitory region (KIR) found in the N-terminal domain of SOCS1 and 
SOCS3 inhibits the activity of JAKs by acting as a pseudo-substrate (Yasukawa et 
al., 1999). SOCS1 binds directly to the phosphorylated activation loop of JAK2, 
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whereas SOCS3 shows only weak affinity for JAK2 and is thought to bind to the 
receptor in close proximity of the kinase (Giordanetto and Kroemer, 2003; Nicholson 
et al., 2000; Sasaki et al., 2000). Third, SOCS proteins can regulate signal 
transduction by linking their substrates to ubiquitination and proteasomal 
degradation via the SOCS box. This latter domain was found to recruit Elongin B 
and C (B/C) proteins (Kamura et al., 1998; Zhang et al., 1999) which can associate 
to a Cullin-Rbx module reconstituting an E3 ubiquitin ligase complex (Kamura et al., 
2001). The involvement of the SOCS box in proteasomal degradation will be 
discussed in more detail in the next section. In addition to proteasomal turnover, 
SOCS proteins can also direct the internalisation and routing of cytokine receptors 
as was for example demonstrated for the growth hormone (GH) and granulocyte-
colony stimulating factor (G-CSF) receptors (Irandoust et al., 2007; Landsman and 
Waxman, 2005).  SOCS proteins not only control kinetics and magnitude of 
signalling but can also be involved in the shaping of cytokine responses.  For 
example, SOCS3 that is induced by different cytokine receptors regulates both the 
quantity and type of STAT signalling generated from the IL-6R.  In the absence of 
SOCS3, IL-6 induces a wider transcriptional response that is dominated by 
interferon (IFN)-like gene expression owing to an excess of STAT1 phosphorylation 
(Croker et al., 2003; Lang et al., 2003; Yasukawa et al., 2003).  SOCS proteins thus 
regulate cytokine receptor signalling at different levels and by multiple 
complementary mechanisms, the importance of which differs according to both the 
individual SOCS molecule and the triggered cytokine pathway.  
 
 
THE ROLE OF THE SOCS BOX IN TARGET PROTEIN DEGRADATION 
 
Protein degradation by the ubiquitin-proteasome pathway requires a cascade 
of enzymatic reactions involving an E1 ubiquitin-activating enzyme, an E2 ubiquitin-
conjugating enzyme, and finally an E3 ligating enzyme.  This latter enzyme defines 
substrate specificity and covalently associates ubiquitin to lysine side chains in the 
substrate.  The Elongin C-Cullin-SOCS box (ECS)-type E3 ubiquitin ligases include 
among others the Von Hippel-Lindau (VHL) tumor suppressor protein and the SOCS 
family members, that fulfill the role of substrate recognition unit of the complex (Ivan 
and Kaelin, 2001; Kibel et al., 1995; Kile et al., 2002). The SOCS box domain of 
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these proteins mediates the interaction with Elongin C by the B/C box, a 
xxLxxxCxxx (A/I/L/V) conserved sequence (Aso et al., 1996; Duan et al., 1995; 
Kamura et al., 1998; Kibel et al., 1995).  Elongin B binds Elongin C and this dimer 
acts as a linker that bridges the substrate recognized by the SOCS box protein to a 
Cullin scaffold protein.  This association with a Cullin protein is further supported by 
a conserved Cullin box motif, located downstream of the B/C box in the SOCS box 
(Kamura et al., 2004).  Cullin in turns recruits a RING finger-containing protein Rbx, 
thereby completing the assembly of the E3 ligase complex (figure 3A) (Iwai et al., 
1999; Pause et al., 1997). 
 
 
 
 
 
 
Figure 3: Involvement of the SOCS box in protein degradation 
(A.) Mechanism by which SOCS can target associated proteins for proteasome-mediated 
destruction. (B.) Proposed mechanism whereby SOCS themselves can be targeted for 
degradation by E3 recruitment or other SOCS proteins. 
 
 
SOCS can act as the substrate recognition component of an ECS-type E3 
ubiquitin ligase to regulate the half-life of proteins.  First of all, signal transduction of 
several cytokines is prolonged in the presence of proteasome inhibitors (Callus and 
Mathey-Prevot, 1998; Verdier et al., 1998).  More specifically, it was demonstrated 
that SOCS1 promotes the ubiquitination and turnover of JAK2 and the TEL-JAK2 
oncogene in a SOCS box dependent fashion (Frantsve et al., 2001; Kamizono et al., 
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2001; Ungureanu et al., 2002) while SOCS3 can target receptors for proteasomal 
degradation as it accelerates destruction of CD33 and sialic acid-binding 
immunoglobulin-like lectin (Siglec) 7, members of the Siglec family of receptors (Orr 
et al., 2007a; Orr et al., 2007b).  This proteolytic activity is not restricted to the 
receptor complex or associated JAKs but also targets substrates as diverse as the 
signal transducer VAV, the p65/RelA subunit of NF-κB, the Toll-like receptor (TLR) 
adaptor Mal and the E7 protein of Human papilloma viruses (HPV) in case of 
SOCS1 (De Sepulveda et al., 2000; Kamio et al., 2004; Mansell et al., 2006; Ryo et 
al., 2003).   Furthermore, SOCS1 and SOCS3 can both promote destruction of 
Insulin Receptor Substrate (IRS) 1 or IRS2 and focal adhesion kinase (FAK) (Liu et 
al., 2003; Rui et al., 2002). Compellingly, an essential role for the SOCS box of 
these SOCS members was demonstrated in vivo. Transgenic mice expressing a 
SOCS box deletion variant of SOCS1 or SOCS3 exhibit impaired regulation of 
respectively INFγ (Zhang et al., 2001) and Granulocyte-colony stimulating factor (G-
CSF) signalling and response to inflammatory stimuli (Boyle et al., 2007).  
 
In contrast to SOCS1 and SOCS3, CIS and SOCS2 cannot directly inhibit 
JAK activity thus implicating a stronger dependency on substrate competition or 
proteasomal degradation of target proteins. CIS association was demonstrated to 
induce proteasome-dependent degradation of the erythropoietine receptor (EpoR) 
and growth hormone receptor (GHR) (Landsman and Waxman, 2005; Ram and 
Waxman, 2000; Verdier et al., 1998). The SOCS box of SOCS2 appeared to be 
crucial for the negative regulation of GH signalling (Greenhalgh et al., 2005). The 
crystal structure of the SOCS2-Elongin B/C complex revealed a SOCS box ubiquitin 
ligase architecture similar to the one of VHL (Bullock et al., 2006), further supporting 
a role for SOCS2 in E3 ligase activity. The SOCS box shows an extensive 
interaction with Elongin C, centered around the B/C box motif. The SOCS box also 
directly interacts with Elongin B (figure 4A and 4B).   
 
The remaining SOCS members SOCS4-SOCS7 have been less extensively 
examined.  SOCS4 and SOCS5 are induced upon epidermal growth factor (EGF) 
stimulation and subsequent SOCS box dependent turnover of EGFR was reported, 
thereby inhibiting the mitogenic signalling (Kario et al., 2005; Nicholson et al., 2005).  
Also, the structural resolution of the SOCS4-Elongin B/C complex revealed a 
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molecular basis for SOCS-mediated EGFR degradation (Bullock et al., 2007).  
SOCS6 was found to interact with haem-oxidized IRP2 ubiquitin ligase 1 (HOIL1), 
thereby driving ubiquitination and degradation of associated proteins (Bayle et al., 
2006). This observation illustrates that SOCS proteins may interact with different E3 
ubiquitin ligases in addition to a common ECS-based complex.  Even though more 
direct evidence for SOCS ubiquitin ligase activity remains to be demonstrated for 
the latter SOCS members, together these data point to the key role of the SOCS 
box in mediating protein turnover as a general SOCS mechanism of action.  While 
many receptor complexes recruit SOCS, only a few of these receptors or their 
associated JAK/STAT proteins are known targets for SOCS mediated degradation. 
This may indicate a broader role for SOCS proteins in the regulation of downstream 
substrates. Accordingly, proteasomal targeting of substrates as diverse as other 
SOCS proteins, TLR adaptors and viral proteins have been reported (Kamio et al., 
2004; Mansell et al., 2006; Piessevaux et al., 2006; Tannahill et al., 2005). 
 
The crystal structures of SOCS2 and SOCS4 with Elongins B and C show a 
remarkable difference. While the interactions of the Elongins with the SOCS box are 
very similar, the SOCS box itself assumes a different orientation versus the SH2 
domain (figure 4A and 4B). Based on the structural information of SOCS2, it was 
proposed that in SOCS1-3 and CIS the C-terminus is buried in the core of the 
structure where it stabilizes the interaction between the SH2 domain and the SOCS 
box. This packing partially exposes the N-terminal ESS providing better accessibility 
for the SOCS1 and SOCS3 KIR domain. This domain organization precludes C-
terminal extensions and explains the strictly conserved length of the C-terminal 
parts in CIS and SOCS1-3 (Bullock et al., 2006). In contrast, the SOCS4-7 subclass 
contains extended C-termini and there the N-terminal ESS helix is buried in the 
SOCS box / SH2 interface to fulfill an equivalent packing role as could be 
demonstrated in the SOCS4 structure.  The function of the C-terminus is then 
redefined to stabilize an interface with the N-terminal domain (Bullock et al., 2007). 
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Figure 4: Structure of SOCS and SOCS-Elongin B/C complexes 
A. Structure of the SOCS2-Elongin B-Elongin C complex.  B. Structure of the SOCS4-
Elongin B-Elongin C complex. In A & B, the SOCS SH2 and pre-SH2 domain is colored 
orange, the SOCS box is colored red, Elongin B is yellow, Elongin C is green. In the SOCS4 
complex, the SH2 domain differs from its orientation in the SOCS2 complex.  
C & D. Accessible surface plot of SOCS4, when the SOCS4 molecule is oriented as in the 
ribbon plot below (E)(In E, the SOCS box is colored red). In C, the surface is colored 
according to the atom colors. In D, the surface is colored according to residue conservation 
in the human SOCS proteins. Strictly conserved residues are colored red, unconserved 
residues are colored dark blue. The Elongin binding site (circled area) is hydrophobic and 
highly conserved. 
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THE SOCS BOX AND SOCS PROTEIN TURNOVER 
 
Effect of E3 ligase environment on SOCS stability 
 
Next to its role in the degradation of associated substrates, the SOCS box 
may also be involved in the regulation of the expression levels of the SOCS proteins 
themselves. Reports in the literature are however somewhat paradoxical indicating 
that the functional significance of the interaction between Elongin B/C and the 
SOCS box is complex. Some data suggest that the Elongin B/C complex 
constitutively links SOCS to E3 ligase activity, thereby promoting its degradation by 
the proteasome.  Accordingly, mutations or post-translational modifications of SOCS 
proteins that disrupt Elongin B/C recruitment  have a positive effect on protein 
stability as has been shown for SOCS1 (Chen et al., 2002; Kamura et al., 
1998){Lirnander, 2004 #156}, SOCS3 (Sasaki et al., 2003; Zhang et al., 1999) and 
CIS (Ram and Waxman, 2000; Verdier et al., 1998). Overall, it appears that the 
proteasomal pathway plays a key role in SOCS protein down-modulation (Bayle et 
al., 2006; Narazaki et al., 1998; Sasaki et al., 2003; Verdier et al., 1998; Zhang et 
al., 1999).  In addition, CIS and SOCS3 are found to be degraded concomitantly 
with their GHR or Siglec receptor target respectively (see above), suggesting a 
stimulation-dependent mechanism for SOCS turnover (Orr et al., 2007a; Orr et al., 
2007b; Ram and Waxman, 2000). In contrast, the interaction between the SOCS 
box and Elongin B/C has also been shown to stabilize SOCS proteins (Haan et al., 
2003; Hanada et al., 2001; Kamura et al., 1998; Narazaki et al., 1998; Zhang et al., 
1999; Zhang et al., 2001). In the same line, the VHL protein required Elongin B/C 
binding for correct folding and stable expression (Feldman et al., 1999; Kamura et 
al., 2002; Melville et al., 2003). The interaction of the SOCS box with both Elongins 
is dominated by hydrophobic interactions. Removing the Elongins in the crystal 
structure of SOCS2 or SOCS4 exposes a large hydrophobic surface patch in both 
Elongin C and in the SOCS box (figure 4C). It is therefore not unlikely that the 
structure of the SOCS box will be unstable and undergo structural changes in the 
absence of Elongins. No structure of a SOCS box in the absence of Elongins has 
been determined:  the crystal structures of SOCS2, SOCS4 and VHL were only 
determined upon co-crystallization with Elongin B and C (Bullock et al., 2006; 
Bullock et al., 2007; Stebbins et al., 1999).  Together, these observations imply that 
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assembly of the E3 ligase induces structural reorganization and stabilization of the 
different components.       
 
While the cytokine-dependent regulation of SOCS synthesis is well 
documented, the mechanisms controlling SOCS turnover remain elusive with a 
paradoxical role for the SOCS box. Conceivably, stabilization by Elongin B/C 
recruitment represents a mechanism whereby SOCS proteins are themselves 
prevented from proteasomal degradation.  This protection may allow SOCS proteins 
molecules to function properly in an ubiquitin ligase complex.  At some point 
however, negative control is required for SOCS turnover which could occur via 
either co-degradation with the targeted protein or by the degrading action of another 
SOCS member.   
 
 
SOCS cross-modulation 
 
Emerging evidence points to regulatory cross-talk between SOCS family 
members. SOCS protein down-modulation is likely necessary to restore cellular 
sensitivity. Initially, it was found that SOCS2 exerts a dual effect on GH signal 
transduction: low SOCS2 levels moderately suppressed GH actions whereas higher 
levels restored and even enhanced signalling by blocking the inhibitory effects of 
other SOCS proteins (Favre et al., 1999; Greenhalgh et al., 2002).  This dual role of 
SOCS2 was further supported by the observation that SOCS2-deficient mice 
exhibited an overgrowth phenotype (Metcalf et al., 2000), while SOCS2 transgenic 
mice also grew significantly larger than their wild type littermates (Greenhalgh et al., 
2002).  Interference of SOCS2 with other SOCS proteins has been observed in 
several cytokine receptor systems including prolactin receptor (PRL) (Dif et al., 
2001; Pezet et al., 1999), IL-2 and IL-3 (Tannahill et al., 2005), IFN type I and leptin 
signalling (Lavens et al., 2006; Piessevaux et al., 2006).  A stimulatory role for 
SOCS2 was also proposed in mesenchymal precursor cells where it could 
potentiate osteoblast differentiation through upregulation of JunB expression, 
possibly through its negative effect on other SOCS proteins (Ouyang et al., 2006). In 
vivo observations further support a stimulatory role of SOCS2. Proteasomal 
degradation of SOCS1 induced by endogenous SOCS2 was proposed as the 
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molecular mechanism behind the constitutively activated phenotype associated with 
VHL-mediated Renal Cell Carcinoma (Wu et al., 2007). SOCS2 upregulation was 
found to correlate with advanced stages of chronic myeloid leukemia (CML) 
(Schultheis et al., 2002; Zheng et al., 2006)  or acute myeloid leukemia (AML) 
(Faderl et al., 2003)(personal communication, Dr. I Touw), possibly by inhibiting the 
tumor suppressor function of other SOCS proteins. 
 
Although the exact nature of these SOCS interactions and consequent cross-
regulation is yet to be determined, the effect relied on the presence of the SOCS 
box of the targeted SOCS and the B/C box of SOCS2 (Piessevaux et al., 2006). 
Using MAPPIT we found that SOCS2 (and SOCS6 and -7) can bind with all 
members of the SOCS protein family and the SOCS box of the targeted SOCS 
appears to be implicated. This might indicate that SOCS2 can promote turnover of 
associated SOCS molecules by linking them to proteasomal activity (figure 3B).  
Mapping SOCS residue conservation on the surface of the SOCS structures shows 
that the Elongin binding site is the only conserved feature in the surface of SOCS 
proteins, indicating the importance of Elongin binding and a similar way of Elongin 
binding for all SOCS proteins (figure 4D).   The conserved patch in the SOCS box is 
a possible SOCS2 binding site.  SOCS2 may also compete for recruitment of the 
Elongin B/C proteins to other SOCS proteins, resulting in destabilization of these 
other SOCS proteins lacking the complex.  In analogy with SOCS2, SOCS6 may 
also potentiate cytokine signalling by controlling SOCS protein stability (Piessevaux 
et al., 2006).  This latter finding might explain the improvement in glucose 
metabolism observed in SOCS6 transgenic mice (Li et al., 2004).  Furthermore, the 
Drosophila melanogaster SOCS protein SOCS44A, which is most similar to SOCS6, 
was found to enhance the activity of the EGFR/MAPK signalling cascade, providing 
further evidence for a positive role for SOCS6 in cytokine signalling (Rawlings et al., 
2004a).  
In line with such a SOCS cross-regulatory mechanism is the sequential 
induction pattern of different SOCS molecules.  In contrast to CIS, SOCS1 and 
SOCS3, which are typically induced in a rapid and transient manner upon receptor 
activation, expression of SOCS2 usually occurs later after cytokine stimulation and 
is more prolonged (Adams et al., 1998; Brender et al., 2001; Pezet et al., 1999; 
Tannahill et al., 2005).  Accordingly, the cytokine induced levels of some SOCS 
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members might act to restore cellular sensitivity for subsequent stimulation by 
suppressing the inhibitory effects of other SOCS proteins.   
 
 
Other mechanisms regulating SOCS turnover 
 
Next to the effects of Elongin B/C and the modulation by other SOCS 
proteins, the half-life time of SOCS molecules can be controlled by other protein-
protein interactions.  SOCS1 levels are negatively regulated by association with the 
tripartite motif (TRIM)8/Glioblastoma Expressed RING-finger Protein (GERP) which 
is a putative E3 ubiquitin ligase (Toniato et al., 2002), while SOCS6 is stabilized by 
the Ring-finger HOIL-1 protein (Bayle et al., 2006). Phosphorylation is also 
implicated in the control of SOCS turnover.  SOCS1 expression levels are positively 
regulated through phosphorylation by the Pim serine/threonine kinase (Chen et al., 
2002).  In contrast, JAK-dependent phosphorylation of SOCS3 at two tyrosine 
residues in the SOCS box correlates with disrupted Elongin C interaction and 
accelerated SOCS3 degradation (Haan et al., 2003).  It remains to be determined 
whether other SOCS can also be modulated by phosphorylation. Given the high 
degree of conservation of SOCS box tyrosine residues this mechanism may also 
occur for other SOCS proteins, but evidence for this is lacking so far. An 
unstructured PEST (proline-, glutamic acid-, serine and threonine rich) motif in the 
SH2 domain of SOCS3 can negatively regulate its protein stability (Babon et al., 
2006). This multitude of mechanisms controlling SOCS stability suggests that the 
turnover of SOCS must be crucial in cytokine mediated responses.   
 
 
ADAPTOR FUNCTIONS OF THE SOCS BOX 
 
The SOCS box functions primarily as a linker that associates substrate 
binding domains such as the SH2 domain for SOCS proteins with the ubiquitin 
ligase components Elongin C and B (Hilton et al., 1998).  In addition, this domain 
also couples SOCS actions to other downstream signalling pathways like the MAPK 
pathway.  SOCS3 is phosphorylated on C-terminal tyrosines in response to insulin, 
IL-6 and many growth factors including IL-2, Epo, EGF and PDGF (Cacalano et al., 
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2001; Peraldi et al., 2001; Sommer et al., 2005). Upon stimulation by the latter 
growth factors phosphorylated SOCS3 can interact with the Ras inhibitor p120 
RasGAP, thereby inhibiting its functions. This way, SOCS3 maintains ERK 
activation and ensures cell survival and proliferation through the Ras/MAPK 
pathway (Cacalano et al., 2001).  As phosphorylated SOCS3 was still able to block 
STAT5 activation, SOCS3 can act as a molecular switch turning off JAK-STAT 
mediated signals while sustaining ERK activation through the same receptor. 
Tyrosine phosphorylation of the SOCS box of SOCS3 was also found to mediate 
association and activation of the adaptor proteins Nck and Crk-L, which are known 
to couple activated receptors to multiple downstream signalling pathways and the 
actin cytoskeleton (Sitko et al., 2004). The effects of SOCS3 phosphorylation 
induced by insulin and IL-6 remains unclear but it can be envisioned that also here 
binding sites for SH2-containing molecules are created, thereby providing a link to 
other signalling systems (Peraldi et al., 2001; Sommer et al., 2005).  
Similar to SOCS3, other SOCS members posses a conserved tyrosine residue in 
the SOCS box (Hilton et al., 1998) and many of these are in a potential SH2 
domain-binding motif. It remains to be elucidated how these tyrosines contribute to 
SOCS function. In this context, CIS was reported to promote T cell receptor 
mediated proliferation and to prolong survival of activated T cells.  The latter 
responses are dependent on increased MAPK activation and a direct interaction of 
CIS and protein kinase Cθ (Li et al., 2000). It remains to be determined if the SOCS 
box is implicated in these regulatory events. 
 
 
THE SOCS BOX CAN PARTICIPATE IN SUBSTRATE RECOGNITION 
 
A SOCS box can be a critical determinant for substrate recognition, as we 
recently demonstrated for CIS. The Elongin B/C recruitment site (B/C box), as well 
as a conserved C-terminal tyrosine (Y253) are required for CIS binding to EpoR, 
GHR and leptin receptor motifs (Lavens et al., 2007; Uyttendaele et al., 
2007)(Piessevaux et al., submitted to JBC). Indirect effects on the structural integrity 
of CIS due to deletion of these sites can be excluded, as SOCS box independent  
interactions were observed with the unrelated  TLR adaptor MyD88 (Lavens et al., 
2007)(Piessevaux et al., submitted to JBC).  This SOCS box dependency appeared 
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to be unique for CIS, as none of the other examined SOCS members required 
Elongin B/C association or the homologous tyrosine for receptor substrate 
interaction. At present 70 proteins harboring a SOCS box have been described in 
the human genome (according to Pfam), possibly their substrate binding could also 
be controlled by Elongin B/C recruitment. 
 
We could show that under physiological conditions CIS can exist in an 
uncoupled form, lending further support to a regulatory mechanism by which free 
CIS can be bound and regulated by the cellular Elongin B/C levels (Piessevaux et 
al., submitted to JBC). This way, the SOCS box may represent a regulatory on/off 
switch acting on the SH2 domain of CIS thereby controlling receptor binding. 
Accordingly, a CIS variant with a defective SH2 domain (CIS R107K) behaved as a 
dominant negative variant (Aman et al., 1999; Ram and Waxman, 2000) and we 
propose that this effect is due to the scavenging of Elongin B/C by the mutant 
resulting in loss of substrate binding by endogenous CIS. Our observation that 
Elongin B/C association cannot be uncoupled from CIS receptor binding further 
supports a major contribution for the recruitment of E3 ligase activity in CIS-
mediated inhibition. This Elongin B/C-dependency also implicates that CIS activity 
may be suppressed by SOCS2 in a dual way.  SOCS2 that is expressed at a later 
stage may scavenge Elongin B/C from CIS leading to loss of receptor interaction.   
Subsequently, SOCS2 can bind with uncomplexed CIS resulting in proteasomal 
targeting of CIS. Further studies are needed to establish the physiological 
significance of this modulatory mechanism. Given the important physiological 
processes in which CIS takes part such as the GHR-mediated growth or EpoR-
dependent haematopoeisis, this molecular on/off switch may constitute a safety lock 
to ensure complete inhibition of cytokine activity since only CIS molecules that are 
able to recruit the E3 ligase activity will associate with the receptor. 
 
 
MEDICAL IMPLICATIONS 
 
Aberrant control of SOCS protein function, e.g. by deregulated expression 
levels, can contribute to several pathologies. Certain pathogens have developed 
strategies to induce the host SOCS system for manipulating cytokine signalling and 
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evading immune counter actions (Alexander et al., 1999; Moutsopoulos et al., 2006; 
Stoiber et al., 2001; Zimmermann et al., 2006).  Alterations in SOCS protein levels, 
and more specifically SOCS3, has been implicated in the pathogenesis of various 
inflammatory diseases including rheumatoid arthritis (RA), Crohn’s disease and 
inflammatory bowel diseases (IBD) (Egan et al., 2003; Isomaki et al., 2007; Lovato 
et al., 2003; Rakoff-Nahoum et al., 2006; Suzuki et al., 2001). A prominent role for 
increased SOCS3 levels in leptin resistance and consequent obesity was also 
reported (Bjorbaek et al., 1998; Dunn et al., 2005; Howard et al., 2004; Mori et al., 
2004). Furthermore, SOCS1 and SOCS3 might be players in the development of 
insulin resistance associated with type 2 diabetes (Emanuelli et al., 2001; Emanuelli 
et al., 2000; Kawazoe et al., 2001; Ueki et al., 2005; Ueki et al., 2004).  Upregulated 
SOCS1 and SOCS3 expression also seems to be responsible for the 
unresponsiveness to IFN therapy in the treatment of hepatitis C virus infection or 
leukaemia (Bode et al., 2003; Roman-Gomez et al., 2004; Sakai et al., 2002).  
Compellingly, development and progression of tumors in various human cancers 
was correlated with both inactivation (Farabegoli et al., 2005; Galm et al., 2003; He 
et al., 2003; Komazaki et al., 2004; Nagai et al., 2003; Watanabe et al., 2004; 
Wikman et al., 2002; Yoshikawa et al., 2001) and inappropriate upregulation of 
certain SOCS proteins (Evans et al., 2007; Haffner et al., 2007; Komyod et al., 
2007; Raccurt et al., 2003; Roman-Gomez et al., 2004).  As mentioned above, 
increased expression of SOCS2 in malignancies like chronic myeloid leukemia 
(CML) (Schultheis et al., 2002; Zheng et al., 2006), could contribute to 
transformation by negative interference with other SOCS molecules that normally 
would suppress tumor development. 
 
Manipulation of SOCS protein function might provide novel therapeutic 
options in the treatment of these disorders.  Besides administration of SOCS 
proteins or mimetics and the specific downregulation of SOCS expression by siRNA 
or antisense approaches, the emerging knowledge about SOCS regulation may 
provide a structural basis for SOCS inhibitor design.  The SOCS protein structure 
reveals specific domains that can be targeted to alter their function and expression: 
these include the SH2 domain to modulate association with other signalling 
molecules and the SOCS box to control SOCS stability and actions. Definitely, 
further insights in the molecular mechanisms behind SOCS regulation will be 
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important to completely understand their control of signalling pathways and their 
relationship with pathologies. 
 
 
CONCLUDING REMARKS 
 
Through their regulation of diverse signal transduction pathways, SOCS 
proteins are involved in a variety of crucial processes including immune functions, 
haematopoeiesis, growth and metabolism.  Accordingly, regulation of SOCS 
functions it self is subjected to tight control. Here a complex role for the SOCS box 
emerges (figure 5).  
 
 
 
 
 
 
 
Figure 5: Versatility of SOCS functions 
The different domains of the SOCS box mediate distinct interactions and functions. Some of 
them are specific for some SOCS members (e.g. KIR-dependent inhibition of JAK activity by 
SOCS1 and SOCS3) while others appear to be general (competition for receptor motifs).  
The SOCS box is involved in functions as diverse as target degradation, control of SOCS 
stability and receptor interaction. 
 
 
First, the domain is involved in the destruction of targets by linking them to 
the proteasomal machinery.  Second, it may also protect SOCS from this 
proteasome mediated turnover.  Third, the SOCS box is involved in a cross-
Chapter 11: Versatility of the SOCS box domain 
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regulatory mechanism in which a restricted set of SOCS proteins can interfere with 
the inhibitory actions of other members of the family.  As the latter mechanism will 
exert a negative effect on SOCS half-life time, this also may provide an explanation 
for the apparent duality of the SOCS box on SOCS stability. Together, these data 
suggest that the association between the SOCS box and the Elongin B/C complex 
could function, at least in part, to fine-tune the concentration and actions of SOCS 
proteins in cells. Finally, the SOCS box can also be involved in a unique regulatory 
mechanism controlling SH2 domain functions as was demonstrated for CIS. 
 
Since SOCS proteins are involved in several important human pathologies, a 
full understanding of the mechanisms controlling their activity is of great importance. 
This should not be underestimated given the remarkably different contribution of the 
SOCS box in the activity pattern of individual SOCS proteins. Full insight into their 
finely tuned activity will require detailed analysis of the mechanisms controlling their 
expression levels and interaction patterns. 
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Interactions between proteins are fundamental to virtually every biological process. 
Therefore, the characterisation of such protein-protein interactions is imperative in 
the understanding of cellular mechanisms and makes them new targets for drug 
design. Proteins can function as components of large, highly structured complexes 
such as ribosomes, enhanceosomes or the proteasome complex. But protein 
associations also contribute to the regulation of signal transduction, which are 
generally of a temporary nature. Full characterisation of a particular protein-protein 
interaction or the comprehensive large-scale determination of the proteome within a 
particular organism necessitates the complementary use of different methodologies.  
Each approach will add unique advantages and opportunities but will also have 
specific drawbacks. As discussed in chapter 4, a broad range of both biochemical 
and genetic techniques have been developed to study protein-protein interactions. 
Biochemical methods have the advantage that signalling complexes can be 
analysed in its entirety. However, the inevitable lysis step in these approaches 
disrupts the normal cellular context, which can lead to false positive interactions 
between proteins normally residing in separate cellular compartments. Also, protein 
interactions involved in dynamic intracellular processes including signal transduction 
may be too weak or transient to be detected with biochemical techniques. Genetic 
approaches use hybrid bait and prey molecules, of which interaction generates a 
measurable signal. The most commonly used, yeast-two-hybrid, is cost-effective, 
easy to implement and scalable. This method suffers from two major intrinsic 
limitations: interactions between mammalian proteins often require post-translational 
modifications which are hard to reproduce in yeast cells and as the bait-prey 
interaction need to occur in the nucleus this will exclude the analysis of membrane 
bound proteins. In order to work in an optimal physiological context, a variety of two-
hybrid systems in mammalian cells, have been developed. MAPPIT is such a 
technique that relies on signal transduction via type I cytokine receptors 
(www.mappit.be) (Eyckerman et al., 2001). Interaction of bait and prey hybrids leads 
to functional complementation of a signalling-deficient receptor by STAT3 
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recruitment sites in the prey protein. Throughout this thesis MAPPIT was extensively 
used to study (cross)regulation by SOCS molecules. The technology was also 
expanded by application of different variants and by working in diverse cellular 
contexts, demonstrating the versatility of MAPPIT as an analytical tool. 
 
Since cytokine signalling cascades are vital to many physiological processes, strict 
control of these pathways is equally important. SOCS proteins are an important 
family of regulators of these cytokine responses. Biochemical and genetic studies 
have provided profound insights into the modes of action and selectivity by which 
the different SOCS proteins regulate distinct signal transduction pathways. Anyhow, 
the mechanisms underlying SOCS functions need to be further elucidated. Better 
insight into these may help to understand the regulatory mechanisms underlying 
differential cellular responsiveness to cytokines. The importance of this is 
underscored by the contribution of inappropriately regulated SOCS levels to several 
pathologies. 
 
In the first part of this thesis we focussed on the role of SOCS proteins in 
modulation of leptin signalling. This cytokine-like hormone is crucially involved in 
body weight regulation by communicating the status of body fat stores to the 
hypothalamus. Aberrantly high leptin levels are associated with the majority of the 
obesity cases, pointing to a central failure to respond correctly to the leptin signal. 
Accumulating evidence indicates that alterations in cellular LR signalling, with a key 
role for SOCS3, have a major contribution in this leptin resistance (Munzberg et al., 
2005). We found that CIS and SOCS2 are new interaction partners of the LR. In 
general, the closely related CIS and SOCS2 proteins display a great overlap in their 
binding mode with cytokine receptors. By using MAPPIT and peptide affinity 
chromatography we observed a differential interaction pattern of CIS and SOCS2 
with phosphotyrosine motifs of the LR. Whereas both CIS and SOCS2 associate 
with the P-Y1077 position, only CIS interacts with the more membrane proximal P-
Y985. We analysed the functionality of SOCS2 in the context of LR signalling and 
showed that it can impede STAT5 recruitment. We further observed that SOCS2 
interferes with CIS association at P-Y1077 and unexpectedly also at the P-Y985 
position, although SOCS2 itself does not interact with this tyrosine.  Since SOCS2 
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was found to associate with CIS and the interfering effect appeared to be dependent 
on Elongin B/C recruitment to SOCS2, proteasomal degradation of CIS is likely 
involved. This observed cross-regulation between SOCS proteins was analysed in 
more detail in the second part of this thesis (see further). We conclude that besides 
the well characterized inhibitory actions of SOCS3, other SOCS proteins interact 
with the LR and may be implicated in the modulation of its signalling. Upregulation 
of CIS or SOCS2 expression is not detectable in the hypothalamus upon leptin 
administration in mice (Bjorbaek et al., 1998), but it should be considered that 
SOCS proteins can mediate cross-talk between different signalling pathways. Also 
their expression may be relevant in peripheral cell types and accordingly, SOCS2 
and CIS expression upon leptin stimulation were found in RINm5F insulinoma cells 
(Lavens et al., 2006).  
Leptin has been increasingly recognized as a regulator of peripheral functions like 
immune responses, reproduction, angiogenesis and haematopoiesis. Nevertheless, 
signalling events induced by leptin in haematopoietic progenitor cells remain far 
from clear. In order to gain more insight in this issue, we studied the interaction 
partners of the LR in a haematopoietic background. We adapted the MAPPIT 
strategy to this cellular context that is characterized by prevalent STAT5 signalling 
by exchanging the gp130 part of the preys by a portion of the cytoplasmatic tail of 
the βc-receptor containing STAT5 interaction sites. This so-called βc-MAPPIT was 
successfully used in different haematopoietic cell lines. The interaction of different 
signalling molecules with tyrosine motifs of the LR was tested. Known interactions 
could be confirmed: we found binding of STAT5 to the P-Y1077 and of SOCS3 to 
the P-Y985 and P-Y1077 motif (Eyckerman et al., 2000; Gong et al., 2007; 
Hekerman et al., 2005). Furthermore, we reported the involvement of the 
phospholipase C pathway in haematopoietic leptin signalling by showing the 
interaction of PLCγ with the P-Y1077. Since our previous interaction studies with the 
classical MAPPIT method demonstrated binding of CIS and SOCS2 to the LR in 
HEK-293T cells, we next examined all SOCS family members on LR interaction. 
CIS and SOCS7 were found to both interact with the P-Y985 and P-Y1077 motifs, 
while SOCS2 and -6 only bind to the P-Y1077 of the LR. Association of SOCS2, -6 
and -7 at P-Y1077 may be indirect as it was recently reported that IRS4 functions as 
an adaptor of the LR at this position, recruiting different proteins including these 
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SOCS members (Wauman et al., 2007). The inability to distinct direct from indirect 
interactions is inherent to all two-hybrid methods and full proof of this requires in 
vitro interaction analysis of the purified recombinant binding partners. These data 
further support the implication of other SOCS molecules, besides SOCS3, in the 
modulation of leptin signalling.  Also, our study provides a basis for more detailed 
functional analysis of leptin signalling in haematopoietic cells. 
 
The second part of this thesis deals with the versatile functions of the SOCS box on 
the regulation of SOCS proteins and cytokine signalling. A growing body of 
evidence indicates that the functions of some SOCS proteins may not be simply 
inhibitory. In this respect, SOCS2 was described as a dual regulator, exerting both 
inhibitory and stimulatory effects on GH signalling in vitro and in vivo (Favre et al., 
1999; Greenhalgh et al., 2002; Metcalf et al., 2000). We unravelled the underlying 
mechanism of this paradoxal effect. First we showed that SOCS2 antagonizes the 
inhibition of SOCS1 and SOCS3 in a SOCS box-dependent manner, thereby 
restoring signalling via the GHR, LR and IFN type I receptor. This interfering 
capacity of SOCS2 was found to depend on Elongin B/C recruitment. Accordingly, 
degradation of SOCS1 was promoted by SOCS2 but not by the Elongin B/C 
recruitment-deficient mutant, suggesting that SOCS2 targets other SOCS proteins 
for proteasomal degradation. Using MAPPIT we demonstrated that SOCS2 can bind 
to all members of the SOCS protein family. We finally provide evidence for the 
involvement of SOCS6 in a similar interfering mechanism. This might reflect a 
crucial physiological role of SOCS2 in restoring cellular responsiveness after 
cytokine activation. It can be presumed that SOCS2 requires a threshold 
concentration to act on SOCS protein degradation. In line with this, SOCS2 
expression usually occurs at later time points compared with CIS, SOCS1 and -3 
and is more prolonged (Adams et al., 1998; Brender et al., 2001; Pezet et al., 1999; 
Tannahill et al., 2005). Elevated SOCS expression is associated with several 
pathologies demonstrating the importance of a tight control of SOCS protein 
expression levels. Enhanced SOCS2 levels for example correlate with some 
cancers like chronic myeloid leukaemia (Schultheis et al., 2002; Zheng et al., 2006). 
It will be of special interest to examine whether SOCS2 interference with the tumor 
suppressor functions of other SOCS proteins is the underlying mechanism 
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contributing to oncogenesis. We uncovered in this thesis a novel level of inter-SOCS 
regulation that is most likely involved in restoring basal cellular responsiveness, 
adding a further layer of complexity to regulation of cytokine responses. Although 
the SOCS box of the targeted SOCS seems to be implicated in the interaction with 
the inhibitory SOCS, the precise nature of this inter-SOCS interaction is still unclear 
and needs further examination. Detailed analysis of the kinetics of relative 
expression levels and the binding affinities of all interacting components in a 
particular cellular background will be required to achieve full and global insights into 
the precise regulatory control.   
Finally, we demonstrated that besides the SH2 domain, the SOCS box can also be 
involved in substrate recognition by SOCS proteins. Receptor interaction and 
functionality of CIS were shown to require Elongin B/C recruitment to the SOCS 
box. This Elongin B/C dependency seems to be an exclusive property of CIS since 
none of the other examined SOCS members was found to need Elongin recruitment 
for interaction with target receptor motifs. This is reminiscent of the effects observed 
for the Y253F mutation in the C-terminal part of the CIS SOCS box as this mutation 
also completely abrogates functional interaction with most cytokine receptor 
interaction motifs (Lavens et al., 2007; Uyttendaele et al., 2007). Modelling studies 
based on the crystal structure of SOCS2 and SOCS4 in complex with Elongin B/C 
(Bullock et al., 2006; Bullock et al., 2007) predict that the C-terminus of CIS is buried 
in the interface between the SH2 domain and the SOCS box. Based on this model a 
direct interaction of the SOCS box or Y253 with the phosphopeptide substrate could 
be excluded. We propose that the correct positioning of the CIS C-terminus and 
more specifically of Y253 is essential for substrate binding and that it is induced by 
structural changes in the SOCS box upon binding of Elongins. Taken together, we 
report that Elongin B/C association to CIS may control substrate binding via 
allosteric modulation of the SOCS box. This represents a unique regulatory 
mechanism by which the SOCS box may form an on/off switch acting on the SH2 
domain. Our observation that Elongin B/C association cannot be uncoupled from 
CIS functions further supports a major contribution for the recruitment of E3 ligase 
activity in CIS-mediated inhibition. Furthermore, this implicates that the previous 
observation concerning SOCS2 interference with the interaction of CIS at the Y985 
of the LR, can be explained in a dual way. First, SOCS2 that binds Elongin C with 
higher affinity than CIS may scavenge Elongin B/C complexes from CIS leading to 
loss of substrate binding. Second, SOCS2 can interact with unbound CIS leading to 
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degradation of the free CIS pool. The list of multiprotein complexes containing 
Elongin B/C is growing, suggesting that dependent of the expression, localization 
and relative binding affinities of all these B/C box containing proteins, a competition 
for Elongin B/C will occur. Accordingly, the availability of free Elongin B/C complex 
may determine CIS activity. Perhaps, this Elongin B/C dependency of CIS may 
function as a ‘safety lock’ that guarantees total termination of signalling as only the 
CIS molecules that are able to recruit the proteasomal machinery will contribute to 
inhibition. The remarkable discrepancy observed between the unaltered phenotype 
of CIS-deficient mice and the severe defects in growth, mammary gland 
development and immune effects of CIS transgenic mice (Li et al., 2000; Matsumoto 
et al., 1999) may also be indicative of the high risk of unrestrained CIS activity.  
 
Taken together, our findings further underscore the functional complexity of the 
SOCS box. The diverse effects of this domain are reviewed in chapter 11 and the 
SOCS box increasingly appears as an important modulator of cytokine actions. 
Undoubtedly, knowledge of how SOCS proteins are regulated and/or degraded, 
may lead to development of new strategies that utilize the properties of SOCS for 
therapeutic purposes. Further clarification of the nature of SOCS regulation will have 
to deal with major questions: Given the many receptor complexes that are known to 
recruit SOCS, why did we only identify few substrates of the ubiquitin E3 ligase 
activity of each SOCS protein in comparison?  Some receptors and JAK2 are 
reported to be degraded by SOCS but no clear evidence exists concerning other 
receptor complex components like STATs. Probably, SOCS substrates go beyond 
the cytokine receptor complex since targets as diverse as other SOCS proteins, 
TLR adaptors and viral proteins have been reported (Kamio et al., 2004; Mansell et 
al., 2006; Piessevaux et al., 2006; Tannahill et al., 2005). Further studies are also 
required to define if the cross-regulatory mechanism functions beyond the SOCS 
family. At present 210 proteins harboring a SOCS box have been described in the 
mammalian genome. Possibly they could also be subjected to cross-modulation 
through SOCS-box dependent degradation or scavenging of Elongin B/C. Of note, 
the manipulation of SOCS actions might provide potent therapeutic options in the 
treatment of several disorders. Better understanding of the specific domains or 
residues that have to be targeted to alter their function and expression may provide 
a structural basis for SOCS inhibitor design in the development of therapies. 
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